WO2013090648A1 - Modified nucleoside, nucleotide, and nucleic acid compositions - Google Patents
Modified nucleoside, nucleotide, and nucleic acid compositions Download PDFInfo
- Publication number
- WO2013090648A1 WO2013090648A1 PCT/US2012/069610 US2012069610W WO2013090648A1 WO 2013090648 A1 WO2013090648 A1 WO 2013090648A1 US 2012069610 W US2012069610 W US 2012069610W WO 2013090648 A1 WO2013090648 A1 WO 2013090648A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- modified
- lipid
- nucleic acid
- formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 191
- 108020004707 nucleic acids Chemical class 0.000 title abstract description 396
- 102000039446 nucleic acids Human genes 0.000 title abstract description 396
- 150000007523 nucleic acids Chemical class 0.000 title abstract description 390
- 125000003729 nucleotide group Chemical class 0.000 title description 105
- 239000002773 nucleotide Chemical class 0.000 title description 75
- 239000002777 nucleoside Substances 0.000 title description 61
- 150000003833 nucleoside derivatives Chemical class 0.000 title description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 74
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 64
- 229920001184 polypeptide Polymers 0.000 claims abstract description 48
- 230000000694 effects Effects 0.000 claims abstract description 13
- -1 lipidoid Substances 0.000 claims description 175
- 238000000034 method Methods 0.000 claims description 173
- 238000009472 formulation Methods 0.000 claims description 142
- 239000002105 nanoparticle Substances 0.000 claims description 142
- 150000002632 lipids Chemical class 0.000 claims description 141
- 229920000642 polymer Polymers 0.000 claims description 104
- 210000004027 cell Anatomy 0.000 claims description 84
- 230000004048 modification Effects 0.000 claims description 62
- 238000012986 modification Methods 0.000 claims description 62
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 56
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 50
- 239000002502 liposome Substances 0.000 claims description 40
- 210000001519 tissue Anatomy 0.000 claims description 35
- 108020004999 messenger RNA Proteins 0.000 claims description 34
- 235000012000 cholesterol Nutrition 0.000 claims description 28
- 239000004005 microsphere Substances 0.000 claims description 25
- 125000002091 cationic group Chemical group 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 claims description 19
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 claims description 19
- 229940029575 guanosine Drugs 0.000 claims description 18
- 230000000144 pharmacologic effect Effects 0.000 claims description 16
- 150000002148 esters Chemical class 0.000 claims description 15
- 230000000799 fusogenic effect Effects 0.000 claims description 15
- 210000004962 mammalian cell Anatomy 0.000 claims description 14
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Natural products C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 13
- 229930185560 Pseudouridine Natural products 0.000 claims description 13
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 13
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 13
- 239000000017 hydrogel Substances 0.000 claims description 13
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 12
- 229920001983 poloxamer Polymers 0.000 claims description 12
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 12
- 239000003894 surgical glue Substances 0.000 claims description 12
- LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 claims description 11
- HXVVOLDXHIMZJZ-UHFFFAOYSA-N 3-[2-[2-[2-[bis[3-(dodecylamino)-3-oxopropyl]amino]ethyl-[3-(dodecylamino)-3-oxopropyl]amino]ethylamino]ethyl-[3-(dodecylamino)-3-oxopropyl]amino]-n-dodecylpropanamide Chemical compound CCCCCCCCCCCCNC(=O)CCN(CCC(=O)NCCCCCCCCCCCC)CCN(CCC(=O)NCCCCCCCCCCCC)CCNCCN(CCC(=O)NCCCCCCCCCCCC)CCC(=O)NCCCCCCCCCCCC HXVVOLDXHIMZJZ-UHFFFAOYSA-N 0.000 claims description 11
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 11
- 238000005538 encapsulation Methods 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 10
- 229960000502 poloxamer Drugs 0.000 claims description 10
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 10
- 238000007920 subcutaneous administration Methods 0.000 claims description 10
- RVHYPUORVDKRTM-UHFFFAOYSA-N 1-[2-[bis(2-hydroxydodecyl)amino]ethyl-[2-[4-[2-[bis(2-hydroxydodecyl)amino]ethyl]piperazin-1-yl]ethyl]amino]dodecan-2-ol Chemical compound CCCCCCCCCCC(O)CN(CC(O)CCCCCCCCCC)CCN(CC(O)CCCCCCCCCC)CCN1CCN(CCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)CC1 RVHYPUORVDKRTM-UHFFFAOYSA-N 0.000 claims description 9
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 108010073385 Fibrin Proteins 0.000 claims description 8
- 102000009123 Fibrin Human genes 0.000 claims description 8
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 8
- 235000014633 carbohydrates Nutrition 0.000 claims description 8
- 229950003499 fibrin Drugs 0.000 claims description 8
- 238000007918 intramuscular administration Methods 0.000 claims description 8
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims description 7
- 108010049003 Fibrinogen Proteins 0.000 claims description 7
- 102000008946 Fibrinogen Human genes 0.000 claims description 7
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 229940012952 fibrinogen Drugs 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 229960003786 inosine Drugs 0.000 claims description 7
- 239000002479 lipoplex Substances 0.000 claims description 7
- GLGLUQVVDHRLQK-WRBBJXAJSA-N n,n-dimethyl-2,3-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/CCCCCCCC GLGLUQVVDHRLQK-WRBBJXAJSA-N 0.000 claims description 7
- 239000000565 sealant Substances 0.000 claims description 7
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 6
- 229930010555 Inosine Natural products 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 claims description 5
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 claims description 5
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 5
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 241000288906 Primates Species 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 229940088598 enzyme Drugs 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Natural products O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 claims description 4
- BGTXMQUSDNMLDW-AEHJODJJSA-N 2-amino-9-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)F BGTXMQUSDNMLDW-AEHJODJJSA-N 0.000 claims description 4
- 108090000190 Thrombin Proteins 0.000 claims description 4
- 230000004075 alteration Effects 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 230000003204 osmotic effect Effects 0.000 claims description 4
- 235000021309 simple sugar Nutrition 0.000 claims description 4
- 229960004072 thrombin Drugs 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 230000002601 intratumoral effect Effects 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 108010054147 Hemoglobins Proteins 0.000 claims description 2
- 102000001554 Hemoglobins Human genes 0.000 claims description 2
- 239000008156 Ringer's lactate solution Substances 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 2
- 210000002615 epidermis Anatomy 0.000 claims description 2
- 238000005534 hematocrit Methods 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 206010033675 panniculitis Diseases 0.000 claims description 2
- 239000002953 phosphate buffered saline Substances 0.000 claims description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 80
- 102000004169 proteins and genes Human genes 0.000 abstract description 62
- 229940124447 delivery agent Drugs 0.000 abstract description 24
- 239000013022 formulation composition Substances 0.000 abstract description 8
- 239000002243 precursor Substances 0.000 abstract description 5
- 230000003915 cell function Effects 0.000 abstract description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 117
- 125000005415 substituted alkoxy group Chemical group 0.000 description 63
- 229920001223 polyethylene glycol Polymers 0.000 description 62
- 230000000670 limiting effect Effects 0.000 description 60
- 125000005843 halogen group Chemical group 0.000 description 54
- 235000018102 proteins Nutrition 0.000 description 53
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 51
- 238000012384 transportation and delivery Methods 0.000 description 51
- 125000005017 substituted alkenyl group Chemical group 0.000 description 49
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 48
- 125000000217 alkyl group Chemical group 0.000 description 47
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 47
- 125000004426 substituted alkynyl group Chemical group 0.000 description 46
- 108700011259 MicroRNAs Proteins 0.000 description 45
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 45
- 229920002477 rna polymer Polymers 0.000 description 44
- 125000003835 nucleoside group Chemical group 0.000 description 41
- 150000001875 compounds Chemical class 0.000 description 40
- 239000008194 pharmaceutical composition Substances 0.000 description 40
- 150000003839 salts Chemical class 0.000 description 40
- 230000027455 binding Effects 0.000 description 37
- 230000014616 translation Effects 0.000 description 37
- 239000002679 microRNA Substances 0.000 description 36
- 125000004103 aminoalkyl group Chemical group 0.000 description 34
- 229910052760 oxygen Inorganic materials 0.000 description 34
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 34
- 125000000623 heterocyclic group Chemical group 0.000 description 32
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 31
- 229910052717 sulfur Inorganic materials 0.000 description 31
- 125000003107 substituted aryl group Chemical group 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 29
- 125000005021 aminoalkenyl group Chemical group 0.000 description 28
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 27
- 125000003302 alkenyloxy group Chemical group 0.000 description 27
- 125000002947 alkylene group Chemical group 0.000 description 27
- 125000005133 alkynyloxy group Chemical group 0.000 description 27
- 125000005014 aminoalkynyl group Chemical group 0.000 description 27
- 150000003573 thiols Chemical class 0.000 description 26
- 125000004474 heteroalkylene group Chemical group 0.000 description 25
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 24
- 239000002245 particle Substances 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 23
- 239000000306 component Substances 0.000 description 23
- 239000002539 nanocarrier Substances 0.000 description 23
- 235000000346 sugar Nutrition 0.000 description 23
- 229920001400 block copolymer Polymers 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 22
- 238000001727 in vivo Methods 0.000 description 22
- 239000004055 small Interfering RNA Substances 0.000 description 22
- 125000001424 substituent group Chemical group 0.000 description 22
- 230000001225 therapeutic effect Effects 0.000 description 22
- 239000002904 solvent Substances 0.000 description 20
- 125000005309 thioalkoxy group Chemical group 0.000 description 20
- 238000001890 transfection Methods 0.000 description 20
- NIDVTARKFBZMOT-PEBGCTIMSA-N N(4)-acetylcytidine Chemical compound O=C1N=C(NC(=O)C)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NIDVTARKFBZMOT-PEBGCTIMSA-N 0.000 description 19
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 19
- 229940104302 cytosine Drugs 0.000 description 18
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 18
- 239000000546 pharmaceutical excipient Substances 0.000 description 18
- 108020004459 Small interfering RNA Proteins 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 238000013268 sustained release Methods 0.000 description 17
- 239000012730 sustained-release form Substances 0.000 description 17
- 229940035893 uracil Drugs 0.000 description 17
- 239000002202 Polyethylene glycol Substances 0.000 description 16
- 125000002431 aminoalkoxy group Chemical group 0.000 description 16
- 230000015788 innate immune response Effects 0.000 description 16
- 238000013519 translation Methods 0.000 description 16
- 229930024421 Adenine Natural products 0.000 description 15
- 229920002873 Polyethylenimine Polymers 0.000 description 15
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 15
- 229960000643 adenine Drugs 0.000 description 15
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 15
- 238000013270 controlled release Methods 0.000 description 15
- 125000005020 hydroxyalkenyl group Chemical group 0.000 description 15
- 125000004043 oxo group Chemical group O=* 0.000 description 15
- 229920000728 polyester Polymers 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 230000002163 immunogen Effects 0.000 description 14
- 229960005486 vaccine Drugs 0.000 description 14
- 108020004705 Codon Proteins 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 13
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 125000005242 carbamoyl alkyl group Chemical group 0.000 description 13
- 210000003494 hepatocyte Anatomy 0.000 description 13
- 125000005016 hydroxyalkynyl group Chemical group 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 108020005176 AU Rich Elements Proteins 0.000 description 12
- 229920001661 Chitosan Polymers 0.000 description 12
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 108020004635 Complementary DNA Proteins 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 11
- 108091023045 Untranslated Region Proteins 0.000 description 11
- 229920001577 copolymer Polymers 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 11
- 210000003097 mucus Anatomy 0.000 description 11
- 239000004417 polycarbonate Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 11
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 11
- 229940045145 uridine Drugs 0.000 description 11
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 10
- 125000002252 acyl group Chemical group 0.000 description 10
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 description 10
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 10
- 125000004181 carboxyalkyl group Chemical group 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 125000003827 glycol group Chemical group 0.000 description 10
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 108020005345 3' Untranslated Regions Proteins 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 9
- 229920000229 biodegradable polyester Polymers 0.000 description 9
- 239000004622 biodegradable polyester Substances 0.000 description 9
- 125000005111 carboxyalkoxy group Chemical group 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 125000003473 lipid group Chemical group 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- 229920000058 polyacrylate Polymers 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 229910052711 selenium Inorganic materials 0.000 description 9
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 8
- 125000005080 alkoxycarbonylalkenyl group Chemical group 0.000 description 8
- 125000005086 alkoxycarbonylalkynyl group Chemical group 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 8
- 229920000768 polyamine Polymers 0.000 description 8
- 229920002721 polycyanoacrylate Polymers 0.000 description 8
- 229940096913 pseudoisocytidine Drugs 0.000 description 8
- 125000004964 sulfoalkyl group Chemical group 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000002619 bicyclic group Chemical group 0.000 description 7
- 239000001506 calcium phosphate Substances 0.000 description 7
- 229910000389 calcium phosphate Inorganic materials 0.000 description 7
- 235000011010 calcium phosphates Nutrition 0.000 description 7
- 125000005158 carboxyaminoalkyl group Chemical group 0.000 description 7
- 230000021615 conjugation Effects 0.000 description 7
- 239000011258 core-shell material Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 210000000066 myeloid cell Anatomy 0.000 description 7
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 7
- 229920000656 polylysine Polymers 0.000 description 7
- 229920002635 polyurethane Polymers 0.000 description 7
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 7
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 7
- 108020003589 5' Untranslated Regions Proteins 0.000 description 6
- HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 6
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 6
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 229920001165 Poly(4-hydroxy-l-proline ester Polymers 0.000 description 6
- 108010039918 Polylysine Proteins 0.000 description 6
- 108091030071 RNAI Proteins 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 229960001231 choline Drugs 0.000 description 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 230000009368 gene silencing by RNA Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000004814 polyurethane Substances 0.000 description 6
- 229920005604 random copolymer Polymers 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 5
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 5
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 5
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 5
- 108010003272 Hyaluronate lyase Proteins 0.000 description 5
- 102000001974 Hyaluronidases Human genes 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000004952 Polyamide Substances 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 229960005305 adenosine Drugs 0.000 description 5
- 125000001300 boranyl group Chemical group [H]B([H])[*] 0.000 description 5
- 238000007385 chemical modification Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 229960002773 hyaluronidase Drugs 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 230000000149 penetrating effect Effects 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 229920000747 poly(lactic acid) Polymers 0.000 description 5
- 229920002647 polyamide Polymers 0.000 description 5
- 229920001610 polycaprolactone Polymers 0.000 description 5
- 229920000515 polycarbonate Polymers 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 5
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- QXDXBKZJFLRLCM-UAKXSSHOSA-N 5-hydroxyuridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(O)=C1 QXDXBKZJFLRLCM-UAKXSSHOSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102100034235 ELAV-like protein 1 Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108091007780 MiR-122 Proteins 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 4
- 229920002732 Polyanhydride Polymers 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 229920001710 Polyorthoester Polymers 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 229920002396 Polyurea Polymers 0.000 description 4
- 229910052770 Uranium Inorganic materials 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000004945 acylaminoalkyl group Chemical group 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 229920002988 biodegradable polymer Polymers 0.000 description 4
- 239000004621 biodegradable polymer Substances 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 229920006317 cationic polymer Polymers 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 229920000359 diblock copolymer Polymers 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229940099552 hyaluronan Drugs 0.000 description 4
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 108091051828 miR-122 stem-loop Proteins 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 102000028499 poly(A) binding Human genes 0.000 description 4
- 108091023021 poly(A) binding Proteins 0.000 description 4
- 229920000570 polyether Polymers 0.000 description 4
- 229920000193 polymethacrylate Polymers 0.000 description 4
- 229920006324 polyoxymethylene Polymers 0.000 description 4
- 229920001299 polypropylene fumarate Polymers 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- CDQXHVDVGLVACE-UHFFFAOYSA-N propan-2-amine Chemical compound [CH2]C(C)N CDQXHVDVGLVACE-UHFFFAOYSA-N 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 150000003230 pyrimidines Chemical class 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 150000003290 ribose derivatives Chemical class 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- 239000002047 solid lipid nanoparticle Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 229940113082 thymine Drugs 0.000 description 4
- MPDKOGQMQLSNOF-GBNDHIKLSA-N 2-amino-5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrimidin-6-one Chemical compound O=C1NC(N)=NC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 MPDKOGQMQLSNOF-GBNDHIKLSA-N 0.000 description 3
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 3
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 3
- 101800002011 Amphipathic peptide Proteins 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108091027757 Deoxyribozyme Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 3
- 108091093094 Glycol nucleic acid Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 229920001273 Polyhydroxy acid Polymers 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
- 108091000106 RNA cap binding Proteins 0.000 description 3
- 102000028391 RNA cap binding Human genes 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- MVCRZALXJBDOKF-JPZHCBQBSA-N beta-hydroxywybutosine 5'-monophosphate Chemical compound C1=NC=2C(=O)N3C(CC(O)[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O MVCRZALXJBDOKF-JPZHCBQBSA-N 0.000 description 3
- 150000001721 carbon Chemical class 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000010575 fractional recrystallization Methods 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- BYSGBSNPRWKUQH-UJDJLXLFSA-N glycogen Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000004682 mucosal barrier function Effects 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 150000004713 phosphodiesters Chemical class 0.000 description 3
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001432 poly(L-lactide) Polymers 0.000 description 3
- 229920002627 poly(phosphazenes) Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000002342 ribonucleoside Substances 0.000 description 3
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000012385 systemic delivery Methods 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- OMDMTHRBGUBUCO-IUCAKERBSA-N (1s,5s)-5-(2-hydroxypropan-2-yl)-2-methylcyclohex-2-en-1-ol Chemical compound CC1=CC[C@H](C(C)(C)O)C[C@@H]1O OMDMTHRBGUBUCO-IUCAKERBSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- YZSZLBRBVWAXFW-LNYQSQCFSA-N (2R,3R,4S,5R)-2-(2-amino-6-hydroxy-6-methoxy-3H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1(O)NC(N)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YZSZLBRBVWAXFW-LNYQSQCFSA-N 0.000 description 2
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 2
- KYJLJOJCMUFWDY-UUOKFMHZSA-N (2r,3r,4s,5r)-2-(6-amino-8-azidopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound [N-]=[N+]=NC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KYJLJOJCMUFWDY-UUOKFMHZSA-N 0.000 description 2
- MYUOTPIQBPUQQU-CKTDUXNWSA-N (2s,3r)-2-amino-n-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-methylsulfanylpurin-6-yl]carbamoyl]-3-hydroxybutanamide Chemical compound C12=NC(SC)=NC(NC(=O)NC(=O)[C@@H](N)[C@@H](C)O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MYUOTPIQBPUQQU-CKTDUXNWSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- OYTVCAGSWWRUII-DWJKKKFUSA-N 1-Methyl-1-deazapseudouridine Chemical compound CC1C=C(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O OYTVCAGSWWRUII-DWJKKKFUSA-N 0.000 description 2
- MIXBUOXRHTZHKR-XUTVFYLZSA-N 1-Methylpseudoisocytidine Chemical compound CN1C=C(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O MIXBUOXRHTZHKR-XUTVFYLZSA-N 0.000 description 2
- KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 description 2
- UTQUILVPBZEHTK-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-methylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UTQUILVPBZEHTK-ZOQUXTDFSA-N 0.000 description 2
- HXVKEKIORVUWDR-FDDDBJFASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(methylaminomethyl)-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(CNC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HXVKEKIORVUWDR-FDDDBJFASA-N 0.000 description 2
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 2
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 2
- GUNOEKASBVILNS-UHFFFAOYSA-N 1-methyl-1-deaza-pseudoisocytidine Chemical compound CC(C=C1C(C2O)OC(CO)C2O)=C(N)NC1=O GUNOEKASBVILNS-UHFFFAOYSA-N 0.000 description 2
- GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 description 2
- UTAIYTHAJQNQDW-KQYNXXCUSA-N 1-methylguanosine Chemical compound C1=NC=2C(=O)N(C)C(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UTAIYTHAJQNQDW-KQYNXXCUSA-N 0.000 description 2
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 2
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical class C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 2
- UZYQSNQJLWTICD-UHFFFAOYSA-N 2-(n-benzoylanilino)-2,2-dinitroacetic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)O)([N+]([O-])=O)[N+]([O-])=O)C(=O)C1=CC=CC=C1 UZYQSNQJLWTICD-UHFFFAOYSA-N 0.000 description 2
- BVLGKOVALHRKNM-XUTVFYLZSA-N 2-Thio-1-methylpseudouridine Chemical compound CN1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O BVLGKOVALHRKNM-XUTVFYLZSA-N 0.000 description 2
- CWXIOHYALLRNSZ-JWMKEVCDSA-N 2-Thiodihydropseudouridine Chemical compound C1C(C(=O)NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O CWXIOHYALLRNSZ-JWMKEVCDSA-N 0.000 description 2
- NUBJGTNGKODGGX-YYNOVJQHSA-N 2-[5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-1-yl]acetic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CN(CC(O)=O)C(=O)NC1=O NUBJGTNGKODGGX-YYNOVJQHSA-N 0.000 description 2
- VJKJOPUEUOTEBX-TURQNECASA-N 2-[[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl]methylamino]ethanesulfonic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CNCCS(O)(=O)=O)=C1 VJKJOPUEUOTEBX-TURQNECASA-N 0.000 description 2
- LCKIHCRZXREOJU-KYXWUPHJSA-N 2-[[5-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-1-yl]methylamino]ethanesulfonic acid Chemical compound C(NCCS(=O)(=O)O)N1C=C([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C(NC1=O)=O LCKIHCRZXREOJU-KYXWUPHJSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- OTDJAMXESTUWLO-UUOKFMHZSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-3H-purine-6-thione Chemical compound C12=NC(N)=NC(S)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OTDJAMXESTUWLO-UUOKFMHZSA-N 0.000 description 2
- HPKQEMIXSLRGJU-UUOKFMHZSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-methyl-3h-purine-6,8-dione Chemical compound O=C1N(C)C(C(NC(N)=N2)=O)=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HPKQEMIXSLRGJU-UUOKFMHZSA-N 0.000 description 2
- PBFLIOAJBULBHI-JJNLEZRASA-N 2-amino-n-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]carbamoyl]acetamide Chemical compound C1=NC=2C(NC(=O)NC(=O)CN)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O PBFLIOAJBULBHI-JJNLEZRASA-N 0.000 description 2
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 2
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 2
- VKNASXZDGZNEDA-UHFFFAOYSA-N 2-cyanoethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC#N VKNASXZDGZNEDA-UHFFFAOYSA-N 0.000 description 2
- SFPNZPQIIAJXGL-UHFFFAOYSA-N 2-ethoxyethyl 2-methylprop-2-enoate Chemical class CCOCCOC(=O)C(C)=C SFPNZPQIIAJXGL-UHFFFAOYSA-N 0.000 description 2
- RLZMYTZDQAVNIN-ZOQUXTDFSA-N 2-methoxy-4-thio-uridine Chemical compound COC1=NC(=S)C=CN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O RLZMYTZDQAVNIN-ZOQUXTDFSA-N 0.000 description 2
- QCPQCJVQJKOKMS-VLSMUFELSA-N 2-methoxy-5-methyl-cytidine Chemical compound CC(C(N)=N1)=CN([C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)C1OC QCPQCJVQJKOKMS-VLSMUFELSA-N 0.000 description 2
- TUDKBZAMOFJOSO-UHFFFAOYSA-N 2-methoxy-7h-purin-6-amine Chemical compound COC1=NC(N)=C2NC=NC2=N1 TUDKBZAMOFJOSO-UHFFFAOYSA-N 0.000 description 2
- STISOQJGVFEOFJ-MEVVYUPBSA-N 2-methoxy-cytidine Chemical compound COC(N([C@@H]([C@@H]1O)O[C@H](CO)[C@H]1O)C=C1)N=C1N STISOQJGVFEOFJ-MEVVYUPBSA-N 0.000 description 2
- WBVPJIKOWUQTSD-ZOQUXTDFSA-N 2-methoxyuridine Chemical compound COC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 WBVPJIKOWUQTSD-ZOQUXTDFSA-N 0.000 description 2
- FXGXEFXCWDTSQK-UHFFFAOYSA-N 2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(N)=C2NC=NC2=N1 FXGXEFXCWDTSQK-UHFFFAOYSA-N 0.000 description 2
- VZQXUWKZDSEQRR-SDBHATRESA-N 2-methylthio-N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C12=NC(SC)=NC(NCC=C(C)C)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VZQXUWKZDSEQRR-SDBHATRESA-N 0.000 description 2
- QEWSGVMSLPHELX-UHFFFAOYSA-N 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine Chemical compound C12=NC(SC)=NC(NCC=C(C)CO)=C2N=CN1C1OC(CO)C(O)C1O QEWSGVMSLPHELX-UHFFFAOYSA-N 0.000 description 2
- JUMHLCXWYQVTLL-KVTDHHQDSA-N 2-thio-5-aza-uridine Chemical compound [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C(=S)NC(=O)N=C1 JUMHLCXWYQVTLL-KVTDHHQDSA-N 0.000 description 2
- VRVXMIJPUBNPGH-XVFCMESISA-N 2-thio-dihydrouridine Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)NC1=S VRVXMIJPUBNPGH-XVFCMESISA-N 0.000 description 2
- ZVGONGHIVBJXFC-WCTZXXKLSA-N 2-thio-zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)N=CC=C1 ZVGONGHIVBJXFC-WCTZXXKLSA-N 0.000 description 2
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 2
- RDPUKVRQKWBSPK-UHFFFAOYSA-N 3-Methylcytidine Natural products O=C1N(C)C(=N)C=CN1C1C(O)C(O)C(CO)O1 RDPUKVRQKWBSPK-UHFFFAOYSA-N 0.000 description 2
- UTQUILVPBZEHTK-UHFFFAOYSA-N 3-Methyluridine Natural products O=C1N(C)C(=O)C=CN1C1C(O)C(O)C(CO)O1 UTQUILVPBZEHTK-UHFFFAOYSA-N 0.000 description 2
- BINGDNLMMYSZFR-QYVSTXNMSA-N 3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,7-dimethyl-5h-imidazo[1,2-a]purin-9-one Chemical compound C1=NC=2C(=O)N3C(C)=C(C)N=C3NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BINGDNLMMYSZFR-QYVSTXNMSA-N 0.000 description 2
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 2
- RDPUKVRQKWBSPK-ZOQUXTDFSA-N 3-methylcytidine Chemical compound O=C1N(C)C(=N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RDPUKVRQKWBSPK-ZOQUXTDFSA-N 0.000 description 2
- FGFVODMBKZRMMW-XUTVFYLZSA-N 4-Methoxy-2-thiopseudouridine Chemical compound COC1=C(C=NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O FGFVODMBKZRMMW-XUTVFYLZSA-N 0.000 description 2
- HOCJTJWYMOSXMU-XUTVFYLZSA-N 4-Methoxypseudouridine Chemical compound COC1=C(C=NC(=O)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O HOCJTJWYMOSXMU-XUTVFYLZSA-N 0.000 description 2
- VTGBLFNEDHVUQA-XUTVFYLZSA-N 4-Thio-1-methyl-pseudouridine Chemical compound S=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 VTGBLFNEDHVUQA-XUTVFYLZSA-N 0.000 description 2
- OCMSXKMNYAHJMU-JXOAFFINSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidine-5-carbaldehyde Chemical compound C1=C(C=O)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 OCMSXKMNYAHJMU-JXOAFFINSA-N 0.000 description 2
- OZHIJZYBTCTDQC-JXOAFFINSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2-thione Chemical compound S=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 OZHIJZYBTCTDQC-JXOAFFINSA-N 0.000 description 2
- QUZQVVNSDQCAOL-WOUKDFQISA-N 4-demethylwyosine Chemical compound N1C(C)=CN(C(C=2N=C3)=O)C1=NC=2N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QUZQVVNSDQCAOL-WOUKDFQISA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- LOICBOXHPCURMU-UHFFFAOYSA-N 4-methoxy-pseudoisocytidine Chemical compound COC1NC(N)=NC=C1C(C1O)OC(CO)C1O LOICBOXHPCURMU-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- SJVVKUMXGIKAAI-UHFFFAOYSA-N 4-thio-pseudoisocytidine Chemical compound NC(N1)=NC=C(C(C2O)OC(CO)C2O)C1=S SJVVKUMXGIKAAI-UHFFFAOYSA-N 0.000 description 2
- FAWQJBLSWXIJLA-VPCXQMTMSA-N 5-(carboxymethyl)uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CC(O)=O)=C1 FAWQJBLSWXIJLA-VPCXQMTMSA-N 0.000 description 2
- VSCNRXVDHRNJOA-PNHWDRBUSA-N 5-(carboxymethylaminomethyl)uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CNCC(O)=O)=C1 VSCNRXVDHRNJOA-PNHWDRBUSA-N 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 2
- NFEXJLMYXXIWPI-JXOAFFINSA-N 5-Hydroxymethylcytidine Chemical compound C1=C(CO)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NFEXJLMYXXIWPI-JXOAFFINSA-N 0.000 description 2
- ITGWEVGJUSMCEA-KYXWUPHJSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(C#CC)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ITGWEVGJUSMCEA-KYXWUPHJSA-N 0.000 description 2
- DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 description 2
- BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 description 2
- XUNBIDXYAUXNKD-DBRKOABJSA-N 5-aza-2-thio-zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)N=CN=C1 XUNBIDXYAUXNKD-DBRKOABJSA-N 0.000 description 2
- OSLBPVOJTCDNEF-DBRKOABJSA-N 5-aza-zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CN=C1 OSLBPVOJTCDNEF-DBRKOABJSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 2
- HLZXTFWTDIBXDF-PNHWDRBUSA-N 5-methoxycarbonylmethyl-2-thiouridine Chemical compound S=C1NC(=O)C(CC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HLZXTFWTDIBXDF-PNHWDRBUSA-N 0.000 description 2
- YIZYCHKPHCPKHZ-PNHWDRBUSA-N 5-methoxycarbonylmethyluridine Chemical compound O=C1NC(=O)C(CC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YIZYCHKPHCPKHZ-PNHWDRBUSA-N 0.000 description 2
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 2
- SNNBPMAXGYBMHM-JXOAFFINSA-N 5-methyl-2-thiouridine Chemical compound S=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SNNBPMAXGYBMHM-JXOAFFINSA-N 0.000 description 2
- RPQQZHJQUBDHHG-FNCVBFRFSA-N 5-methyl-zebularine Chemical compound C1=C(C)C=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RPQQZHJQUBDHHG-FNCVBFRFSA-N 0.000 description 2
- USVMJSALORZVDV-UHFFFAOYSA-N 6-(gamma,gamma-dimethylallylamino)purine riboside Natural products C1=NC=2C(NCC=C(C)C)=NC=NC=2N1C1OC(CO)C(O)C1O USVMJSALORZVDV-UHFFFAOYSA-N 0.000 description 2
- OZTOEARQSSIFOG-MWKIOEHESA-N 6-Thio-7-deaza-8-azaguanosine Chemical compound Nc1nc(=S)c2cnn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1 OZTOEARQSSIFOG-MWKIOEHESA-N 0.000 description 2
- CBNRZZNSRJQZNT-IOSLPCCCSA-O 6-thio-7-deaza-guanosine Chemical compound CC1=C[NH+]([C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)C(NC(N)=N2)=C1C2=S CBNRZZNSRJQZNT-IOSLPCCCSA-O 0.000 description 2
- RFHIWBUKNJIBSE-KQYNXXCUSA-O 6-thio-7-methyl-guanosine Chemical compound C1=2NC(N)=NC(=S)C=2N(C)C=[N+]1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RFHIWBUKNJIBSE-KQYNXXCUSA-O 0.000 description 2
- MJJUWOIBPREHRU-MWKIOEHESA-N 7-Deaza-8-azaguanosine Chemical compound NC=1NC(C2=C(N=1)N(N=C2)[C@H]1[C@H](O)[C@H](O)[C@H](O1)CO)=O MJJUWOIBPREHRU-MWKIOEHESA-N 0.000 description 2
- ISSMDAFGDCTNDV-UHFFFAOYSA-N 7-deaza-2,6-diaminopurine Chemical compound NC1=NC(N)=C2NC=CC2=N1 ISSMDAFGDCTNDV-UHFFFAOYSA-N 0.000 description 2
- YVVMIGRXQRPSIY-UHFFFAOYSA-N 7-deaza-2-aminopurine Chemical compound N1C(N)=NC=C2C=CN=C21 YVVMIGRXQRPSIY-UHFFFAOYSA-N 0.000 description 2
- ZTAWTRPFJHKMRU-UHFFFAOYSA-N 7-deaza-8-aza-2,6-diaminopurine Chemical compound NC1=NC(N)=C2NN=CC2=N1 ZTAWTRPFJHKMRU-UHFFFAOYSA-N 0.000 description 2
- SMXRCJBCWRHDJE-UHFFFAOYSA-N 7-deaza-8-aza-2-aminopurine Chemical compound NC1=NC=C2C=NNC2=N1 SMXRCJBCWRHDJE-UHFFFAOYSA-N 0.000 description 2
- LHCPRYRLDOSKHK-UHFFFAOYSA-N 7-deaza-8-aza-adenine Chemical compound NC1=NC=NC2=C1C=NN2 LHCPRYRLDOSKHK-UHFFFAOYSA-N 0.000 description 2
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 2
- VJNXUFOTKNTNPG-IOSLPCCCSA-O 7-methylinosine Chemical compound C1=2NC=NC(=O)C=2N(C)C=[N+]1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VJNXUFOTKNTNPG-IOSLPCCCSA-O 0.000 description 2
- ABXGJJVKZAAEDH-IOSLPCCCSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-(dimethylamino)-3h-purine-6-thione Chemical compound C1=NC=2C(=S)NC(N(C)C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ABXGJJVKZAAEDH-IOSLPCCCSA-N 0.000 description 2
- ADPMAYFIIFNDMT-KQYNXXCUSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-(methylamino)-3h-purine-6-thione Chemical compound C1=NC=2C(=S)NC(NC)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ADPMAYFIIFNDMT-KQYNXXCUSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 2
- 102100031786 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 102000049320 CD36 Human genes 0.000 description 2
- 108010045374 CD36 Antigens Proteins 0.000 description 2
- 241000710777 Classical swine fever virus Species 0.000 description 2
- 241000710127 Cricket paralysis virus Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- YKWUPFSEFXSGRT-JWMKEVCDSA-N Dihydropseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1C(=O)NC(=O)NC1 YKWUPFSEFXSGRT-JWMKEVCDSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000711557 Hepacivirus Species 0.000 description 2
- 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 description 2
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 2
- 241001546602 Horismenus Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 108091028066 Mir-126 Proteins 0.000 description 2
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100032970 Myogenin Human genes 0.000 description 2
- 108010056785 Myogenin Proteins 0.000 description 2
- RSPURTUNRHNVGF-IOSLPCCCSA-N N(2),N(2)-dimethylguanosine Chemical compound C1=NC=2C(=O)NC(N(C)C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RSPURTUNRHNVGF-IOSLPCCCSA-N 0.000 description 2
- ZBYRSRLCXTUFLJ-IOSLPCCCSA-O N(2),N(7)-dimethylguanosine Chemical compound CNC=1NC(C=2[N+](=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C=2N=1)C)=O ZBYRSRLCXTUFLJ-IOSLPCCCSA-O 0.000 description 2
- SLEHROROQDYRAW-KQYNXXCUSA-N N(2)-methylguanosine Chemical compound C1=NC=2C(=O)NC(NC)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SLEHROROQDYRAW-KQYNXXCUSA-N 0.000 description 2
- WVGPGNPCZPYCLK-WOUKDFQISA-N N(6),N(6)-dimethyladenosine Chemical compound C1=NC=2C(N(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WVGPGNPCZPYCLK-WOUKDFQISA-N 0.000 description 2
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 2
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
- WVGPGNPCZPYCLK-UHFFFAOYSA-N N-Dimethyladenosine Natural products C1=NC=2C(N(C)C)=NC=NC=2N1C1OC(CO)C(O)C1O WVGPGNPCZPYCLK-UHFFFAOYSA-N 0.000 description 2
- UNUYMBPXEFMLNW-DWVDDHQFSA-N N-[(9-beta-D-ribofuranosylpurin-6-yl)carbamoyl]threonine Chemical compound C1=NC=2C(NC(=O)N[C@@H]([C@H](O)C)C(O)=O)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UNUYMBPXEFMLNW-DWVDDHQFSA-N 0.000 description 2
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 2
- LZCNWAXLJWBRJE-ZOQUXTDFSA-N N4-Methylcytidine Chemical compound O=C1N=C(NC)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LZCNWAXLJWBRJE-ZOQUXTDFSA-N 0.000 description 2
- GOSWTRUMMSCNCW-UHFFFAOYSA-N N6-(cis-hydroxyisopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1OC(CO)C(O)C1O GOSWTRUMMSCNCW-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229920005689 PLLA-PGA Polymers 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 229940022005 RNA vaccine Drugs 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 2
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- JCZSFCLRSONYLH-UHFFFAOYSA-N Wyosine Natural products N=1C(C)=CN(C(C=2N=C3)=O)C=1N(C)C=2N3C1OC(CO)C(O)C1O JCZSFCLRSONYLH-UHFFFAOYSA-N 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000003838 adenosines Chemical class 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 108010067396 dornase alfa Proteins 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 229940044700 hylenex Drugs 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 210000003093 intracellular space Anatomy 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 108091023663 let-7 stem-loop Proteins 0.000 description 2
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 2
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 108700021021 mRNA Vaccine Proteins 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- XOTXNXXJZCFUOA-UGKPPGOTSA-N methyl 2-[1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-2,4-dioxopyrimidin-5-yl]acetate Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CC(=O)OC)=C1 XOTXNXXJZCFUOA-UGKPPGOTSA-N 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 108091023685 miR-133 stem-loop Proteins 0.000 description 2
- 108091079658 miR-142-1 stem-loop Proteins 0.000 description 2
- 108091071830 miR-142-2 stem-loop Proteins 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229920006030 multiblock copolymer Polymers 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- MAFHEURJBRFHIT-YEUCEMRASA-N n,n-dimethyl-1,2-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(C)C(N(C)C)OCCCCCCCC\C=C/CCCCCCCC MAFHEURJBRFHIT-YEUCEMRASA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 150000002972 pentoses Chemical class 0.000 description 2
- 150000008298 phosphoramidates Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 229920000962 poly(amidoamine) Polymers 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 229920002714 polyornithine Polymers 0.000 description 2
- 108010055896 polyornithine Proteins 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 125000004219 purine nucleobase group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 2
- JRPHGDYSKGJTKZ-UHFFFAOYSA-N selenophosphoric acid Chemical class OP(O)([SeH])=O JRPHGDYSKGJTKZ-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 229940063673 spermidine Drugs 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 229920000428 triblock copolymer Polymers 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229960003636 vidarabine Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 2
- QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 2
- JCZSFCLRSONYLH-QYVSTXNMSA-N wyosin Chemical compound N=1C(C)=CN(C(C=2N=C3)=O)C=1N(C)C=2N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JCZSFCLRSONYLH-QYVSTXNMSA-N 0.000 description 2
- RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FEYSZYNQSA-N β-dextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)C(O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FEYSZYNQSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical group CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- FWZOXUYXRMSMKT-AUGURXLVSA-N (12z,15z)-n,n-dimethyl-2-nonylhenicosa-12,15-dien-1-amine Chemical compound CCCCCCCCCC(CN(C)C)CCCCCCCCC\C=C/C\C=C/CCCCC FWZOXUYXRMSMKT-AUGURXLVSA-N 0.000 description 1
- DFLGHUGIWAYXFV-XVTLYKPTSA-N (12z,15z)-n,n-dimethylhenicosa-12,15-dien-4-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(N(C)C)CCC DFLGHUGIWAYXFV-XVTLYKPTSA-N 0.000 description 1
- SYPDLJYRMSBNEX-AUGURXLVSA-N (13z,16z)-n,n-dimethyl-3-nonyldocosa-13,16-dien-1-amine Chemical compound CCCCCCCCCC(CCN(C)C)CCCCCCCCC\C=C/C\C=C/CCCCC SYPDLJYRMSBNEX-AUGURXLVSA-N 0.000 description 1
- VKRSOPFWJRDTME-HDXUUTQWSA-N (13z,16z)-n,n-dimethyldocosa-13,16-dien-5-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(N(C)C)CCCC VKRSOPFWJRDTME-HDXUUTQWSA-N 0.000 description 1
- BZZLBAMHZHKRFK-XVTLYKPTSA-N (14z,17z)-n,n-dimethyltricosa-14,17-dien-4-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCCC(N(C)C)CCC BZZLBAMHZHKRFK-XVTLYKPTSA-N 0.000 description 1
- MRGAZQLDRACERW-HDXUUTQWSA-N (14z,17z)-n,n-dimethyltricosa-14,17-dien-6-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(N(C)C)CCCCC MRGAZQLDRACERW-HDXUUTQWSA-N 0.000 description 1
- BZRXZULJYFAROV-HDXUUTQWSA-N (15z,18z)-n,n-dimethyltetracosa-15,18-dien-5-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCCC(N(C)C)CCCC BZRXZULJYFAROV-HDXUUTQWSA-N 0.000 description 1
- NYRYVZIUPOHALZ-QGLGPCELSA-N (15z,18z)-n,n-dimethyltetracosa-15,18-dien-7-amine Chemical compound CCCCCCC(N(C)C)CCCCCCC\C=C/C\C=C/CCCCC NYRYVZIUPOHALZ-QGLGPCELSA-N 0.000 description 1
- DELUIQJQMCTOCD-HDXUUTQWSA-N (16z,19z)-n,n-dimethylpentacosa-16,19-dien-6-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCCC(N(C)C)CCCCC DELUIQJQMCTOCD-HDXUUTQWSA-N 0.000 description 1
- DGQYVBDAVMYDJC-QGLGPCELSA-N (17z,20z)-n,n-dimethylhexacosa-17,20-dien-7-amine Chemical compound CCCCCCC(N(C)C)CCCCCCCCC\C=C/C\C=C/CCCCC DGQYVBDAVMYDJC-QGLGPCELSA-N 0.000 description 1
- FFEFKDZFCYQVMR-AUGURXLVSA-N (18z,21z)-n,n-dimethylheptacosa-18,21-dien-10-amine Chemical compound CCCCCCCCCC(N(C)C)CCCCCCC\C=C/C\C=C/CCCCC FFEFKDZFCYQVMR-AUGURXLVSA-N 0.000 description 1
- PQCKBHAUVIAIRC-QGLGPCELSA-N (18z,21z)-n,n-dimethylheptacosa-18,21-dien-8-amine Chemical compound CCCCCCCC(N(C)C)CCCCCCCCC\C=C/C\C=C/CCCCC PQCKBHAUVIAIRC-QGLGPCELSA-N 0.000 description 1
- ZFQNFOUTWXVNBG-QGLGPCELSA-N (19z,22z)-n,n-dimethyloctacosa-19,22-dien-7-amine Chemical compound CCCCCCC(N(C)C)CCCCCCCCCCC\C=C/C\C=C/CCCCC ZFQNFOUTWXVNBG-QGLGPCELSA-N 0.000 description 1
- POBBAOCNGBEZJQ-AUGURXLVSA-N (20z,23z)-n,n-dimethylnonacosa-20,23-dien-10-amine Chemical compound CCCCCCCCCC(N(C)C)CCCCCCCCC\C=C/C\C=C/CCCCC POBBAOCNGBEZJQ-AUGURXLVSA-N 0.000 description 1
- IHKVCZISZBWDEJ-NFYLBXPESA-N (20z,23z)-n-ethyl-n-methylnonacosa-20,23-dien-10-amine Chemical compound CCCCCCCCCC(N(C)CC)CCCCCCCCC\C=C/C\C=C/CCCCC IHKVCZISZBWDEJ-NFYLBXPESA-N 0.000 description 1
- GRQMMQSAFMPMNM-AUGURXLVSA-N (21z,24z)-n,n-dimethyltriaconta-21,24-dien-9-amine Chemical compound CCCCCCCCC(N(C)C)CCCCCCCCCCC\C=C/C\C=C/CCCCC GRQMMQSAFMPMNM-AUGURXLVSA-N 0.000 description 1
- FVHCEZRYPCZLAX-AUGURXLVSA-N (22z,25z)-n,n-dimethylhentriaconta-22,25-dien-10-amine Chemical compound CCCCCCCCCC(N(C)C)CCCCCCCCCCC\C=C/C\C=C/CCCCC FVHCEZRYPCZLAX-AUGURXLVSA-N 0.000 description 1
- JDQVUHMYUPHIKQ-OUVOGOSVSA-N (2r)-1-(3,7-dimethyloctoxy)-n,n-dimethyl-3-[(9z,12z)-octadeca-9,12-dienoxy]propan-2-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOC[C@@H](N(C)C)COCCC(C)CCCC(C)C JDQVUHMYUPHIKQ-OUVOGOSVSA-N 0.000 description 1
- PAHBLXLIQGGJOF-YZVUUIKASA-N (2r)-n,n-dimethyl-1-[(9z,12z)-octadeca-9,12-dienoxy]-3-octoxypropan-2-amine Chemical compound CCCCCCCCOC[C@@H](N(C)C)COCCCCCCCC\C=C/C\C=C/CCCCC PAHBLXLIQGGJOF-YZVUUIKASA-N 0.000 description 1
- MQECTKDGEQSNNL-UMCMBGNQSA-N (2r,3r,4s,5r)-2-[6-(14-aminotetradecoxyperoxyperoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NOOOOOCCCCCCCCCCCCCCN)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MQECTKDGEQSNNL-UMCMBGNQSA-N 0.000 description 1
- UUDVSZSQPFXQQM-GIWSHQQXSA-N (2r,3s,4r,5r)-2-(6-aminopurin-9-yl)-3-fluoro-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)F UUDVSZSQPFXQQM-GIWSHQQXSA-N 0.000 description 1
- PHFMCMDFWSZKGD-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(methylamino)-2-methylsulfanylpurin-9-yl]oxolane-3,4-diol Chemical compound C1=NC=2C(NC)=NC(SC)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O PHFMCMDFWSZKGD-IOSLPCCCSA-N 0.000 description 1
- RAUUWSIWMBUIDV-VTMHRMHWSA-N (2s)-1-[(13z,16z)-docosa-13,16-dienoxy]-3-hexoxy-n,n-dimethylpropan-2-amine Chemical compound CCCCCCOC[C@H](N(C)C)COCCCCCCCCCCCC\C=C/C\C=C/CCCCC RAUUWSIWMBUIDV-VTMHRMHWSA-N 0.000 description 1
- HAIDSQUTIAIJPL-DKMWFJCXSA-N (2s)-1-heptoxy-n,n-dimethyl-3-[(9z,12z)-octadeca-9,12-dienoxy]propan-2-amine Chemical compound CCCCCCCOC[C@H](N(C)C)COCCCCCCCC\C=C/C\C=C/CCCCC HAIDSQUTIAIJPL-DKMWFJCXSA-N 0.000 description 1
- QNHQHPALHHOYJN-QYZAPVBRSA-N (2s)-1-hexoxy-n,n-dimethyl-3-[(9z,12z)-octadeca-9,12-dienoxy]propan-2-amine Chemical compound CCCCCCOC[C@H](N(C)C)COCCCCCCCC\C=C/C\C=C/CCCCC QNHQHPALHHOYJN-QYZAPVBRSA-N 0.000 description 1
- DRHHGDVXDOGFPJ-GZEYTEAUSA-N (2s)-n,n-dimethyl-1-[(6z,9z,12z)-octadeca-6,9,12-trienoxy]-3-octoxypropan-2-amine Chemical compound CCCCCCCCOC[C@H](N(C)C)COCCCCC\C=C/C\C=C/C\C=C/CCCCC DRHHGDVXDOGFPJ-GZEYTEAUSA-N 0.000 description 1
- RSZMLBIJWSQOHJ-LXMBQAHYSA-N (2s)-n,n-dimethyl-1-[(9z,12z)-octadeca-9,12-dienoxy]-3-[(z)-oct-5-enoxy]propan-2-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOC[C@H](N(C)C)COCCCC\C=C/CC RSZMLBIJWSQOHJ-LXMBQAHYSA-N 0.000 description 1
- GPTUGCGYEMEAOC-IBZYUGMLSA-N (2s,3r)-2-amino-n-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]-methylcarbamoyl]-3-hydroxybutanamide Chemical compound C1=NC=2C(N(C)C(=O)NC(=O)[C@@H](N)[C@H](O)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GPTUGCGYEMEAOC-IBZYUGMLSA-N 0.000 description 1
- KHWUKFBQNNLWIV-KPNWGBFJSA-N (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol hydrochloride Chemical compound Cl.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 KHWUKFBQNNLWIV-KPNWGBFJSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- MISZWZHGSSSVEE-MSUUIHNZSA-N (z)-n,n-dimethylhentriacont-22-en-10-amine Chemical compound CCCCCCCCCC(N(C)C)CCCCCCCCCCC\C=C/CCCCCCCC MISZWZHGSSSVEE-MSUUIHNZSA-N 0.000 description 1
- VAEPXOIOCOVXOD-GYHWCHFESA-N (z)-n,n-dimethylnonacos-14-en-10-amine Chemical compound CCCCCCCCCCCCCC\C=C/CCCC(N(C)C)CCCCCCCCC VAEPXOIOCOVXOD-GYHWCHFESA-N 0.000 description 1
- GOSOKZSRSXUCAH-VXPUYCOJSA-N (z)-n,n-dimethylnonacos-17-en-10-amine Chemical compound CCCCCCCCCCC\C=C/CCCCCCC(N(C)C)CCCCCCCCC GOSOKZSRSXUCAH-VXPUYCOJSA-N 0.000 description 1
- PPDDFVKQPSPFAB-MSUUIHNZSA-N (z)-n,n-dimethyltritriacont-24-en-10-amine Chemical compound CCCCCCCCCC(N(C)C)CCCCCCCCCCCCC\C=C/CCCCCCCC PPDDFVKQPSPFAB-MSUUIHNZSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- UHUSDOQQWJGJQS-QNGWXLTQSA-N 1,2-dioctadecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-QNGWXLTQSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- JEJLGIQLPYYGEE-XIFFEERXSA-N 1,2-dipalmitoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCCCC JEJLGIQLPYYGEE-XIFFEERXSA-N 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- KRNRCQZJTZWJBO-AUGURXLVSA-N 1-[(13z,16z)-docosa-13,16-dienoxy]-n,n-dimethyl-3-octoxypropan-2-amine Chemical compound CCCCCCCCOCC(N(C)C)COCCCCCCCCCCCC\C=C/C\C=C/CCCCC KRNRCQZJTZWJBO-AUGURXLVSA-N 0.000 description 1
- RVUPPLIHRLAJRN-RAVAVGQKSA-N 1-[(1s,2r)-2-decylcyclopropyl]-n,n-dimethylpentadecan-6-amine Chemical compound CCCCCCCCCC[C@@H]1C[C@@H]1CCCCCC(CCCCCCCCC)N(C)C RVUPPLIHRLAJRN-RAVAVGQKSA-N 0.000 description 1
- NPYMBZKQBLXICH-RAVAVGQKSA-N 1-[(1s,2r)-2-hexylcyclopropyl]-n,n-dimethylnonadecan-10-amine Chemical compound CCCCCCCCCC(N(C)C)CCCCCCCCC[C@H]1C[C@H]1CCCCCC NPYMBZKQBLXICH-RAVAVGQKSA-N 0.000 description 1
- BGOKOAWPGAZSES-RGCMKSIDSA-N 1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-5-[(3-methylbut-3-enylamino)methyl]pyrimidine-2,4-dione Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CNCCC(C)=C)=C1 BGOKOAWPGAZSES-RGCMKSIDSA-N 0.000 description 1
- VGHXKGWSRNEDEP-OJKLQORTSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidine-5-carboxylic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)N1C(=O)NC(=O)C(C(O)=O)=C1 VGHXKGWSRNEDEP-OJKLQORTSA-N 0.000 description 1
- XIJAZGMFHRTBFY-FDDDBJFASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-$l^{1}-selanyl-5-(methylaminomethyl)pyrimidin-4-one Chemical compound [Se]C1=NC(=O)C(CNC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XIJAZGMFHRTBFY-FDDDBJFASA-N 0.000 description 1
- KJLRIEFCMSGNSI-HKUMRIAESA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(3-methylbut-3-enylamino)methyl]-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(CNCCC(=C)C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 KJLRIEFCMSGNSI-HKUMRIAESA-N 0.000 description 1
- HLBIEOQUEHEDCR-HKUMRIAESA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(3-methylbut-3-enylamino)methyl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(CNCCC(=C)C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HLBIEOQUEHEDCR-HKUMRIAESA-N 0.000 description 1
- BTFXIEGOSDSOGN-KWCDMSRLSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,3-diazinane-2,4-dione Chemical compound O=C1NC(=O)C(C)CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 BTFXIEGOSDSOGN-KWCDMSRLSA-N 0.000 description 1
- QPHRQMAYYMYWFW-FJGDRVTGSA-N 1-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 QPHRQMAYYMYWFW-FJGDRVTGSA-N 0.000 description 1
- NAOQDUDLOGYDBP-PFONDFGASA-N 1-[(z)-hexadec-9-enoxy]-n,n-dimethyl-3-octoxypropan-2-amine Chemical compound CCCCCCCCOCC(N(C)C)COCCCCCCCC\C=C/CCCCCC NAOQDUDLOGYDBP-PFONDFGASA-N 0.000 description 1
- USYGWEGVUBMGKV-HDXUUTQWSA-N 1-[1-[(9z,12z)-octadeca-9,12-dienoxy]-3-octoxypropan-2-yl]azetidine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(COCCCCCCCC)N1CCC1 USYGWEGVUBMGKV-HDXUUTQWSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical class OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical compound NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- JCNGYIGHEUKAHK-DWJKKKFUSA-N 2-Thio-1-methyl-1-deazapseudouridine Chemical compound CC1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O JCNGYIGHEUKAHK-DWJKKKFUSA-N 0.000 description 1
- VHXUHQJRMXUOST-PNHWDRBUSA-N 2-[1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-2,4-dioxopyrimidin-5-yl]acetamide Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CC(N)=O)=C1 VHXUHQJRMXUOST-PNHWDRBUSA-N 0.000 description 1
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
- SFFCQAIBJUCFJK-UGKPPGOTSA-N 2-[[1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-2,4-dioxopyrimidin-5-yl]methylamino]acetic acid Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CNCC(O)=O)=C1 SFFCQAIBJUCFJK-UGKPPGOTSA-N 0.000 description 1
- SOEYIPCQNRSIAV-IOSLPCCCSA-N 2-amino-5-(aminomethyl)-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=2NC(N)=NC(=O)C=2C(CN)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SOEYIPCQNRSIAV-IOSLPCCCSA-N 0.000 description 1
- BIRQNXWAXWLATA-IOSLPCCCSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-oxo-1h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound C1=C(C#N)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BIRQNXWAXWLATA-IOSLPCCCSA-N 0.000 description 1
- OZNBTMLHSVZFLR-GWTDSMLYSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;6-amino-1h-pyrimidin-2-one Chemical compound NC=1C=CNC(=O)N=1.C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OZNBTMLHSVZFLR-GWTDSMLYSA-N 0.000 description 1
- VWSLLSXLURJCDF-UHFFFAOYSA-N 2-methyl-4,5-dihydro-1h-imidazole Chemical compound CC1=NCCN1 VWSLLSXLURJCDF-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- FZIIBDOXPQOKBP-UHFFFAOYSA-N 2-methyloxetane Chemical compound CC1CCO1 FZIIBDOXPQOKBP-UHFFFAOYSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- YXNIEZJFCGTDKV-JANFQQFMSA-N 3-(3-amino-3-carboxypropyl)uridine Chemical compound O=C1N(CCC(N)C(O)=O)C(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YXNIEZJFCGTDKV-JANFQQFMSA-N 0.000 description 1
- DXEJZRDJXRVUPN-XUTVFYLZSA-N 3-Methylpseudouridine Chemical compound O=C1N(C)C(=O)NC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DXEJZRDJXRVUPN-XUTVFYLZSA-N 0.000 description 1
- HOEIPINIBKBXTJ-IDTAVKCVSA-N 3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4,6,7-trimethylimidazo[1,2-a]purin-9-one Chemical compound C1=NC=2C(=O)N3C(C)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOEIPINIBKBXTJ-IDTAVKCVSA-N 0.000 description 1
- UFQDKRWQSFLPQY-UHFFFAOYSA-N 4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound Cl.C1CN=CN1 UFQDKRWQSFLPQY-UHFFFAOYSA-N 0.000 description 1
- CNJLMVZFWLNOEP-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[4.1.0]heptan-5-one Chemical compound O=C1C(C)CCC2C(C)(C)C12 CNJLMVZFWLNOEP-UHFFFAOYSA-N 0.000 description 1
- ZSIINYPBPQCZKU-BQNZPOLKSA-O 4-Methoxy-1-methylpseudoisocytidine Chemical compound C[N+](CC1[C@H]([C@H]2O)O[C@@H](CO)[C@@H]2O)=C(N)N=C1OC ZSIINYPBPQCZKU-BQNZPOLKSA-O 0.000 description 1
- DMUQOPXCCOBPID-XUTVFYLZSA-N 4-Thio-1-methylpseudoisocytidine Chemical compound CN1C=C(C(=S)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O DMUQOPXCCOBPID-XUTVFYLZSA-N 0.000 description 1
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
- WDNZYZQNVCYYON-JNECXHHRSA-N 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one Chemical compound CC=1C(=NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C1)=O)N.CC=1C(=NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C1)=O)N WDNZYZQNVCYYON-JNECXHHRSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- LQQGJDJXUSAEMZ-UAKXSSHOSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one Chemical compound C1=C(I)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LQQGJDJXUSAEMZ-UAKXSSHOSA-N 0.000 description 1
- PJWBTAIPBFWVHX-FJGDRVTGSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@](F)(O)[C@H](O)[C@@H](CO)O1 PJWBTAIPBFWVHX-FJGDRVTGSA-N 0.000 description 1
- GUCPYIYFQVTFSI-UHFFFAOYSA-N 4-methoxybenzamide Chemical compound COC1=CC=C(C(N)=O)C=C1 GUCPYIYFQVTFSI-UHFFFAOYSA-N 0.000 description 1
- GUOCOOQWZHQBJI-UHFFFAOYSA-N 4-oct-7-enoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OCCCCCCC=C GUOCOOQWZHQBJI-UHFFFAOYSA-N 0.000 description 1
- FIWQPTRUVGSKOD-UHFFFAOYSA-N 4-thio-1-methyl-1-deaza-pseudoisocytidine Chemical compound CC(C=C1C(C2O)OC(CO)C2O)=C(N)NC1=S FIWQPTRUVGSKOD-UHFFFAOYSA-N 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- YHRRPHCORALGKQ-UHFFFAOYSA-N 5,2'-O-dimethyluridine Chemical compound COC1C(O)C(CO)OC1N1C(=O)NC(=O)C(C)=C1 YHRRPHCORALGKQ-UHFFFAOYSA-N 0.000 description 1
- ZYEWPVTXYBLWRT-UHFFFAOYSA-N 5-Uridinacetamid Natural products O=C1NC(=O)C(CC(=O)N)=CN1C1C(O)C(O)C(CO)O1 ZYEWPVTXYBLWRT-UHFFFAOYSA-N 0.000 description 1
- OZQDLJNDRVBCST-SHUUEZRQSA-N 5-amino-2-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazin-3-one Chemical compound O=C1N=C(N)C=NN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 OZQDLJNDRVBCST-SHUUEZRQSA-N 0.000 description 1
- LOEDKMLIGFMQKR-JXOAFFINSA-N 5-aminomethyl-2-thiouridine Chemical compound S=C1NC(=O)C(CN)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LOEDKMLIGFMQKR-JXOAFFINSA-N 0.000 description 1
- ZYEWPVTXYBLWRT-VPCXQMTMSA-N 5-carbamoylmethyluridine Chemical compound O=C1NC(=O)C(CC(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZYEWPVTXYBLWRT-VPCXQMTMSA-N 0.000 description 1
- KBDWGFZSICOZSJ-UHFFFAOYSA-N 5-methyl-2,3-dihydro-1H-pyrimidin-4-one Chemical compound N1CNC=C(C1=O)C KBDWGFZSICOZSJ-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- HXVKEKIORVUWDR-UHFFFAOYSA-N 5-methylaminomethyl-2-thiouridine Natural products S=C1NC(=O)C(CNC)=CN1C1C(O)C(O)C(CO)O1 HXVKEKIORVUWDR-UHFFFAOYSA-N 0.000 description 1
- ZXQHKBUIXRFZBV-FDDDBJFASA-N 5-methylaminomethyluridine Chemical compound O=C1NC(=O)C(CNC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXQHKBUIXRFZBV-FDDDBJFASA-N 0.000 description 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 1
- AFWWNHLDHNSVSD-UHFFFAOYSA-N 6-methyl-7h-purin-2-amine Chemical compound CC1=NC(N)=NC2=C1NC=N2 AFWWNHLDHNSVSD-UHFFFAOYSA-N 0.000 description 1
- FMKSMYDYKXQYRV-UHFFFAOYSA-N 7-cyano-7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1C(C#N)=CN2 FMKSMYDYKXQYRV-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
- PEMQXWCOMFJRLS-UHFFFAOYSA-N Archaeosine Natural products C1=2NC(N)=NC(=O)C=2C(C(=N)N)=CN1C1OC(CO)C(O)C1O PEMQXWCOMFJRLS-UHFFFAOYSA-N 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000709756 Barley yellow dwarf virus Species 0.000 description 1
- 241000709750 Barley yellow dwarf virus-PAV Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 241000723363 Clerodendrum Species 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-altritol Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 102000016662 ELAV Proteins Human genes 0.000 description 1
- 108010053101 ELAV Proteins Proteins 0.000 description 1
- 108700037122 EWS-FLI fusion Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 101710091918 Eukaryotic translation initiation factor 4E Proteins 0.000 description 1
- 102100027304 Eukaryotic translation initiation factor 4E Human genes 0.000 description 1
- 101710126428 Eukaryotic translation initiation factor 4E-2 Proteins 0.000 description 1
- 101710126416 Eukaryotic translation initiation factor 4E-3 Proteins 0.000 description 1
- 101710126432 Eukaryotic translation initiation factor 4E1 Proteins 0.000 description 1
- 101710133325 Eukaryotic translation initiation factor NCBP Proteins 0.000 description 1
- 101710190212 Eukaryotic translation initiation factor isoform 4E Proteins 0.000 description 1
- 101710124729 Eukaryotic translation initiation factor isoform 4E-2 Proteins 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- JNPRQUIWDVDHIT-GYIPPJPDSA-N Herculin Chemical compound CCC\C=C\CCCC\C=C\C(=O)NCC(C)C JNPRQUIWDVDHIT-GYIPPJPDSA-N 0.000 description 1
- JNPRQUIWDVDHIT-UHFFFAOYSA-N Herculin Natural products CCCC=CCCCCC=CC(=O)NCC(C)C JNPRQUIWDVDHIT-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 1
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 108091028080 MiR-132 Proteins 0.000 description 1
- 108091092539 MiR-208 Proteins 0.000 description 1
- 108091007419 MiR-27 Proteins 0.000 description 1
- 108091062140 Mir-223 Proteins 0.000 description 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
- 102100038379 Myogenic factor 6 Human genes 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- SLLVJTURCPWLTP-UHFFFAOYSA-N N-[9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]acetamide Chemical compound C1=NC=2C(NC(=O)C)=NC=NC=2N1C1OC(CO)C(O)C1O SLLVJTURCPWLTP-UHFFFAOYSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- VZQXUWKZDSEQRR-UHFFFAOYSA-N Nucleosid Natural products C12=NC(SC)=NC(NCC=C(C)C)=C2N=CN1C1OC(CO)C(O)C1O VZQXUWKZDSEQRR-UHFFFAOYSA-N 0.000 description 1
- JXNORPPTKDEAIZ-QOCRDCMYSA-N O-4''-alpha-D-mannosylqueuosine Chemical compound NC(N1)=NC(N([C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)C=C2CN[C@H]([C@H]3O)C=C[C@@H]3O[C@H]([C@H]([C@H]3O)O)O[C@H](CO)[C@H]3O)=C2C1=O JXNORPPTKDEAIZ-QOCRDCMYSA-N 0.000 description 1
- XMIFBEZRFMTGRL-TURQNECASA-N OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(CNCCS(O)(=O)=O)c(=O)[nH]c1=S Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(CNCCS(O)(=O)=O)c(=O)[nH]c1=S XMIFBEZRFMTGRL-TURQNECASA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920002387 Phytoglycogen Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001257 Poly(D,L-lactide-co-PEO-co-D,L-lactide) Polymers 0.000 description 1
- 229920001267 Poly(D,L-lactide-co-PPO-co-D,L-lactide) Polymers 0.000 description 1
- 229920001212 Poly(beta amino esters) Polymers 0.000 description 1
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 229920001305 Poly(isodecyl(meth)acrylate) Polymers 0.000 description 1
- 229920000436 Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) Polymers 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920001283 Polyalkylene terephthalate Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 102000015623 Polynucleotide Adenylyltransferase Human genes 0.000 description 1
- 108010024055 Polynucleotide adenylyltransferase Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 1
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 1
- 108091046915 Threose nucleic acid Proteins 0.000 description 1
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 description 1
- 102100035000 Thymosin beta-4 Human genes 0.000 description 1
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 1
- 108010058907 Tiopronin Proteins 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100021869 Tyrosine aminotransferase Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- YXNIEZJFCGTDKV-UHFFFAOYSA-N X-Nucleosid Natural products O=C1N(CCC(N)C(O)=O)C(=O)C=CN1C1C(O)C(O)C(CO)O1 YXNIEZJFCGTDKV-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- TVGUROHJABCRTB-MHJQXXNXSA-N [(2r,3s,4r,5s)-5-[(2r,3r,4r,5r)-2-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound O([C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C=NC=2C(=O)N=C(NC=21)N)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O TVGUROHJABCRTB-MHJQXXNXSA-N 0.000 description 1
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 1
- YWBULOYFCXZCGF-UHFFFAOYSA-N [1,3]thiazolo[4,5-d]pyrimidine Chemical class C1=NC=C2SC=NC2=N1 YWBULOYFCXZCGF-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- LTOCXIVQWDANEX-UXCYUTBZSA-M [Br-].CCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCC\C=C/CCCC.CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C Chemical compound [Br-].CCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCC\C=C/CCCC.CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C LTOCXIVQWDANEX-UXCYUTBZSA-M 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 229960005174 ambroxol Drugs 0.000 description 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- PEMQXWCOMFJRLS-RPKMEZRRSA-N archaeosine Chemical compound C1=2NC(N)=NC(=O)C=2C(C(=N)N)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O PEMQXWCOMFJRLS-RPKMEZRRSA-N 0.000 description 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 125000002680 canonical nucleotide group Chemical group 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- MPBRYMWMMKKRGC-UHFFFAOYSA-M carbocyanin DBTC Chemical compound [Br-].C1=CC=CC2=C([N+](=C(C=C(C)C=C3N(C4=C5C=CC=CC5=CC=C4S3)CC)S3)CC)C3=CC=C21 MPBRYMWMMKKRGC-UHFFFAOYSA-M 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 125000004093 cyano group Chemical class *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UAKOZKUVZRMOFN-JDVCJPALSA-M dimethyl-bis[(z)-octadec-9-enyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CCCCCCCC\C=C/CCCCCCCC UAKOZKUVZRMOFN-JDVCJPALSA-M 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NEIPZWZQHXCYDV-UHFFFAOYSA-N domiodol Chemical compound OCC1COC(CI)O1 NEIPZWZQHXCYDV-UHFFFAOYSA-N 0.000 description 1
- 229960001700 domiodol Drugs 0.000 description 1
- 229960000533 dornase alfa Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 229940099191 duragesic Drugs 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- RRCFLRBBBFZLSB-XIFYLAFSSA-N epoxyqueuosine Chemical compound C1=C(CN[C@@H]2[C@H]([C@@H](O)[C@@H]3O[C@@H]32)O)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RRCFLRBBBFZLSB-XIFYLAFSSA-N 0.000 description 1
- BSHWLCACYCVCJE-UHFFFAOYSA-N eprazinone Chemical compound C=1C=CC=CC=1C(OCC)CN(CC1)CCN1CC(C)C(=O)C1=CC=CC=C1 BSHWLCACYCVCJE-UHFFFAOYSA-N 0.000 description 1
- 229960002561 eprazinone Drugs 0.000 description 1
- 229960003262 erdosteine Drugs 0.000 description 1
- QGFORSXNKQLDNO-UHFFFAOYSA-N erdosteine Chemical compound OC(=O)CSCC(=O)NC1CCSC1=O QGFORSXNKQLDNO-UHFFFAOYSA-N 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- JEJLGIQLPYYGEE-UHFFFAOYSA-N glycerol dipalmitate Natural products CCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCC JEJLGIQLPYYGEE-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- OAMFFXYYHGUAEQ-UHFFFAOYSA-N henicosan-10-amine Chemical compound CCCCCCCCCCCC(N)CCCCCCCCC OAMFFXYYHGUAEQ-UHFFFAOYSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- MHRITDAIAZETRS-UHFFFAOYSA-N hexadecan-8-amine Chemical compound CCCCCCCCC(N)CCCCCCC MHRITDAIAZETRS-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- IKOCLISPVJZJEA-UHFFFAOYSA-N letosteine Chemical compound CCOC(=O)CSCCC1NC(C(O)=O)CS1 IKOCLISPVJZJEA-UHFFFAOYSA-N 0.000 description 1
- 229960004870 letosteine Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- HLZXTFWTDIBXDF-UHFFFAOYSA-N mcm5sU Natural products COC(=O)Cc1cn(C2OC(CO)C(O)C2O)c(=S)[nH]c1=O HLZXTFWTDIBXDF-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- GWKIZNPISGBQGY-GNLDREGESA-N methyl (2S)-4-[4,6-dimethyl-9-oxo-3-[(2R,3R,4S,5R)-2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[1,2-a]purin-7-yl]-2-(methoxycarbonylamino)butanoate Chemical class O[C@@]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(=O)N3C(CC[C@@H](C(=O)OC)NC(=O)OC)=C(C)N=C3N(C)C21 GWKIZNPISGBQGY-GNLDREGESA-N 0.000 description 1
- WCNMEQDMUYVWMJ-UHFFFAOYSA-N methyl 4-[3-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4,6-dimethyl-9-oxoimidazo[1,2-a]purin-7-yl]-3-hydroperoxy-2-(methoxycarbonylamino)butanoate Chemical compound C1=NC=2C(=O)N3C(CC(C(NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O WCNMEQDMUYVWMJ-UHFFFAOYSA-N 0.000 description 1
- WZRYXYRWFAPPBJ-PNHWDRBUSA-N methyl uridin-5-yloxyacetate Chemical compound O=C1NC(=O)C(OCC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 WZRYXYRWFAPPBJ-PNHWDRBUSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 108091047577 miR-149 stem-loop Proteins 0.000 description 1
- 108091035696 miR-149-1 stem-loop Proteins 0.000 description 1
- 108091031096 miR-149-2 stem-loop Proteins 0.000 description 1
- 108091027943 miR-16 stem-loop Proteins 0.000 description 1
- 108091086416 miR-192 stem-loop Proteins 0.000 description 1
- 108091054642 miR-194 stem-loop Proteins 0.000 description 1
- 108091031479 miR-204 stem-loop Proteins 0.000 description 1
- 108091032382 miR-204-1 stem-loop Proteins 0.000 description 1
- 108091085803 miR-204-2 stem-loop Proteins 0.000 description 1
- 108091089766 miR-204-3 stem-loop Proteins 0.000 description 1
- 108091073500 miR-204-4 stem-loop Proteins 0.000 description 1
- 108091053626 miR-204-5 stem-loop Proteins 0.000 description 1
- 108091063796 miR-206 stem-loop Proteins 0.000 description 1
- 108091062762 miR-21 stem-loop Proteins 0.000 description 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 1
- 108091092825 miR-24 stem-loop Proteins 0.000 description 1
- 108091032978 miR-24-3 stem-loop Proteins 0.000 description 1
- 108091064025 miR-24-4 stem-loop Proteins 0.000 description 1
- 108091055059 miR-30c stem-loop Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 101150084874 mimG gene Proteins 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 108010084677 myogenic factor 6 Proteins 0.000 description 1
- NHKQLBKUKIHXPD-ANUFDVCNSA-N n,n-dimethyl-1-[(1s,2r)-2-octylcyclopropyl]pentadecan-8-amine Chemical compound CCCCCCCC[C@@H]1C[C@@H]1CCCCCCCC(CCCCCCC)N(C)C NHKQLBKUKIHXPD-ANUFDVCNSA-N 0.000 description 1
- IWKAIWRFRAJTEM-MSUUIHNZSA-N n,n-dimethyl-1-[(z)-octadec-9-enoxy]-3-octoxypropan-2-amine Chemical compound CCCCCCCCOCC(N(C)C)COCCCCCCCC\C=C/CCCCCCCC IWKAIWRFRAJTEM-MSUUIHNZSA-N 0.000 description 1
- PNJNONWMYGRREY-CYYMFWEFSA-N n,n-dimethyl-1-octoxy-3-[8-[(1s,2s)-2-[[(1r,2r)-2-pentylcyclopropyl]methyl]cyclopropyl]octoxy]propan-2-amine Chemical compound CCCCCCCCOCC(N(C)C)COCCCCCCCC[C@H]1C[C@H]1C[C@@H]1[C@H](CCCCC)C1 PNJNONWMYGRREY-CYYMFWEFSA-N 0.000 description 1
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 description 1
- XBEXBGJMPKDSDI-RENFASQQSA-N n,n-dimethyl-3-[7-[(1s,2r)-2-octylcyclopropyl]heptyl]dodecan-1-amine Chemical compound CCCCCCCCCC(CCN(C)C)CCCCCCC[C@H]1C[C@H]1CCCCCCCC XBEXBGJMPKDSDI-RENFASQQSA-N 0.000 description 1
- FZZRQGRMBHTCSF-UHFFFAOYSA-N n,n-dimethylheptacosan-10-amine Chemical compound CCCCCCCCCCCCCCCCCC(N(C)C)CCCCCCCCC FZZRQGRMBHTCSF-UHFFFAOYSA-N 0.000 description 1
- 229960003652 neltenexine Drugs 0.000 description 1
- SSLHKNBKUBAHJY-HDJSIYSDSA-N neltenexine Chemical compound C1C[C@@H](O)CC[C@@H]1NCC1=CC(Br)=CC(Br)=C1NC(=O)C1=CC=CS1 SSLHKNBKUBAHJY-HDJSIYSDSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- DEKCSXCNXGALFT-UHFFFAOYSA-N nonadecan-10-amine Chemical compound CCCCCCCCCC(N)CCCCCCCCC DEKCSXCNXGALFT-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical group NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000008299 phosphorodiamidates Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229920001245 poly(D,L-lactide-co-caprolactone) Polymers 0.000 description 1
- 229920001253 poly(D,L-lactide-co-caprolactone-co-glycolide) Polymers 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000744 poly(arginines) Polymers 0.000 description 1
- 229920000111 poly(butyric acid) Polymers 0.000 description 1
- 229920001279 poly(ester amides) Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920000212 poly(isobutyl acrylate) Polymers 0.000 description 1
- 229920001306 poly(lactide-co-caprolactone) Polymers 0.000 description 1
- 229920000184 poly(octadecyl acrylate) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920001230 polyarylate Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001228 polyisocyanate Polymers 0.000 description 1
- 239000005056 polyisocyanate Substances 0.000 description 1
- 229920000197 polyisopropyl acrylate Polymers 0.000 description 1
- 239000005076 polymer ester Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920001291 polyvinyl halide Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- FICMSTTYJICTDM-UHFFFAOYSA-N pyridazine;triazine Chemical compound C1=CC=NN=C1.C1=CN=NN=C1 FICMSTTYJICTDM-UHFFFAOYSA-N 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- QQXQGKSPIMGUIZ-AEZJAUAXSA-N queuosine Chemical compound C1=2C(=O)NC(N)=NC=2N([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=C1CN[C@H]1C=C[C@H](O)[C@@H]1O QQXQGKSPIMGUIZ-AEZJAUAXSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000007157 ring contraction reaction Methods 0.000 description 1
- 238000006049 ring expansion reaction Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229960000230 sobrerol Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960000353 stepronin Drugs 0.000 description 1
- JNYSEDHQJCOWQU-UHFFFAOYSA-N stepronin Chemical compound OC(=O)CNC(=O)C(C)SC(=O)C1=CC=CS1 JNYSEDHQJCOWQU-UHFFFAOYSA-N 0.000 description 1
- 125000002328 sterol group Chemical group 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000006169 tetracyclic group Chemical group 0.000 description 1
- XEVMVGUAJRGPOM-UHFFFAOYSA-N tetradecan-5-amine Chemical compound CCCCCCCCCC(N)CCCC XEVMVGUAJRGPOM-UHFFFAOYSA-N 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000005450 thionucleoside Substances 0.000 description 1
- 108010079996 thymosin beta(4) Proteins 0.000 description 1
- 229960004402 tiopronin Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- OMDMTHRBGUBUCO-UHFFFAOYSA-N trans-sobrerol Natural products CC1=CCC(C(C)(C)O)CC1O OMDMTHRBGUBUCO-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- RVCNQQGZJWVLIP-VPCXQMTMSA-N uridin-5-yloxyacetic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(OCC(O)=O)=C1 RVCNQQGZJWVLIP-VPCXQMTMSA-N 0.000 description 1
- YIZYCHKPHCPKHZ-UHFFFAOYSA-N uridine-5-acetic acid methyl ester Natural products COC(=O)Cc1cn(C2OC(CO)C(O)C2O)c(=O)[nH]c1=O YIZYCHKPHCPKHZ-UHFFFAOYSA-N 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 108010027510 vaccinia virus capping enzyme Proteins 0.000 description 1
- WQAJKOXBERTWBK-UHFFFAOYSA-N verdine Natural products CC1CNC2C(C1)OC3(CCC4C5CCC6(O)CC(O)CC(O)C6(C)C5C(=O)C4=C3C)C2C WQAJKOXBERTWBK-UHFFFAOYSA-N 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Hematology (AREA)
Abstract
Description
Claims
Priority Applications (62)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22159380.9A EP4144378A1 (en) | 2011-12-16 | 2012-12-14 | Modified nucleoside, nucleotide, and nucleic acid compositions |
KR1020147019601A KR20140102759A (en) | 2011-12-16 | 2012-12-14 | Modified nucleoside, nucleotide, and nucleic acid compositions |
ES12858350T ES2923757T3 (en) | 2011-12-16 | 2012-12-14 | Modified mRNA compositions |
MX2014007233A MX2014007233A (en) | 2011-12-16 | 2012-12-14 | Modified nucleoside, nucleotide, and nucleic acid compositions. |
AU2012352180A AU2012352180A1 (en) | 2011-12-16 | 2012-12-14 | Modified nucleoside, nucleotide, and nucleic acid compositions |
CN201280069609.3A CN104114572A (en) | 2011-12-16 | 2012-12-14 | Modified nucleoside, nucleotide, and nucleic acid compositions |
LTEPPCT/US2012/069610T LT2791160T (en) | 2011-12-16 | 2012-12-14 | Modified mrna compositions |
SG11201402666WA SG11201402666WA (en) | 2011-12-16 | 2012-12-14 | Modified nucleoside, nucleotide, and nucleic acid compositions |
HRP20220717TT HRP20220717T1 (en) | 2011-12-16 | 2012-12-14 | Modified mrna compositions |
SI201232001T SI2791160T1 (en) | 2011-12-16 | 2012-12-14 | Modified mrna compositions |
PL12858350T PL2791160T3 (en) | 2011-12-16 | 2012-12-14 | Modified mrna compositions |
RU2014129004A RU2649364C2 (en) | 2011-12-16 | 2012-12-14 | Modified nucleoside, nucleotide and nucleic acid compositions |
RS20220503A RS63244B1 (en) | 2011-12-16 | 2012-12-14 | Modified mrna compositions |
DE12858350.7T DE12858350T1 (en) | 2011-12-16 | 2012-12-14 | MODIFIED MRNA COMPOSITIONS |
JP2014547454A JP2015501844A (en) | 2011-12-16 | 2012-12-14 | Modified nucleosides, nucleotides and nucleic acid compositions |
CA2859387A CA2859387A1 (en) | 2011-12-16 | 2012-12-14 | Modified nucleoside, nucleotide, and nucleic acid compositions |
EP12858350.7A EP2791160B1 (en) | 2011-12-16 | 2012-12-14 | Modified mrna compositions |
DK12858350.7T DK2791160T3 (en) | 2011-12-16 | 2012-12-14 | MODIFIED MRNA COMPOSITIONS |
US14/103,188 US9220792B2 (en) | 2012-04-02 | 2013-12-11 | Modified polynucleotides encoding aquaporin-5 |
US14/104,556 US9114113B2 (en) | 2012-04-02 | 2013-12-12 | Modified polynucleotides encoding citeD4 |
US14/104,591 US9233141B2 (en) | 2012-04-02 | 2013-12-12 | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US14/104,531 US9107886B2 (en) | 2012-04-02 | 2013-12-12 | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US14/104,568 US9095552B2 (en) | 2012-04-02 | 2013-12-12 | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 |
US14/104,585 US20140193482A1 (en) | 2012-04-02 | 2013-12-12 | Modified polynucleotides encoding v-myc avian myelocytomatosis viral oncogene homolog |
US14/105,221 US20140255468A1 (en) | 2012-04-02 | 2013-12-13 | Modified polynucleotides encoding programmed cell death 1 |
US14/105,210 US20150044277A1 (en) | 2012-04-02 | 2013-12-13 | Modified polynucleotides encoding caspase 3 |
US14/105,217 US20140255467A1 (en) | 2012-04-02 | 2013-12-13 | Modified polynucleotides encoding cytotoxic t-lymphocyte-associated protein 4 |
US14/105,214 US20140171485A1 (en) | 2012-04-02 | 2013-12-13 | Modified polynucleotides encoding cd28 molecule |
US14/105,224 US9220755B2 (en) | 2012-04-02 | 2013-12-13 | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US14/106,957 US9050297B2 (en) | 2012-04-02 | 2013-12-16 | Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator |
US14/107,029 US20140113959A1 (en) | 2012-04-02 | 2013-12-16 | Modified polynucleotides encoding caspase 6 |
US14/107,105 US9255129B2 (en) | 2012-04-02 | 2013-12-16 | Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 |
US14/106,988 US9301993B2 (en) | 2012-04-02 | 2013-12-16 | Modified polynucleotides encoding apoptosis inducing factor 1 |
US14/107,079 US9149506B2 (en) | 2012-04-02 | 2013-12-16 | Modified polynucleotides encoding septin-4 |
US14/107,053 US9216205B2 (en) | 2012-04-02 | 2013-12-16 | Modified polynucleotides encoding granulysin |
US14/171,249 US9089604B2 (en) | 2012-04-02 | 2014-02-03 | Modified polynucleotides for treating galactosylceramidase protein deficiency |
US14/170,910 US20140155474A1 (en) | 2012-04-02 | 2014-02-03 | Modified polynucleotides for treating cystic fibrosis |
US14/170,744 US20140148502A1 (en) | 2012-04-02 | 2014-02-03 | Modified polynucleotides for treating protein deficiency |
US14/171,119 US20140179771A1 (en) | 2012-04-02 | 2014-02-03 | Modified polynucleotides for treating dolichyl-phosphate (udp-n-acetylglucosamine) n-acetylglucosaminephosphotransferase 1 (glcnac-1-p transferase) protein deficiency |
US14/171,226 US9061059B2 (en) | 2012-04-02 | 2014-02-03 | Modified polynucleotides for treating protein deficiency |
US14/170,914 US20140155475A1 (en) | 2012-04-02 | 2014-02-03 | Modified polynucleotides for treating lipase a, lysosomal acid, cholesterol esterase protein deficiency |
US14/170,903 US20140155473A1 (en) | 2012-04-02 | 2014-02-03 | Modified glucosidase, beta, acid polynucleotides for treating protein deficiency |
US14/170,747 US20140194494A1 (en) | 2012-04-02 | 2014-02-03 | Modified polynucleotides for treating protein deficiency |
US14/170,897 US20140155472A1 (en) | 2012-04-02 | 2014-02-03 | Modified polynucleotides for treating argininosuccinate synthase 1 protein deficiency |
US14/171,235 US20140206755A1 (en) | 2012-04-02 | 2014-02-03 | Modified polynucleotides for treating arylsulfatase a protein deficiency |
US14/170,751 US20140200263A1 (en) | 2012-04-02 | 2014-02-03 | Modified polynucleotides for treating galactosidase, alpha protein deficiency |
US14/171,242 US20140200264A1 (en) | 2012-04-02 | 2014-02-03 | Modified polynucleotides for treating carboxypeptidase n, polypeptide 1 protein deficiency |
US14/280,867 US20140275229A1 (en) | 2012-04-02 | 2014-05-19 | Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1 |
IL232749A IL232749A0 (en) | 2011-12-16 | 2014-05-22 | Modified nucleoside, nucleotide, and nucleic acid compositions |
ZA2014/03783A ZA201403783B (en) | 2011-12-16 | 2014-05-23 | Modified nucleoside, nucleotide, and nucleic acid compositions |
HK15103589.4A HK1203077A1 (en) | 2011-12-16 | 2015-04-13 | Modified nucleoside, nucleotide, and nucleic acid compositions |
US14/694,357 US9283287B2 (en) | 2012-04-02 | 2015-04-23 | Modified polynucleotides for the production of nuclear proteins |
US14/750,004 US9828416B2 (en) | 2012-04-02 | 2015-06-25 | Modified polynucleotides for the production of secreted proteins |
US14/975,141 US9504734B2 (en) | 2012-04-02 | 2015-12-18 | Modified polynucleotides for the production of nuclear proteins |
US15/015,684 US9587003B2 (en) | 2012-04-02 | 2016-02-04 | Modified polynucleotides for the production of oncology-related proteins and peptides |
US15/060,707 US9782462B2 (en) | 2012-04-02 | 2016-03-04 | Modified polynucleotides for the production of proteins associated with human disease |
US15/174,219 US20160289674A1 (en) | 2012-04-02 | 2016-06-06 | Modified polynucleotides for the production of membrane proteins |
US15/425,813 US10501513B2 (en) | 2012-04-02 | 2017-02-06 | Modified polynucleotides for the production of oncology-related proteins and peptides |
US15/440,523 US20180086807A1 (en) | 2012-04-02 | 2017-02-23 | Modified polynucleotides for the production of proteins associated with human disease |
US16/665,985 US20210115101A1 (en) | 2012-04-02 | 2019-10-28 | Modified polynucleotides for the production of proteins associated with human disease |
US16/707,998 US20200247861A1 (en) | 2012-04-02 | 2019-12-09 | Modified polynucleotides for the production of oncology-related proteins and peptides |
US16/860,121 US20220273555A1 (en) | 2012-04-02 | 2020-04-28 | Modified polynucleotides for the production of membrane proteins |
Applications Claiming Priority (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161576705P | 2011-12-16 | 2011-12-16 | |
US61/576,705 | 2011-12-16 | ||
US201261618957P | 2012-04-02 | 2012-04-02 | |
US61/618,957 | 2012-04-02 | ||
US201261648244P | 2012-05-17 | 2012-05-17 | |
US61/648,244 | 2012-05-17 | ||
US201261681712P | 2012-08-10 | 2012-08-10 | |
US61/681,712 | 2012-08-10 | ||
US201261696381P | 2012-09-04 | 2012-09-04 | |
US61/696,381 | 2012-09-04 | ||
US201261709303P | 2012-10-03 | 2012-10-03 | |
US61/709,303 | 2012-10-03 | ||
PCT/US2012/058519 WO2013052523A1 (en) | 2011-10-03 | 2012-10-03 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
USPCT/US2012/058519 | 2012-10-03 | ||
US201261712490P | 2012-10-11 | 2012-10-11 | |
US61/712,490 | 2012-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013090648A1 true WO2013090648A1 (en) | 2013-06-20 |
Family
ID=48610363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/069610 WO2013090648A1 (en) | 2011-12-16 | 2012-12-14 | Modified nucleoside, nucleotide, and nucleic acid compositions |
Country Status (24)
Country | Link |
---|---|
US (18) | US20130156849A1 (en) |
EP (2) | EP4144378A1 (en) |
JP (2) | JP2015501844A (en) |
KR (1) | KR20140102759A (en) |
CN (2) | CN104114572A (en) |
AU (3) | AU2012352180A1 (en) |
CA (2) | CA2859387A1 (en) |
DE (1) | DE12858350T1 (en) |
DK (1) | DK2791160T3 (en) |
ES (1) | ES2923757T3 (en) |
HK (1) | HK1203077A1 (en) |
HR (1) | HRP20220717T1 (en) |
HU (1) | HUE059110T2 (en) |
IL (1) | IL232749A0 (en) |
LT (1) | LT2791160T (en) |
MX (1) | MX2014007233A (en) |
PL (1) | PL2791160T3 (en) |
PT (1) | PT2791160T (en) |
RS (1) | RS63244B1 (en) |
RU (1) | RU2649364C2 (en) |
SG (2) | SG11201402666WA (en) |
SI (1) | SI2791160T1 (en) |
WO (1) | WO2013090648A1 (en) |
ZA (1) | ZA201403783B (en) |
Cited By (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013151665A3 (en) * | 2012-04-02 | 2014-02-20 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
WO2014113089A2 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2015006747A2 (en) | 2013-07-11 | 2015-01-15 | Moderna Therapeutics, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use. |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2015075557A2 (en) | 2013-11-22 | 2015-05-28 | Mina Alpha Limited | C/ebp alpha compositions and methods of use |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
EP2931319A4 (en) * | 2012-12-13 | 2016-05-04 | Moderna Therapeutics Inc | Modified nucleic acid molecules and uses thereof |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
EP3053585A1 (en) * | 2013-12-13 | 2016-08-10 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CN106047879A (en) * | 2016-08-18 | 2016-10-26 | 广州市锐博生物科技有限公司 | Oligonucleotide molecule used for inhibiting expression of mRNA of target gene and composition set thereof |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2017062513A1 (en) | 2015-10-05 | 2017-04-13 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
US9670261B2 (en) | 2012-12-21 | 2017-06-06 | Sanofi | Functionalized exendin-4 derivatives |
WO2017112943A1 (en) | 2015-12-23 | 2017-06-29 | Modernatx, Inc. | Methods of using ox40 ligand encoding polynucleotides |
US9694053B2 (en) | 2013-12-13 | 2017-07-04 | Sanofi | Dual GLP-1/glucagon receptor agonists |
WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
US9750788B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Non-acylated exendin-4 peptide analogues |
US9751926B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Dual GLP-1/GIP receptor agonists |
US9758561B2 (en) | 2014-04-07 | 2017-09-12 | Sanofi | Dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9771406B2 (en) | 2014-04-07 | 2017-09-26 | Sanofi | Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9775904B2 (en) | 2014-04-07 | 2017-10-03 | Sanofi | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
US9789165B2 (en) | 2013-12-13 | 2017-10-17 | Sanofi | Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists |
WO2018009838A1 (en) | 2016-07-07 | 2018-01-11 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems expressing exogenous rna |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
EP3177732A4 (en) * | 2014-08-08 | 2018-04-25 | ModernaTX, Inc. | Compositions and methods for the treatment of ophthalmic diseases and conditions |
US9982029B2 (en) | 2015-07-10 | 2018-05-29 | Sanofi | Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
US10106800B2 (en) | 2005-09-28 | 2018-10-23 | Biontech Ag | Modification of RNA, producing an increased transcript stability and translation efficiency |
EP3122878B1 (en) | 2014-03-24 | 2018-10-24 | Translate Bio, Inc. | Mrna therapy for the treatment of ocular diseases |
WO2018213731A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
US10155031B2 (en) | 2012-11-28 | 2018-12-18 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
WO2019048632A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | Stabilized hnf4a sarna compositions and methods of use |
CN109562153A (en) * | 2016-08-07 | 2019-04-02 | 诺华股份有限公司 | The immunization method that mRNA is mediated |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
EP3364982A4 (en) * | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | Sexually transmitted disease vaccines |
US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
EP3369816A4 (en) * | 2015-10-30 | 2019-06-26 | Bonac Corporation | Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-beta1 gene |
EP3365007A4 (en) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | Broad spectrum influenza virus vaccine |
EP3365009A4 (en) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | Herpes simplex virus vaccine |
EP3364980A4 (en) * | 2015-10-22 | 2019-07-10 | ModernaTX, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
EP3364981A4 (en) * | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Human cytomegalovirus vaccine |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
WO2019158720A1 (en) | 2018-02-16 | 2019-08-22 | Mina Therapeutics Limited | C/ebp alpha sarna compositions and methods of use |
US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
US10413598B2 (en) | 2014-11-12 | 2019-09-17 | Ucl Business Plc | Factor IX gene therapy |
WO2019197845A1 (en) | 2018-04-12 | 2019-10-17 | Mina Therapeutics Limited | Sirt1-sarna compositions and methods of use |
EP3364950A4 (en) * | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Tropical disease vaccines |
EP3364983A4 (en) * | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Respiratory virus vaccines |
US10485884B2 (en) | 2012-03-26 | 2019-11-26 | Biontech Rna Pharmaceuticals Gmbh | RNA formulation for immunotherapy |
US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
WO2019239144A1 (en) | 2018-06-15 | 2019-12-19 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
US10525075B2 (en) | 2013-02-22 | 2020-01-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds, compositions, methods, and kits relating to telomere extension |
RU2714404C2 (en) * | 2014-01-31 | 2020-02-14 | Фэктор Байосайенс Инк. | Methods and products for producing and delivering nucleic acids |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
WO2020056155A3 (en) * | 2018-09-13 | 2020-04-16 | Modernatx, Inc. | Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease |
US10709779B2 (en) | 2014-04-23 | 2020-07-14 | Modernatx, Inc. | Nucleic acid vaccines |
US10724052B2 (en) | 2018-09-07 | 2020-07-28 | Crispr Therapeutics Ag | Universal donor cells |
US10738355B2 (en) | 2011-05-24 | 2020-08-11 | Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh | Individualized vaccines for cancer |
US10758592B2 (en) | 2012-10-09 | 2020-09-01 | Sanofi | Exendin-4 derivatives as dual GLP1/glucagon agonists |
WO2020208361A1 (en) | 2019-04-12 | 2020-10-15 | Mina Therapeutics Limited | Sirt1-sarna compositions and methods of use |
US10806797B2 (en) | 2015-06-05 | 2020-10-20 | Sanofi | Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
WO2021007515A1 (en) | 2019-07-11 | 2021-01-14 | Tenaya Therapeutics, Inc. | Cardiac cell reprogramming with micrornas and other factors |
WO2021032777A1 (en) | 2019-08-19 | 2021-02-25 | Mina Therapeutics Limited | Oligonucleotide conjugate compositions and methods of use |
US11015211B2 (en) | 2018-08-30 | 2021-05-25 | Tenaya Therapeutics, Inc. | Cardiac cell reprogramming with myocardin and ASCL1 |
US11104918B2 (en) | 2019-09-05 | 2021-08-31 | Crispr Therapeutics Ag | Universal donor cells |
WO2021178246A1 (en) | 2020-03-02 | 2021-09-10 | Tenaya Therapeutics, Inc. | Gene vector control by cardiomyocyte-expressed micrornas |
US11116797B2 (en) | 2019-09-05 | 2021-09-14 | Crispr Therapeutics Ag | Universal donor cells |
US11141378B2 (en) | 2008-04-15 | 2021-10-12 | Arbutus Biopharma Corporation | Lipid formulations for nucleic acid delivery |
US11156617B2 (en) | 2015-02-12 | 2021-10-26 | BioNTech RNA Pharmaceuticals GbmH | Predicting T cell epitopes useful for vaccination |
US11173120B2 (en) | 2014-09-25 | 2021-11-16 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
US11207398B2 (en) | 2017-09-14 | 2021-12-28 | Modernatx, Inc. | Zika virus mRNA vaccines |
US11222711B2 (en) | 2013-05-10 | 2022-01-11 | BioNTech SE | Predicting immunogenicity of T cell epitopes |
US11298426B2 (en) | 2003-10-14 | 2022-04-12 | BioNTech SE | Recombinant vaccines and use thereof |
US20220125723A1 (en) | 2010-07-06 | 2022-04-28 | Glaxosmithkline Biologicals Sa | Lipid formulations with viral immunogens |
WO2022113056A1 (en) | 2020-11-30 | 2022-06-02 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
EP3708668B1 (en) | 2014-12-12 | 2022-07-27 | CureVac AG | Artificial nucleic acid molecules for improved protein expression |
US11407997B2 (en) | 2017-02-22 | 2022-08-09 | Crispr Therapeutics Ag | Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders |
US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
US11446383B2 (en) | 2009-07-01 | 2022-09-20 | Arbutus Biopharma Corporation | Lipid formulations for delivery of therapeutic agents |
WO2022200810A1 (en) | 2021-03-26 | 2022-09-29 | Mina Therapeutics Limited | Tmem173 sarna compositions and methods of use |
EP3324979B1 (en) | 2015-07-21 | 2022-10-12 | ModernaTX, Inc. | Infectious disease vaccines |
WO2022229644A1 (en) | 2021-04-28 | 2022-11-03 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
US11492628B2 (en) | 2015-10-07 | 2022-11-08 | BioNTech SE | 3′-UTR sequences for stabilization of RNA |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
US11547764B2 (en) | 2011-06-08 | 2023-01-10 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US11559588B2 (en) | 2017-02-22 | 2023-01-24 | Crispr Therapeutics Ag | Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders |
US11566230B2 (en) | 2020-12-31 | 2023-01-31 | Crispr Therapeutics Ag | Universal donor cells |
US11564997B2 (en) | 2016-06-29 | 2023-01-31 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
US11596645B2 (en) | 2010-07-06 | 2023-03-07 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
WO2023031394A1 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
EP4159741A1 (en) | 2014-07-16 | 2023-04-05 | ModernaTX, Inc. | Method for producing a chimeric polynucleotide encoding a polypeptide having a triazole-containing internucleotide linkage |
WO2023069498A1 (en) | 2021-10-22 | 2023-04-27 | Senda Biosciences, Inc. | Mrna vaccine composition |
US11639370B2 (en) | 2010-10-11 | 2023-05-02 | Glaxosmithkline Biologicals Sa | Antigen delivery platforms |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
US11655475B2 (en) | 2010-07-06 | 2023-05-23 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
WO2023096858A1 (en) | 2021-11-23 | 2023-06-01 | Senda Biosciences, Inc. | A bacteria-derived lipid composition and use thereof |
WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
WO2023122080A1 (en) | 2021-12-20 | 2023-06-29 | Senda Biosciences, Inc. | Compositions comprising mrna and lipid reconstructed plant messenger packs |
EP4219715A2 (en) | 2017-09-08 | 2023-08-02 | MiNA Therapeutics Limited | Stabilized cebpa sarna compositions and methods of use |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
US11718852B2 (en) | 2010-06-30 | 2023-08-08 | Arbutus Biopharma Corporation | Non-liposomal systems for nucleic acid delivery |
WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
US11759422B2 (en) | 2010-08-31 | 2023-09-19 | Glaxosmithkline Biologicals Sa | Pegylated liposomes for delivery of immunogen-encoding RNA |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
US11920148B2 (en) | 2017-02-22 | 2024-03-05 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
US11926817B2 (en) | 2019-08-09 | 2024-03-12 | Nutcracker Therapeutics, Inc. | Microfluidic apparatus and methods of use thereof |
Families Citing this family (313)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005251676B2 (en) | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US9180081B2 (en) * | 2005-03-03 | 2015-11-10 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US8153435B1 (en) | 2005-03-30 | 2012-04-10 | Tracer Detection Technology Corp. | Methods and articles for identifying objects using encapsulated perfluorocarbon tracers |
PL3338765T3 (en) | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Steroid derivative for the delivery of mrna in human genetic diseases |
EP3072961A1 (en) | 2010-04-16 | 2016-09-28 | Children's Medical Center Corporation | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
AU2011248108B2 (en) | 2010-05-04 | 2016-05-26 | Corium Pharma Solutions, Inc. | Method and device for transdermal delivery of parathyroid hormone using a microprojection array |
CA2816420C (en) * | 2010-10-29 | 2018-01-16 | Najib Babul | Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol |
WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
JP6073916B2 (en) | 2011-12-05 | 2017-02-01 | ファクター バイオサイエンス インコーポレイテッド | Methods and products for transfecting cells |
ES2921724T1 (en) | 2011-12-07 | 2022-08-31 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the administration of active agents |
EP2859102A4 (en) | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | Nuclease resistant polynucleotides and uses thereof |
EP3884949A1 (en) | 2012-06-08 | 2021-09-29 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
US9095625B2 (en) * | 2012-08-31 | 2015-08-04 | University Of Massachusetts | Graft-copolymer stabilized metal nanoparticles |
US20150246138A1 (en) * | 2012-09-04 | 2015-09-03 | Lauren Sciences Llc | Bolaamphiphilic compounds, compositions and uses thereof |
US20140284270A1 (en) * | 2012-09-21 | 2014-09-25 | George Fox | RNA pores and methods and compositions for making and using same |
KR20230154283A (en) | 2012-11-01 | 2023-11-07 | 팩터 바이오사이언스 인크. | Methods and products for expressing proteins in cells |
ES2883590T3 (en) | 2012-12-12 | 2021-12-09 | Broad Inst Inc | Supply, modification and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
CN105073178B (en) * | 2012-12-21 | 2019-07-30 | 考里安国际公司 | Microarray and its application method for therapeutic agent delivering |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
EP2970955B1 (en) | 2013-03-14 | 2018-11-14 | Translate Bio, Inc. | Methods for purification of messenger rna |
HUE055044T2 (en) | 2013-03-14 | 2021-10-28 | Translate Bio Inc | Methods and compositions for delivering mrna coded antibodies |
PT2968586T (en) | 2013-03-14 | 2018-11-13 | Ethris Gmbh | Cftr mrna compositions and related methods and uses |
EP3388834B1 (en) * | 2013-03-15 | 2020-04-15 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
EP2968118B1 (en) | 2013-03-15 | 2022-02-09 | Corium, Inc. | Microarray for delivery of therapeutic agent and methods of use |
CN115261411A (en) | 2013-04-04 | 2022-11-01 | 哈佛学院校长同事会 | Therapeutic uses of genome editing with CRISPR/Cas systems |
RU2725502C2 (en) | 2013-06-17 | 2020-07-02 | Те Брод Инститьют Инк. | Delivery, construction and optimization of systems, methods and compositions for targeted action and modeling of diseases and disorders of postmitotic cells |
RU2716420C2 (en) | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Delivery and use of systems of crispr-cas, vectors and compositions for targeted action and therapy in liver |
CN105793425B (en) | 2013-06-17 | 2021-10-26 | 布罗德研究所有限公司 | Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using viral components |
EP3019595A4 (en) | 2013-07-09 | 2016-11-30 | Therapeutic uses of genome editing with crispr/cas systems | |
JP6620093B2 (en) * | 2013-07-23 | 2019-12-11 | アービュートゥス バイオファーマ コーポレイションArbutus Biopharma Corporation | Compositions and methods for delivering messenger RNA |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
AU2014340092B2 (en) | 2013-10-22 | 2019-09-19 | Translate Bio, Inc. | mRNA therapy for Argininosuccinate Synthetase Deficiency |
US9629804B2 (en) | 2013-10-22 | 2017-04-25 | Shire Human Genetic Therapies, Inc. | Lipid formulations for delivery of messenger RNA |
WO2015061491A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
WO2015061461A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Cns delivery of mrna and uses thereof |
DK3066201T3 (en) | 2013-11-07 | 2018-06-06 | Editas Medicine Inc | CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES |
US10098982B2 (en) | 2013-11-20 | 2018-10-16 | Drexel University | Compositions and methods for macrophage conversion |
JP6712948B2 (en) | 2013-12-12 | 2020-06-24 | ザ・ブロード・インスティテュート・インコーポレイテッド | Compositions and methods of using the CRISPR-cas system in nucleotide repeat disorders |
BR112016013207A2 (en) | 2013-12-12 | 2017-09-26 | Massachusetts Inst Technology | administration, use and therapeutic applications of crisp systems and compositions for hbv and viral disorders and diseases |
WO2015089473A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
MX2016007327A (en) | 2013-12-12 | 2017-03-06 | Broad Inst Inc | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components. |
AU2014361781B2 (en) | 2013-12-12 | 2021-04-01 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing |
EP3104889B1 (en) | 2014-02-10 | 2021-10-13 | The Board of Trustees of the Leland Stanford Junior University | Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mrna |
WO2015151048A1 (en) * | 2014-04-01 | 2015-10-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Capped and uncapped rna molecules and block copolymers for intracellular delivery of rna |
SG11201608725YA (en) | 2014-04-25 | 2016-11-29 | Shire Human Genetic Therapies | Methods for purification of messenger rna |
WO2015175748A1 (en) * | 2014-05-14 | 2015-11-19 | Evorx Technologies, Inc. | Methods and compositions for controlling gene expression and treating cancer |
MA48050A (en) | 2014-05-30 | 2020-02-12 | Translate Bio Inc | BIODEGRADABLE LIPIDS FOR THE ADMINISTRATION OF NUCLEIC ACIDS |
WO2015200465A1 (en) | 2014-06-24 | 2015-12-30 | Shire Human Genetic Therapies, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
SI3766916T1 (en) | 2014-06-25 | 2023-01-31 | Acuitas Therapeutics Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2015198326A1 (en) * | 2014-06-26 | 2015-12-30 | Ramot At Tel-Aviv University Ltd. | Liposomal formulations for delivery of nucleic acids |
US9668980B2 (en) * | 2014-07-02 | 2017-06-06 | Rana Therapeutics, Inc. | Encapsulation of messenger RNA |
FR3023483A1 (en) * | 2014-07-09 | 2016-01-15 | Jerome Lemoine | PROCESS FOR PREPARING MESSENGER RNA NANOPARTICLES AND HYPOTONIC AQUEOUS COMPOSITION COMPRISING THE ARNM NANOPARTICLES |
WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
WO2016028682A1 (en) | 2014-08-17 | 2016-02-25 | The Broad Institute Inc. | Genome editing using cas9 nickases |
WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
WO2016049258A2 (en) | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
KR101776368B1 (en) * | 2014-10-02 | 2017-09-07 | 서울시립대학교 산학협력단 | mRNA nanoparticles and manufacturing method thereof |
US9816080B2 (en) | 2014-10-31 | 2017-11-14 | President And Fellows Of Harvard College | Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs) |
EP3218508A4 (en) * | 2014-11-10 | 2018-04-18 | Modernatx, Inc. | Multiparametric nucleic acid optimization |
JP6767976B2 (en) | 2014-12-05 | 2020-10-14 | トランスレイト バイオ, インコーポレイテッド | Messenger RNA therapy for the treatment of joint diseases |
EP3230452A1 (en) | 2014-12-12 | 2017-10-18 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
WO2016094880A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
WO2016100974A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing |
WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
WO2016106244A1 (en) | 2014-12-24 | 2016-06-30 | The Broad Institute Inc. | Crispr having or associated with destabilization domains |
KR20170093254A (en) | 2014-12-29 | 2017-08-14 | 노파르티스 아게 | Methods for producing chimeric antigen receptor-expressing cells |
US20180000953A1 (en) * | 2015-01-21 | 2018-01-04 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
CN114642735A (en) | 2015-01-21 | 2022-06-21 | 菲泽尔克斯公司 | Methods, compositions and systems for delivering therapeutic and diagnostic agents into cells |
EP3247398A4 (en) * | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
JP7199809B2 (en) * | 2015-02-13 | 2023-01-06 | ファクター バイオサイエンス インコーポレイテッド | Nucleic acid product and its administration method |
AU2016233135B2 (en) | 2015-03-19 | 2021-07-08 | Translate Bio, Inc. | mRNA therapy for pompe disease |
JP7114457B2 (en) | 2015-04-17 | 2022-08-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Methods for Improving Efficacy and Growth of Chimeric Antigen Receptor-Expressing Cells |
US10682401B2 (en) | 2015-05-19 | 2020-06-16 | Morphogenesis, Inc. | Multi-indication mRNA cancer immunotherapy |
US10920246B2 (en) * | 2015-05-26 | 2021-02-16 | Ramot At Tel-Aviv University Ltd. | Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
FI3430134T3 (en) | 2015-06-18 | 2023-01-13 | Novel crispr enzymes and systems | |
WO2016205745A2 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Cell sorting |
CN108290933A (en) | 2015-06-18 | 2018-07-17 | 布罗德研究所有限公司 | Reduce the CRISPR enzyme mutants of undershooting-effect |
WO2016205749A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2017004067A1 (en) | 2015-06-29 | 2017-01-05 | Corium International, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
WO2017004143A1 (en) | 2015-06-29 | 2017-01-05 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
AR105433A1 (en) | 2015-07-21 | 2017-10-04 | Novartis Ag | METHODS TO IMPROVE THE EFFECTIVENESS AND EXPANSION OF IMMUNE CELLS |
WO2017019568A1 (en) * | 2015-07-24 | 2017-02-02 | Fibralign Corporation | Composition for targeted delivery of nucleic acid-based therapeutics |
WO2017020026A1 (en) * | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
WO2017031370A1 (en) | 2015-08-18 | 2017-02-23 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
AU2016324310B2 (en) | 2015-09-17 | 2021-04-08 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
EP3349730B1 (en) | 2015-09-18 | 2020-12-02 | Dnarx | Systems for nucleic acid expression in vivo |
WO2017062990A1 (en) * | 2015-10-09 | 2017-04-13 | Case Western Reserve University | Compositions and methods for the delivery of nucleic acids |
US20190255107A1 (en) | 2015-10-09 | 2019-08-22 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
EP3878955A1 (en) | 2015-10-14 | 2021-09-15 | Translate Bio, Inc. | Modification of rna-related enzymes for enhanced production |
CN108472354A (en) | 2015-10-22 | 2018-08-31 | 摩登纳特斯有限公司 | Respiratory syncytial virus vaccines |
CA3024543A1 (en) | 2015-10-22 | 2017-04-27 | The Broad Institute, Inc. | Type vi-b crispr enzymes and systems |
MA46255A (en) * | 2015-10-22 | 2019-07-31 | Modernatx Inc | ANTI-CANCER VACCINES |
JP7109784B2 (en) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Evolved Cas9 protein for gene editing |
WO2017075038A1 (en) * | 2015-10-26 | 2017-05-04 | Rana Therapeutics, Inc. | Nanoparticle formulations for delivery of nucleic acid complexes |
EP3368687B1 (en) | 2015-10-27 | 2021-09-29 | The Broad Institute, Inc. | Compositions and methods for targeting cancer-specific sequence variations |
CN113636947A (en) | 2015-10-28 | 2021-11-12 | 爱康泰生治疗公司 | Novel lipid and lipid nanoparticle formulations for delivery of nucleic acids |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
EP3368689B1 (en) | 2015-10-28 | 2020-06-17 | The Broad Institute, Inc. | Composition for modulating immune responses by use of immune cell gene signature |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017081110A1 (en) * | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
US20190307857A1 (en) | 2015-12-09 | 2019-10-10 | Modernatx, Inc. | MODIFIED mRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF |
WO2017100551A1 (en) | 2015-12-09 | 2017-06-15 | Alexion Pharmaceuticals, Inc. | HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION |
CA3007955A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Lipid nanoparticles for delivery of therapeutic agents |
US20190233814A1 (en) | 2015-12-18 | 2019-08-01 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
PL3394030T3 (en) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
US10793898B2 (en) * | 2015-12-23 | 2020-10-06 | The Regents Of The University Of California | Nano-sensors for nucleic acid detection and discrimination |
CN117025539A (en) | 2015-12-28 | 2023-11-10 | 诺华股份有限公司 | Method for preparing chimeric antigen receptor expressing cells |
WO2017127750A1 (en) | 2016-01-22 | 2017-07-27 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
US11780934B2 (en) | 2016-02-05 | 2023-10-10 | Institut Pasteur | Use of inhibitors of ADAM12 as adjuvants in tumor therapies |
US20210189062A1 (en) | 2016-03-01 | 2021-06-24 | Alexion Pharmaceuticals, Inc. | Biodegradable activated polymers for therapeutic delivery |
CA3020343A1 (en) | 2016-04-08 | 2017-10-12 | Translate Bio, Inc. | Multimeric coding nucleic acid and uses thereof |
WO2017180917A2 (en) | 2016-04-13 | 2017-10-19 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
AU2017253107B2 (en) | 2016-04-19 | 2023-07-20 | Massachusetts Institute Of Technology | CPF1 complexes with reduced indel activity |
CA3026110A1 (en) | 2016-04-19 | 2017-11-02 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
KR102424476B1 (en) | 2016-04-19 | 2022-07-25 | 더 브로드 인스티튜트, 인코퍼레이티드 | Novel CRISPR Enzymes and Systems |
WO2017192544A1 (en) | 2016-05-02 | 2017-11-09 | Massachusetts Institute Of Technology | AMPHIPHILIC NANOPARTICLES FOR CODELIVERY OF WATER-INSOLUBLE SMALL MOLECULES AND RNAi |
JP7066632B2 (en) | 2016-05-09 | 2022-05-13 | アストラゼネカ・アクチエボラーグ | Lipid nanoparticles containing lipophilic anti-inflammatory agents and how to use them |
CA3024500A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding relaxin |
RU2756313C2 (en) | 2016-06-07 | 2021-09-29 | Модернатикс, Инк. | Modified rna encoding vegf-a polypeptides, compositions containing it, and their application methods |
CN109312313A (en) | 2016-06-13 | 2019-02-05 | 川斯勒佰尔公司 | For treating the mRNA therapy of ornithine transcarbamylase deficiency disease |
AU2017286606A1 (en) * | 2016-06-14 | 2018-12-13 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
EP3455357A1 (en) | 2016-06-17 | 2019-03-20 | The Broad Institute Inc. | Type vi crispr orthologs and systems |
WO2018005873A1 (en) | 2016-06-29 | 2018-01-04 | The Broad Institute Inc. | Crispr-cas systems having destabilization domain |
MX2018016389A (en) | 2016-06-30 | 2019-08-16 | Arbutus Biopharma Corp | Compositions and methods for delivering messenger rna. |
WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
WO2018035388A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2018035377A1 (en) | 2016-08-17 | 2018-02-22 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
US20200283743A1 (en) | 2016-08-17 | 2020-09-10 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
CN116837052A (en) | 2016-09-14 | 2023-10-03 | 摩登纳特斯有限公司 | High-purity RNA composition and preparation method thereof |
EP3518981A4 (en) | 2016-10-03 | 2020-06-10 | President and Fellows of Harvard College | Delivery of therapeutic rnas via arrdc1-mediated microvesicles |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
KR101896615B1 (en) * | 2016-10-13 | 2018-09-07 | 한국과학기술연구원 | A method for packing polynucleotide |
WO2018071868A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
JP6980780B2 (en) | 2016-10-21 | 2021-12-15 | モデルナティーエックス, インコーポレイテッド | Human cytomegalovirus vaccine |
EP3532103A1 (en) | 2016-10-26 | 2019-09-04 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
US20190274968A1 (en) * | 2016-10-27 | 2019-09-12 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
US11400109B2 (en) * | 2016-11-10 | 2022-08-02 | Translate Bio, Inc. | Subcutaneous delivery of messenger RNA |
WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
ES2912270T3 (en) * | 2016-11-23 | 2022-05-25 | Mayo Found Medical Education & Res | Transport of biological products by means of particles |
MA50335A (en) | 2016-12-08 | 2020-08-19 | Modernatx Inc | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
US20180185516A1 (en) * | 2016-12-09 | 2018-07-05 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
WO2018111967A1 (en) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Rna affinity purification |
WO2018115973A2 (en) * | 2016-12-22 | 2018-06-28 | Avectas Limited | Vector-free intracellular delivery by reversible permeabilisation |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
KR20190110612A (en) * | 2017-02-01 | 2019-09-30 | 모더나티엑스, 인크. | Immunomodulatory Therapeutic MRNA Compositions Encoding Activating Oncogene Mutant Peptides |
MA47515A (en) | 2017-02-16 | 2019-12-25 | Modernatx Inc | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
WO2018157154A2 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Novel codon-optimized cftr mrna |
WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
KR20190127797A (en) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Cytosine to Guanine Base Editing Agent |
EP3596042B1 (en) | 2017-03-15 | 2022-01-12 | Modernatx, Inc. | Crystal forms of amino lipids |
WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
MA52262A (en) | 2017-03-15 | 2020-02-19 | Modernatx Inc | BROAD SPECTRUM VACCINE AGAINST THE INFLUENZA VIRUS |
WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
KR102185464B1 (en) | 2017-03-15 | 2020-12-03 | 매사추세츠 인스티튜트 오브 테크놀로지 | New CAS13B Ortholog CRISPR Enzyme and System |
HUE060693T2 (en) | 2017-03-15 | 2023-04-28 | Modernatx Inc | Compound and compositions for intracellular delivery of therapeutic agents |
US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
US20200030432A1 (en) * | 2017-03-17 | 2020-01-30 | Modernatx, Inc. | Zoonotic disease rna vaccines |
CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
MA48047A (en) | 2017-04-05 | 2020-02-12 | Modernatx Inc | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
WO2018191388A1 (en) | 2017-04-12 | 2018-10-18 | The Broad Institute, Inc. | Novel type vi crispr orthologs and systems |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
WO2018191719A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipid delivery of therapeutic agents to adipose tissue |
JP2020517638A (en) | 2017-04-20 | 2020-06-18 | エータイアー ファーマ, インコーポレイテッド | Compositions and methods for treating lung inflammation |
AU2018256867A1 (en) | 2017-04-27 | 2019-11-14 | The Johns Hopkins University | Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus |
CN110799492B (en) | 2017-04-28 | 2023-06-27 | 爱康泰生治疗公司 | Novel carbonyl lipid and lipid nanoparticle formulations for delivery of nucleic acids |
WO2018204777A2 (en) | 2017-05-05 | 2018-11-08 | The Broad Institute, Inc. | Methods for identification and modification of lncrna associated with target genotypes and phenotypes |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
EP3624824A1 (en) | 2017-05-16 | 2020-03-25 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
US10842853B2 (en) * | 2017-05-22 | 2020-11-24 | Baxalta Incorporated | Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia B |
WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
US10034951B1 (en) | 2017-06-21 | 2018-07-31 | New England Biolabs, Inc. | Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity |
US20200165593A1 (en) | 2017-07-21 | 2020-05-28 | Modernatx, Inc. | Modified mRNA Encoding a Propionyl-CoA Carboxylase and Uses Thereof |
EP3658672A1 (en) | 2017-07-24 | 2020-06-03 | Modernatx, Inc. | Modified mrna encoding a glucose-6-phosphatase and uses thereof |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
EP3668833A1 (en) | 2017-08-16 | 2020-06-24 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
JP7408098B2 (en) | 2017-08-18 | 2024-01-05 | モデルナティエックス インコーポレイテッド | RNA polymerase variants |
MA49922A (en) | 2017-08-18 | 2021-06-02 | Modernatx Inc | PROCESSES FOR HPLC ANALYSIS |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
JP7275111B2 (en) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | Method for producing lipid nanoparticles |
GB201714430D0 (en) * | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
AU2018338318B2 (en) | 2017-09-21 | 2022-12-22 | Massachusetts Institute Of Technology | Systems, methods, and compositions for targeted nucleic acid editing |
JP2021500863A (en) * | 2017-09-29 | 2021-01-14 | インテリア セラピューティクス,インコーポレイテッド | Polynucleotides, compositions and methods for genome editing |
US20200255828A1 (en) | 2017-10-04 | 2020-08-13 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
AU2018355427A1 (en) | 2017-10-25 | 2020-04-30 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2019089828A1 (en) | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
IL274230B2 (en) * | 2017-10-31 | 2023-12-01 | Modernatx Inc | Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide |
US11547614B2 (en) | 2017-10-31 | 2023-01-10 | The Broad Institute, Inc. | Methods and compositions for studying cell evolution |
EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
EP3727428A1 (en) | 2017-12-20 | 2020-10-28 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
WO2019131770A1 (en) * | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | Nucleic acid-containing lipid nano-particle and use thereof |
CN109988777A (en) * | 2017-12-29 | 2019-07-09 | 南京金斯瑞生物科技有限公司 | Glutamine synthetase gene and application |
US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
CA3091543A1 (en) * | 2018-02-19 | 2019-08-22 | Combined Therapeutics, Inc. | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
US20190292596A1 (en) * | 2018-03-21 | 2019-09-26 | Roche Molecular Systems, Inc. | Modified nucleoside phosphates with high thermal stability |
KR102114787B1 (en) * | 2018-04-02 | 2020-05-26 | 중앙대학교 산학협력단 | Preparing method for 3 dimension corneal endothelial graft comprising ribonuclease 5 overexepressing corneal endothelial cells |
US10968257B2 (en) | 2018-04-03 | 2021-04-06 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
SG11202008225PA (en) * | 2018-04-17 | 2020-11-27 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
US20200149070A1 (en) * | 2018-04-24 | 2020-05-14 | Ligandal, Inc. | Methods and compositions for genome editing |
EP4311541A3 (en) * | 2018-04-25 | 2024-02-07 | Ethris GmbH | Cryoprotective agents for particulate formulations |
JP7241782B2 (en) | 2018-06-22 | 2023-03-17 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Sustained Release Compositions and Methods for Treatment of Temporomandibular Joint Degenerative Diseases |
JP2021528096A (en) * | 2018-06-28 | 2021-10-21 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | Exosome extracellular vesicles and how to use them |
EP3821003A4 (en) | 2018-07-09 | 2022-07-20 | Gro Biosciences Inc. | Non-standard amino acid containing compositions and uses thereof |
EP3821012A4 (en) | 2018-07-13 | 2022-04-20 | The Regents of The University of California | Retrotransposon-based delivery vehicle and methods of use thereof |
WO2020028133A1 (en) | 2018-07-30 | 2020-02-06 | Trucode Gene Repair, Inc. | Lipid nanoparticle formulations comprising nucleic acid mimics |
WO2020028830A1 (en) * | 2018-08-03 | 2020-02-06 | Sangamo Therapeutics, Inc. | Improved clinical parameters by expression of factor viii |
JP2021532815A (en) | 2018-08-07 | 2021-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | New Cas12b enzyme and system |
US20210317429A1 (en) | 2018-08-20 | 2021-10-14 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
AU2019325702A1 (en) | 2018-08-24 | 2021-02-25 | Translate Bio, Inc. | Methods for purification of messenger RNA |
WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
EP3844267A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
CA3113449A1 (en) | 2018-09-21 | 2020-03-26 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
US11072808B2 (en) | 2018-10-04 | 2021-07-27 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed RNA |
EP3861108A1 (en) | 2018-10-04 | 2021-08-11 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed rna |
BR112021006539A2 (en) | 2018-10-09 | 2021-07-06 | Univ British Columbia | compositions and competent systems of vesicles competent for transfection free of organic solvents and detergents and related methods |
WO2020080475A1 (en) * | 2018-10-18 | 2020-04-23 | 武田薬品工業株式会社 | Method for activation/proliferation of t cells |
US20210395721A1 (en) | 2018-10-24 | 2021-12-23 | Codiak Biosciences, Inc. | Methods to improve potency of electroporation |
EP3908568A1 (en) | 2019-01-11 | 2021-11-17 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
CN109810184B (en) * | 2019-01-17 | 2022-07-12 | 武汉明德生物科技股份有限公司 | Human NF155 antigen, human NF155 antibody detection kit, preparation method and application thereof |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
WO2020168362A1 (en) | 2019-02-15 | 2020-08-20 | Crispr Therapeutics Ag | Gene editing for hemophilia a with improved factor viii expression |
US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
CN113795579A (en) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | RNA polymerase variants for co-transcriptional capping |
AU2020231349A1 (en) * | 2019-03-01 | 2021-09-23 | Flagship Pioneering Innovations Vi, Llc | Compositions, methods, and kits for delivery of polyribonucleotides |
MX2021010559A (en) | 2019-03-07 | 2021-12-15 | Univ California | Crispr-cas effector polypeptides and methods of use thereof. |
US20220177863A1 (en) | 2019-03-18 | 2022-06-09 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
MX2021011426A (en) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Methods and compositions for editing nucleotide sequences. |
EP3947646A1 (en) * | 2019-04-05 | 2022-02-09 | Precision BioSciences, Inc. | Methods of preparing populations of genetically-modified immune cells |
EP3953455A1 (en) | 2019-04-12 | 2022-02-16 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
US11490453B2 (en) * | 2019-05-16 | 2022-11-01 | Apple Inc. | Self-organizing device |
US20220220469A1 (en) | 2019-05-20 | 2022-07-14 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
RU2721562C1 (en) * | 2019-06-04 | 2020-05-20 | Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" | Method of loading inorganic nanoparticles or organic molecules into porous particles of micron or submicron size |
JP2022536112A (en) * | 2019-06-05 | 2022-08-12 | ガイド セラピューティクス,インコーポレーテッド | Analysis of materials for tissue delivery |
US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
US20230097090A1 (en) | 2019-08-14 | 2023-03-30 | Acuitas Therapeutics, Inc. | Improved lipid nanoparticles for delivery of nucleic acids |
JP2022548304A (en) | 2019-09-19 | 2022-11-17 | モデルナティエックス インコーポレイテッド | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
WO2021061594A1 (en) * | 2019-09-27 | 2021-04-01 | Merck Sharp & Dohme Corp. | Method for measuring nucleic acid content in lipid nanoprticles using ultraviolet spectrometry |
KR20220082885A (en) | 2019-11-15 | 2022-06-17 | 후지필름 가부시키가이샤 | Lipid composition |
EP4065158A2 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
CN111041025B (en) | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | mRNA targeting molecule based on combination of N-acetylgalactosamine polypeptide and preparation method thereof |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
CN111217867B (en) * | 2020-02-18 | 2024-03-22 | 福建瑞博奥科技有限公司 | Method for preparing floxuridine |
CN112121180B (en) * | 2020-02-19 | 2023-08-25 | 深圳厚存纳米药业有限公司 | Composite nanoparticles of poloxamer and or poloxamer and PEG lipids |
CN111944157B (en) * | 2020-02-21 | 2022-02-11 | 武汉中科先进技术研究院有限公司 | Nano magnetic bead and application thereof in 2019 novel coronavirus nucleic acid extraction, amplification and detection |
EP4110377A2 (en) | 2020-02-27 | 2023-01-04 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
CN115397856A (en) | 2020-03-30 | 2022-11-25 | 生物技术公司 | RNA compositions targeting claudin-18.2 |
WO2021205077A1 (en) | 2020-04-09 | 2021-10-14 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
WO2021257595A1 (en) | 2020-06-15 | 2021-12-23 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery for muscular dystrophies |
CN111744019B (en) | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | Mannose-based mRNA targeted delivery system and application thereof |
US20240024451A1 (en) | 2020-07-31 | 2024-01-25 | Combined Therapeutics, Inc. | Compositions and methods for improved vaccination |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN112076149B (en) * | 2020-09-09 | 2022-03-01 | 上海交通大学 | Coumarin targeted controlled-release nanogel and preparation method thereof |
WO2022054955A1 (en) | 2020-09-14 | 2022-03-17 | 富士フイルム株式会社 | Lipid composition |
AU2021405281A1 (en) | 2020-12-22 | 2023-07-06 | CureVac SE | Rna vaccine against sars-cov-2 variants |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
EP4319803A1 (en) | 2021-04-08 | 2024-02-14 | Vaxthera SAS | Coronavirus vaccine comprising a mosaic protein |
KR20240021170A (en) | 2021-05-12 | 2024-02-16 | 더 브로드 인스티튜트, 인코퍼레이티드 | Modified mRNA, modified non-coding RNA, and uses thereof |
KR20230008627A (en) | 2021-07-07 | 2023-01-16 | 주식회사 제넥신 | Hyaluronic acid-lipid derivatives, lipid nanoparticles comprising the same, and uses thereof |
WO2023003826A2 (en) * | 2021-07-20 | 2023-01-26 | The Regents Of The University Of California | Single- and multi-epitope peptide and mrna vaccines to generate tolerogenic effects for allergic and autoimmune disease by targeting liver sinusoidal endothelial cells |
WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
TW202325263A (en) | 2021-09-14 | 2023-07-01 | 美商雷納嘉德醫療管理公司 | Acyclic lipids and methods of use thereof |
TW202328067A (en) | 2021-09-14 | 2023-07-16 | 美商雷納嘉德醫療管理公司 | Cyclic lipids and methods of use thereof |
WO2023064469A1 (en) | 2021-10-13 | 2023-04-20 | Modernatx, Inc. | Compositions of mrna-encoded il15 fusion proteins and methods of use thereof |
WO2023081756A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
WO2023091490A1 (en) | 2021-11-16 | 2023-05-25 | Senda Biosciences, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
WO2023091787A1 (en) | 2021-11-22 | 2023-05-25 | Senda Biosciences, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
WO2023131254A1 (en) * | 2022-01-06 | 2023-07-13 | 上海吉量医药工程有限公司 | Pseudouridine modified at n1 position and use thereof in mrna synthesis |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2023147090A1 (en) | 2022-01-27 | 2023-08-03 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
WO2023149775A1 (en) * | 2022-02-07 | 2023-08-10 | 한국과학기술원 | Oligonucleotide for gene delivery and lipid nanoparticle for gene delivery comprising same |
WO2023172747A1 (en) * | 2022-03-11 | 2023-09-14 | W. L. Gore & Associates, Inc. | Bioabsorbable particles and method of use |
WO2023183616A1 (en) | 2022-03-25 | 2023-09-28 | Senda Biosciences, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
WO2023218431A1 (en) | 2022-05-13 | 2023-11-16 | BioNTech SE | Rna compositions targeting hiv |
WO2023230295A1 (en) | 2022-05-25 | 2023-11-30 | BioNTech SE | Rna compositions for delivery of monkeypox antigens and related methods |
WO2023232747A1 (en) | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes for delivery of nucleic acids |
WO2023239593A1 (en) * | 2022-06-08 | 2023-12-14 | Merck Sharp & Dohme Llc | Method for sustained delivery of mrna vaccines |
EP4327829A1 (en) | 2022-08-26 | 2024-02-28 | Ethris GmbH | Stabilization of lipid or lipidoid nanoparticle suspensions |
WO2024042236A1 (en) | 2022-08-26 | 2024-02-29 | Ethris Gmbh | Stable lipid or lipidoid nanoparticle suspensions |
WO2024049979A2 (en) | 2022-08-31 | 2024-03-07 | Senda Biosciences, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
WO2024056809A1 (en) | 2022-09-15 | 2024-03-21 | Novartis Ag | Treatment of autoimmune disorders using chimeric antigen receptor therapy |
WO2024064934A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of plasmodium csp antigens and related methods |
WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
WO2024063789A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
WO2024064931A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of liver stage antigens and related methods |
WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
WO2024074634A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
CN115671045B (en) * | 2022-12-30 | 2023-04-07 | 华南理工大学 | Non-liver-targeting nucleic acid nano preparation and preparation method and application thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303378B1 (en) * | 1997-10-24 | 2001-10-16 | Valentis, Inc. | Methods for preparing polynucleotide transfection complexes |
US20020064517A1 (en) * | 1998-04-30 | 2002-05-30 | Stewart A. Cederholm-Williams | Fibrin sealant as a transfection/transformation vehicle for gene therapy |
US20020130430A1 (en) * | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
US20060018971A1 (en) * | 2004-05-12 | 2006-01-26 | Terrence Scott | Nucleic acid microspheres, production and delivery thereof |
US20080274463A1 (en) * | 2007-05-04 | 2008-11-06 | Ventana Medical Systems, Inc. | Method for quantifying biomolecules conjugated to a nanoparticle |
US20090264511A1 (en) * | 2007-12-10 | 2009-10-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor vii gene |
US20090286852A1 (en) | 2005-08-23 | 2009-11-19 | Katalin Kariko | RNA containing modified nucleosides and methods of use thereof |
US20100015232A1 (en) * | 2006-07-07 | 2010-01-21 | Aarhus Universitet | Nanoparticles for nucleic acid delivery |
US20110244026A1 (en) * | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
WO2011130624A2 (en) * | 2010-04-16 | 2011-10-20 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
Family Cites Families (1391)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US618885A (en) | 1899-02-07 | Railway-car brake | ||
US618862A (en) | 1899-02-07 | Automatic stoker | ||
US533554A (en) | 1895-02-05 | Henry d | ||
US618957A (en) | 1899-02-07 | Inda may kelly | ||
US618953A (en) | 1899-02-07 | Apparatus for preventing pounding or water-hammering in circulating-pipes of heating | ||
US618896A (en) | 1899-02-07 | Potato-bug gatherer | ||
US618873A (en) | 1899-02-07 | Oyster-tongs | ||
US533537A (en) | 1895-02-05 | Watchmakers calipers | ||
US576705A (en) | 1897-02-09 | Vegetable cutter and grater | ||
US681712A (en) | 1898-03-26 | 1901-09-03 | American Railway Electric Light Co | Means for controlling electric currents. |
US648244A (en) | 1899-04-28 | 1900-04-24 | Orrin A Dever | Tank-mold. |
US696381A (en) | 1900-03-01 | 1902-03-25 | Hugo Loewenbach | Paper-feeding machine. |
US709303A (en) | 1901-11-19 | 1902-09-16 | Edward Chester & Company Ltd | Construction of tanks. |
US712490A (en) | 1902-01-13 | 1902-11-04 | Francis Blossom | Economizer system. |
US2008526A (en) | 1932-11-03 | 1935-07-16 | Wappler Frederick Charles | Method and means for treating living tissue |
US2588623A (en) | 1948-05-10 | 1952-03-11 | Eliscu Frank | Surgical instrument for intradermal injection of fluids |
US3467096A (en) | 1966-04-12 | 1969-09-16 | Ferrell S Horn | Multiple hypodermic syringe arrangement |
US3572336A (en) | 1968-04-30 | 1971-03-23 | Daniel R Hershberg | Syringe |
BE757653A (en) | 1969-10-21 | 1971-04-16 | Ugine Kuhlmann | NEW DRUGS DERIVED FROM NUCLEIC ACIDS AND METHODS FOR THEIR PREPARATION |
BE786542A (en) | 1971-07-22 | 1973-01-22 | Dow Corning | SUCTION DEVICE ALLOWING TO OBTAIN CELL SAMPLES |
US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US4411657A (en) | 1980-05-19 | 1983-10-25 | Anibal Galindo | Hypodermic needle |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4474569A (en) | 1982-06-28 | 1984-10-02 | Denver Surgical Developments, Inc. | Antenatal shunt |
JPS5927900A (en) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | Oligonucleotide derivative and its preparation |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
FR2540122B1 (en) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION |
US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4824941A (en) | 1983-03-10 | 1989-04-25 | Julian Gordon | Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US4579849A (en) | 1984-04-06 | 1986-04-01 | Merck & Co., Inc. | N-alkylguanine acyclonucleosides as antiviral agents |
US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
FR2567892B1 (en) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS |
US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
CA1288073C (en) | 1985-03-07 | 1991-08-27 | Paul G. Ahlquist | Rna transformation vector |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
EP0204401A1 (en) | 1985-04-09 | 1986-12-10 | Biogen, Inc. | Method of improving the yield of polypeptides produced in a host cell by stabilizing mRNA |
US4762779A (en) | 1985-06-13 | 1988-08-09 | Amgen Inc. | Compositions and methods for functionalizing nucleic acids |
US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
US4695273A (en) | 1986-04-08 | 1987-09-22 | I-Flow Corporation | Multiple needle holder and subcutaneous multiple channel infusion port |
US4879111A (en) | 1986-04-17 | 1989-11-07 | Cetus Corporation | Treatment of infections with lymphokines |
JPS638396A (en) | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | Poly-labeled oligonucleotide derivative |
US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
CA1340843C (en) | 1987-07-31 | 1999-12-07 | J. Lawrence Burg | Selective amplification of target polynucleotide sequences |
US6090591A (en) | 1987-07-31 | 2000-07-18 | The Board Of Trustees Of The Leland Stanford Junior University | Selective amplification of target polynucleotide sequences |
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
DE3738460A1 (en) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | MODIFIED OLIGONUCLEOTIDS |
AU624601B2 (en) | 1988-01-21 | 1992-06-18 | Genentech Inc. | Amplification and detection of nucleic acid sequences |
CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
JP2650159B2 (en) | 1988-02-24 | 1997-09-03 | アクゾ・ノベル・エヌ・ベー | Nucleic acid amplification method |
US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
WO1989007947A1 (en) | 1988-03-04 | 1989-09-08 | Cancer Research Campaign Technology Limited | Improvements relating to antigens |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
US5021335A (en) | 1988-06-17 | 1991-06-04 | The Board Of Trustees Of The Leland Stanford Junior University | In situ transcription in cells and tissues |
US5168038A (en) | 1988-06-17 | 1992-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | In situ transcription in cells and tissues |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5262536A (en) | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
US5759802A (en) | 1988-10-26 | 1998-06-02 | Tonen Corporation | Production of human serum alubumin A |
FR2638359A1 (en) | 1988-11-03 | 1990-05-04 | Tino Dalto | SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN |
US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
US5599923A (en) | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
ES2200016T3 (en) | 1989-03-21 | 2004-03-01 | Vical Incorporated | EXPRESSION OF EXECUTIVE POLINUCLEOTIDIC SEQUENCES IN A VERTEBRATE. |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US5012818A (en) | 1989-05-04 | 1991-05-07 | Joishy Suresh K | Two in one bone marrow surgical needle |
IE66597B1 (en) | 1989-05-10 | 1996-01-24 | Akzo Nv | Method for the synthesis of ribonucleic acid (RNA) |
US5240855A (en) | 1989-05-12 | 1993-08-31 | Pioneer Hi-Bred International, Inc. | Particle gun |
US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
US5451463A (en) | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
US5545522A (en) | 1989-09-22 | 1996-08-13 | Van Gelder; Russell N. | Process for amplifying a target polynucleotide sequence using a single primer-promoter complex |
EP0942000B1 (en) | 1989-10-24 | 2004-06-23 | Isis Pharmaceuticals, Inc. | 2'-Modified oligonucleotides |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
NO904633L (en) | 1989-11-09 | 1991-05-10 | Molecular Diagnostics Inc | AMPLIFICATION OF NUCLEIC ACIDS BY TRANSCRIPABLE HAIRNEL PROBE. |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5215899A (en) | 1989-11-09 | 1993-06-01 | Miles Inc. | Nucleic acid amplification employing ligatable hairpin probe and transcription |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5292873A (en) | 1989-11-29 | 1994-03-08 | The Research Foundation Of State University Of New York | Nucleic acids labeled with naphthoquinone probe |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
US6783931B1 (en) | 1990-01-11 | 2004-08-31 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
US7037646B1 (en) | 1990-01-11 | 2006-05-02 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
AU7579991A (en) | 1990-02-20 | 1991-09-18 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
ES2116977T3 (en) | 1990-05-11 | 1998-08-01 | Microprobe Corp | SOLID SUPPORTS FOR NUCLEIC ACID HYBRIDIZATION TESTS AND METHODS TO IMMOBILIZE OLIGONUCLEOTIDES IN A COVALENT WAY. |
US5194370A (en) | 1990-05-16 | 1993-03-16 | Life Technologies, Inc. | Promoter ligation activated transcription amplification of nucleic acid sequences |
EP0542874A4 (en) | 1990-07-25 | 1994-05-11 | Syngene Inc | Circular extension for generating multiple nucleic acid complements |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
US6140496A (en) | 1990-10-09 | 2000-10-31 | Benner; Steven Albert | Precursors for deoxyribonucleotides containing non-standard nucleosides |
ATE198598T1 (en) | 1990-11-08 | 2001-01-15 | Hybridon Inc | CONNECTION OF MULTIPLE REPORTER GROUPS ON SYNTHETIC OLIGONUCLEOTIDES |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
US6100024A (en) | 1991-02-08 | 2000-08-08 | Promega Corporation | Methods and compositions for nucleic acid detection by target extension and probe amplification |
DK0610201T4 (en) | 1991-03-18 | 2008-02-04 | Centocor Inc | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
US5426180A (en) | 1991-03-27 | 1995-06-20 | Research Corporation Technologies, Inc. | Methods of making single-stranded circular oligonucleotides |
ES2134212T3 (en) | 1991-04-25 | 1999-10-01 | Chugai Pharmaceutical Co Ltd | HUMAN ANTIBODY RECONSTITUTED AGAINST THE RECEIVER OF INTERLEUKIN 6 HUMAN. |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5169766A (en) | 1991-06-14 | 1992-12-08 | Life Technologies, Inc. | Amplification of nucleic acid molecules |
US5371241A (en) | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
US5199441A (en) | 1991-08-20 | 1993-04-06 | Hogle Hugh H | Fine needle aspiration biopsy apparatus and method |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (en) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | INJECTION NEEDLE ARRANGEMENT |
DE59208572D1 (en) | 1991-10-17 | 1997-07-10 | Ciba Geigy Ag | Bicyclic nucleosides, oligonucleotides, processes for their preparation and intermediates |
US5298422A (en) | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
US5595726A (en) | 1992-01-21 | 1997-01-21 | Pharmacyclics, Inc. | Chromophore probe for detection of nucleic acid |
JPH07503372A (en) | 1992-01-23 | 1995-04-13 | バイカル・インコーポレイテッド | In vitro gene transfer |
FR2687679B1 (en) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | OLIGOTHIONUCLEOTIDES. |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
JP3368603B2 (en) | 1992-02-28 | 2003-01-20 | オリンパス光学工業株式会社 | Gene therapy treatment device |
ES2149768T3 (en) | 1992-03-25 | 2000-11-16 | Immunogen Inc | CONJUGATES OF BINDING AGENTS OF CELLS DERIVED FROM CC-1065. |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
US6132419A (en) | 1992-05-22 | 2000-10-17 | Genetronics, Inc. | Electroporetic gene and drug therapy |
US5514545A (en) | 1992-06-11 | 1996-05-07 | Trustees Of The University Of Pennsylvania | Method for characterizing single cells based on RNA amplification for diagnostics and therapeutics |
EP0577558A2 (en) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates |
US6670178B1 (en) | 1992-07-10 | 2003-12-30 | Transkaryotic Therapies, Inc. | In Vivo production and delivery of insulinotropin for gene therapy |
US5272250A (en) | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
DE69310179T2 (en) | 1992-07-31 | 1997-07-31 | Behringwerke Ag | METHOD FOR INTRODUCING DEFINED SEQUENCES AT THE 3 'END OF POLYNUCLEOTIDES |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5240885A (en) | 1992-09-21 | 1993-08-31 | Corning Incorporated | Rare earth-doped, stabilized cadmium halide glasses |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
AU5665694A (en) | 1992-11-04 | 1994-05-24 | Denver Biomaterials Inc. | Apparatus for removal of pleural effusion fluid |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
CA2153692C (en) | 1993-01-12 | 2011-11-08 | Roy R. Lobb | Recombinant anti-vla4 antibody molecules |
CA2159631A1 (en) | 1993-03-30 | 1994-10-13 | Sanofi | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
FR2703253B1 (en) | 1993-03-30 | 1995-06-23 | Centre Nat Rech Scient | APPLICATOR OF ELECTRIC PULSES FOR TREATING BIOLOGICAL TISSUES. |
DE4311944A1 (en) | 1993-04-10 | 1994-10-13 | Degussa | Coated sodium percarbonate particles, process for their preparation and detergent, cleaning and bleaching compositions containing them |
US7135312B2 (en) | 1993-04-15 | 2006-11-14 | University Of Rochester | Circular DNA vectors for synthesis of RNA and DNA |
US5773244A (en) | 1993-05-19 | 1998-06-30 | Regents Of The University Of California | Methods of making circular RNA |
US5851829A (en) | 1993-07-16 | 1998-12-22 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
US6294664B1 (en) | 1993-07-29 | 2001-09-25 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
US5672491A (en) | 1993-09-20 | 1997-09-30 | The Leland Stanford Junior University | Recombinant production of novel polyketides |
US6432711B1 (en) | 1993-11-03 | 2002-08-13 | Diacrin, Inc. | Embryonic stem cells capable of differentiating into desired cell lines |
US6096503A (en) | 1993-11-12 | 2000-08-01 | The Scripps Research Institute | Method for simultaneous identification of differentially expresses mRNAs and measurement of relative concentrations |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
ES2224113T5 (en) | 1994-02-16 | 2009-05-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | ANTIGEN POLYPEPTIDE ASSOCIATED WITH MELANOMA, EPITHOPOS OF THE SAME AND VACCINES AGAINST MELANOMA. |
DE69530914T2 (en) * | 1994-02-17 | 2004-03-11 | New York Blood Center, Inc. | BIOLOGICAL BIOADHESIVE PREPARATIONS CONTAINING FIBRINE ADHESIVE AND LIPOSOMES, METHODS FOR THEIR PRODUCTION AND USE |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
IL112820A0 (en) | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
CA2184375C (en) | 1994-03-18 | 2006-05-02 | Sergei M. Gryaznov | Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5457041A (en) | 1994-03-25 | 1995-10-10 | Science Applications International Corporation | Needle array and method of introducing biological substances into living cells using the needle array |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5464395A (en) | 1994-04-05 | 1995-11-07 | Faxon; David P. | Catheter for delivering therapeutic and/or diagnostic agents to the tissue surrounding a bodily passageway |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
ATE368118T1 (en) | 1994-05-18 | 2007-08-15 | Bayer Bioscience Gmbh | FOR ENZYMES THAT HAVE THE ABILITY TO SYNTHESE LINEAR ALPHA 1,4-GLUCANS IN PLANTS, FUNGI AND MICROORGANISMS, DNA CODING SEQUENCES |
CA2191362A1 (en) | 1994-06-02 | 1995-12-14 | Mark Selby | Nucleic acid immunization using a virus-based infection/transfection system |
GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
ATE306930T1 (en) | 1994-08-12 | 2005-11-15 | Immunomedics Inc | IMMUNE CONJUGATES AND HUMAN ANTIBODIES SPECIFIC FOR B-CELL LYMPHOMA AND LEUKEMIA CELLS |
US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5665545A (en) | 1994-11-28 | 1997-09-09 | Akzo Nobel N.V. | Terminal repeat amplification method |
US5641665A (en) | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
US5588960A (en) | 1994-12-01 | 1996-12-31 | Vidamed, Inc. | Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence |
US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
DE69637239T2 (en) | 1995-01-06 | 2008-05-29 | Plant Research International B.V. | FOR CARBOHYDRATE POLYMERS-CONSTITUTING ENZYME-ENCODING DNA SEQUENCES AND METHOD FOR PRODUCING TRANSGENIC PLANTS |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5824497A (en) | 1995-02-10 | 1998-10-20 | Mcmaster University | High efficiency translation of mRNA molecules |
EP0727187B1 (en) | 1995-02-15 | 2003-08-06 | Joseph Eldor | Multiple hole spinal needle |
EP0735144B1 (en) | 1995-03-28 | 2002-06-05 | Japan Science and Technology Corporation | Method for molecular indexing of genes using restriction enzymes |
US5869230A (en) | 1995-03-30 | 1999-02-09 | Beth Israel Hospital Association | Gene transfer into the kidney |
US5986054A (en) | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
FR2733762B1 (en) | 1995-05-02 | 1997-08-01 | Genset Sa | METHOD FOR THE SPECIFIC COUPLING OF THE HAIR OF THE 5 'END OF A RNAM FRAGMENT AND PREPARATION OF RNAM AND COMPLETE DNA |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
US6111095A (en) | 1995-06-07 | 2000-08-29 | Merck & Co., Inc. | Capped synthetic RNA, analogs, and aptamers |
US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
US5713863A (en) | 1996-01-11 | 1998-02-03 | Interventional Technologies Inc. | Catheter with fluid medication injectors |
US5766903A (en) | 1995-08-23 | 1998-06-16 | University Technology Corporation | Circular RNA and uses thereof |
US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
WO1997011085A1 (en) | 1995-09-19 | 1997-03-27 | University Of Massachusetts | Inhibited biological degradation of oligodeoxynucleotides |
US5830879A (en) | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
US6265387B1 (en) | 1995-10-11 | 2001-07-24 | Mirus, Inc. | Process of delivering naked DNA into a hepatocyte via bile duct |
EP0771873A3 (en) | 1995-10-27 | 1998-03-04 | Takeda Chemical Industries, Ltd. | Neuronal cell-specific receptor protein |
CU22584A1 (en) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | PHARMACEUTICAL COMPOSITIONS CONTAINING A MONOCLONAL ANTIBODY THAT RECOGNIZES THE CD6 HUMAN LEUKOCYTARY DIFFERENTIATION ANTIGEN AND ITS USES FOR THE DIAGNOSIS AND TREATMENT OF PSORIASIS |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US5962271A (en) | 1996-01-03 | 1999-10-05 | Cloutech Laboratories, Inc. | Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
US6261584B1 (en) | 1996-02-02 | 2001-07-17 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
WO1997030064A1 (en) | 1996-02-16 | 1997-08-21 | Stichting Rega Vzw | Hexitol containing oligonucleotides and their use in antisense strategies |
US6534312B1 (en) | 1996-02-22 | 2003-03-18 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
US6090391A (en) | 1996-02-23 | 2000-07-18 | Aviron | Recombinant tryptophan mutants of influenza |
SE9601245D0 (en) | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
US6300487B1 (en) | 1996-03-19 | 2001-10-09 | Cell Therapuetics, Inc. | Mammalian lysophosphatidic acid acyltransferase |
TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
US20030073908A1 (en) | 1996-04-26 | 2003-04-17 | 2000 Injectx, Inc. | Method and apparatus for delivery of genes, enzymes and biological agents to tissue cells |
US5712127A (en) | 1996-04-29 | 1998-01-27 | Genescape Inc. | Subtractive amplification |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
ATE438717T1 (en) | 1996-06-05 | 2009-08-15 | Novartis Vaccines & Diagnostic | DP-75 CODING DNA AND METHOD OF USE THEREOF |
US7329741B2 (en) | 1996-06-05 | 2008-02-12 | Chiron Corporation | Polynucleotides that hybridize to DP-75 and their use |
WO1997048370A2 (en) | 1996-06-21 | 1997-12-24 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
JP2002515786A (en) | 1996-06-28 | 2002-05-28 | ソントラ メディカル,エル.ピー. | Ultrasound enhancement of transdermal delivery |
US5939262A (en) | 1996-07-03 | 1999-08-17 | Ambion, Inc. | Ribonuclease resistant RNA preparation and utilization |
US5677124A (en) | 1996-07-03 | 1997-10-14 | Ambion, Inc. | Ribonuclease resistant viral RNA standards |
US7288266B2 (en) | 1996-08-19 | 2007-10-30 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
US5849546A (en) | 1996-09-13 | 1998-12-15 | Epicentre Technologies Corporation | Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside triphosphates |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
WO1998013493A2 (en) | 1996-09-24 | 1998-04-02 | Lxr Biotechnology, Inc. | A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
ATE292980T1 (en) | 1996-10-11 | 2005-04-15 | Univ California | IMMUNO-STIMULATING OLIGONUCLEOTIDE CONJUGATES |
EP0839912A1 (en) | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
US5980887A (en) | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
US5759179A (en) | 1996-12-31 | 1998-06-02 | Johnson & Johnson Medical, Inc. | Needle and valve assembly for use with a catheter |
WO1998031700A1 (en) | 1997-01-21 | 1998-07-23 | The General Hospital Corporation | Selection of proteins using rna-protein fusions |
EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
ES2274566T3 (en) | 1997-02-07 | 2007-05-16 | MERCK & CO., INC. | SYNTHETIC GAG GENES OF HIV. |
US6251665B1 (en) | 1997-02-07 | 2001-06-26 | Cem Cezayirli | Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom |
US6228640B1 (en) | 1997-02-07 | 2001-05-08 | Cem Cezayirli | Programmable antigen presenting cell of CD34 lineage |
US6696291B2 (en) | 1997-02-07 | 2004-02-24 | Merck & Co., Inc. | Synthetic HIV gag genes |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
US5914269A (en) | 1997-04-04 | 1999-06-22 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of epidermal growth factor receptor expression |
WO1998047913A2 (en) | 1997-04-18 | 1998-10-29 | The University Of Medicine And Dentistry Of New Jersey | Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog |
US5958688A (en) | 1997-04-28 | 1999-09-28 | The Trustees Of The University Of Pennsylvania | Characterization of mRNA patterns in neurites and single cells for medical diagnosis and therapeutics |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US5989911A (en) | 1997-05-09 | 1999-11-23 | University Of Massachusetts | Site-specific synthesis of pseudouridine in RNA |
US6761726B1 (en) | 1998-05-15 | 2004-07-13 | Pyng Medical Corp. | Method and apparatus for the intraosseous introduction of a device such as an infusion tube |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
US6124091A (en) | 1997-05-30 | 2000-09-26 | Research Corporation Technologies, Inc. | Cell growth-controlling oligonucleotides |
CA2291483C (en) | 1997-06-06 | 2012-09-18 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
AU731909B2 (en) | 1997-07-01 | 2001-04-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
CN1275085A (en) | 1997-07-21 | 2000-11-29 | 法玛西雅和厄普约翰公司 | Cytolysis of target cell, reagent and composition for cytolysis and compound for preparing these reagents |
US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
CA2298811A1 (en) | 1997-07-31 | 1999-02-11 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for the treatment of grafts |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
ES2389519T3 (en) | 1997-09-18 | 2012-10-26 | The Trustees Of The University Of Pennsylvania | Attenuated vif DNA immunization cassettes for genetic vaccines |
AU9319398A (en) | 1997-09-19 | 1999-04-05 | Sequitur, Inc. | Sense mrna therapy |
US6004573A (en) | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
JP2001519162A (en) | 1997-10-07 | 2001-10-23 | ユニバーシティ・オブ・メリーランド・バイオテクノロジー・インスティチュート | Method for introducing and expressing RNA in animal cells |
CA2306796A1 (en) | 1997-10-20 | 1999-04-29 | Genzyme Transgenics Corporation | Novel modified msp-1 nucleic acid sequences and methods for increasing mrna levels and protein expression in cell systems |
US6019747A (en) | 1997-10-21 | 2000-02-01 | I-Flow Corporation | Spring-actuated infusion syringe |
US6077251A (en) | 1997-10-30 | 2000-06-20 | Ting; Windsor | Medicinal agent administration system |
EP1987845B1 (en) | 1997-11-20 | 2012-03-21 | Vical Incorporated | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor. |
US7655777B2 (en) | 1997-11-24 | 2010-02-02 | Monsanto Technology Llc | Nucleic acid molecules associated with the tocopherol pathway |
ZA9811377B (en) | 1997-12-12 | 1999-08-27 | Expression Genetics Inc | Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid[ for the delivery of a bioactive agent via tissue and cellular uptake. |
US6517869B1 (en) | 1997-12-12 | 2003-02-11 | Expression Genetics, Inc. | Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the delivery of a bioactive agent via tissue and cellular uptake |
US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
WO1999033982A2 (en) | 1997-12-23 | 1999-07-08 | Chiron Corporation | Human genes and gene expression products i |
US6383811B2 (en) | 1997-12-30 | 2002-05-07 | Mirus Corporation | Polyampholytes for delivering polyions to a cell |
EP2138191A1 (en) | 1998-01-05 | 2009-12-30 | University Of Washington | Enhanced transport using membrane disruptive agents |
US8287483B2 (en) | 1998-01-08 | 2012-10-16 | Echo Therapeutics, Inc. | Method and apparatus for enhancement of transdermal transport |
CA2317777C (en) | 1998-01-08 | 2005-05-03 | Sontra Medical, Inc. | Sonophoretic enhanced transdermal transport |
IT1298087B1 (en) | 1998-01-08 | 1999-12-20 | Fiderm S R L | DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS |
US6365346B1 (en) | 1998-02-18 | 2002-04-02 | Dade Behring Inc. | Quantitative determination of nucleic acid amplification products |
US5955310A (en) | 1998-02-26 | 1999-09-21 | Novo Nordisk Biotech, Inc. | Methods for producing a polypeptide in a bacillus cell |
US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
US6429301B1 (en) | 1998-04-17 | 2002-08-06 | Whitehead Institute For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
GB9808327D0 (en) | 1998-04-20 | 1998-06-17 | Chiron Spa | Antidiotypic compounds |
US6395253B2 (en) | 1998-04-23 | 2002-05-28 | The Regents Of The University Of Michigan | Microspheres containing condensed polyanionic bioactive agents and methods for their production |
US7521178B1 (en) | 1998-04-23 | 2009-04-21 | Takara Bio Inc. | Method for synthesizing DNA |
US20090208418A1 (en) | 2005-04-29 | 2009-08-20 | Innexus Biotechnology Internaltional Ltd. | Superantibody synthesis and use in detection, prevention and treatment of disease |
MXPA00011312A (en) | 1998-05-20 | 2003-04-22 | Expression Genetics Inc | A hepatocyte targeting polyethylene glyco-grafted poly-l-lysine polymeric gene carrier. |
US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
CN1313873A (en) | 1998-07-13 | 2001-09-19 | 表达遗传学公司 | Polyester analogus of poly-L-Lysine as a soluble, biodegradable gene delivery carrier |
EP2428249B1 (en) | 1998-07-13 | 2015-10-07 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6222030B1 (en) | 1998-08-03 | 2001-04-24 | Agilent Technologies, Inc. | Solid phase synthesis of oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection |
EP1112084B2 (en) | 1998-08-11 | 2012-04-25 | Biogen Idec Inc. | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
GB9817662D0 (en) | 1998-08-13 | 1998-10-07 | Crocker Peter J | Substance delivery |
US20020065236A1 (en) | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
US20090017533A1 (en) | 1998-09-29 | 2009-01-15 | Shire Human Genetic Therapies, Inc., A Delaware Corporation | Optimized messenger rna |
US6924365B1 (en) | 1998-09-29 | 2005-08-02 | Transkaryotic Therapies, Inc. | Optimized messenger RNA |
CA2348779A1 (en) | 1998-11-03 | 2000-05-11 | Yale University | Multidomain polynucleotide molecular sensors |
MY155913A (en) | 1998-11-09 | 2015-12-15 | Biogen Inc | Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transpants |
WO2000027428A1 (en) | 1998-11-09 | 2000-05-18 | Idec Pharmaceuticals Corporation | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
WO2000027340A2 (en) | 1998-11-12 | 2000-05-18 | The Children's Medical Center Corporation | USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF |
JP4854853B2 (en) | 1998-11-12 | 2012-01-18 | ライフ テクノロジーズ コーポレーション | Transfection drug |
US6210931B1 (en) | 1998-11-30 | 2001-04-03 | The United States Of America As Represented By The Secretary Of Agriculture | Ribozyme-mediated synthesis of circular RNA |
US20040171980A1 (en) | 1998-12-18 | 2004-09-02 | Sontra Medical, Inc. | Method and apparatus for enhancement of transdermal transport |
AU3128000A (en) | 1998-12-23 | 2000-07-31 | Human Genome Sciences, Inc. | Peptidoglycan recognition proteins |
GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
US6255476B1 (en) | 1999-02-22 | 2001-07-03 | Pe Corporation (Ny) | Methods and compositions for synthesis of labelled oligonucleotides and analogs on solid-supports |
EP1155124A2 (en) | 1999-02-22 | 2001-11-21 | European Molecular Biology Laboratory | In vitro translation system |
US7629311B2 (en) | 1999-02-24 | 2009-12-08 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
CA2363141C (en) | 1999-02-26 | 2010-04-06 | Chiron Corporation | Microemulsions with adsorbed macromolecules and microparticles |
AU763173B2 (en) | 1999-03-01 | 2003-07-17 | Atossa Genetics, Inc. | Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts |
US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
AU778809B2 (en) | 1999-03-29 | 2004-12-23 | Statens Serum Institut | Method for producing a nucleotide sequence construct with optimised codons for an HIV genetic vaccine based on primary, early HIV isolate and synthetic envelope BX08 constructs |
CN1311005C (en) | 1999-04-09 | 2007-04-18 | 迪纳尔生物技术公司 | Process for the preparation of monodisperse polymer particles |
KR100782896B1 (en) | 1999-05-04 | 2007-12-06 | 엑시콘 에이/에스 | L-Ribo-LNA analogues |
WO2000067796A1 (en) | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
US8663692B1 (en) | 1999-05-07 | 2014-03-04 | Pharmasol Gmbh | Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same |
US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
US7074403B1 (en) | 1999-06-09 | 2006-07-11 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target B-cells |
US6346382B1 (en) | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
AU4332399A (en) | 1999-06-04 | 2000-12-28 | Cheng-Ming Chuong | Rna polymerase chain reaction |
US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
US6303573B1 (en) | 1999-06-07 | 2001-10-16 | The Burnham Institute | Heart homing peptides and methods of using same |
WO2000075304A1 (en) | 1999-06-08 | 2000-12-14 | Aventis Pasteur | Immunostimulant oligonucleotide |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
JP2003503071A (en) | 1999-06-30 | 2003-01-28 | アドバンスド セル テクノロジー、インコーポレイテッド | Cytoplasmic transfer to dedifferentiated recipient cells |
US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
CN1360631A (en) | 1999-07-09 | 2002-07-24 | 美国家用产品公司 | Methods and compositions for preventing formation of aberrant RNA during transcription of plasmid sequence |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
EP2829609A1 (en) | 1999-08-24 | 2015-01-28 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
US20050112141A1 (en) | 2000-08-30 | 2005-05-26 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
US6551338B1 (en) | 1999-09-01 | 2003-04-22 | Mcgill University | Method and device for myogenesis and angiogenesis of the heart |
US20040106567A1 (en) | 1999-09-07 | 2004-06-03 | Hagstrom James E. | Intravascular delivery of non-viral nucleic acid |
EP1619254B1 (en) | 1999-09-09 | 2010-12-22 | CureVac GmbH | Transfer of mRNA using polycationic compounds |
AU7398200A (en) | 1999-09-17 | 2001-04-24 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
US6623457B1 (en) | 1999-09-22 | 2003-09-23 | Becton, Dickinson And Company | Method and apparatus for the transdermal administration of a substance |
WO2002064799A2 (en) | 1999-09-28 | 2002-08-22 | Transkaryotic Therapies, Inc. | Optimized messenger rna |
WO2001025488A2 (en) | 1999-10-06 | 2001-04-12 | Quark Biotech, Inc. | Method for enrichment of natural antisense messenger rna |
US7060291B1 (en) | 1999-11-24 | 2006-06-13 | Transave, Inc. | Modular targeted liposomal delivery system |
US6613026B1 (en) | 1999-12-08 | 2003-09-02 | Scimed Life Systems, Inc. | Lateral needle-less injection apparatus and method |
US6277974B1 (en) | 1999-12-14 | 2001-08-21 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
US6245929B1 (en) | 1999-12-20 | 2001-06-12 | General Electric Company | Catalyst composition and method for producing diaryl carbonates, using bisphosphines |
EP1157045B1 (en) | 1999-12-22 | 2004-10-20 | Basell Poliolefine Italia S.p.A. | Alpha-olefin polymerization catalyst system which contains an aromatic silane compound |
SE515932C2 (en) | 1999-12-23 | 2001-10-29 | Prostalund Operations Ab | Method and apparatus for the treatment of prostate |
US7737108B1 (en) | 2000-01-07 | 2010-06-15 | University Of Washington | Enhanced transport using membrane disruptive agents |
WO2001051661A2 (en) | 2000-01-13 | 2001-07-19 | Amsterdam Support Diagnostics B.V. | A universal nucleic acid amplification system for nucleic acids in a sample |
US6552006B2 (en) | 2000-01-31 | 2003-04-22 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
CA2395811A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
TR200202799T3 (en) | 2000-02-24 | 2003-03-21 | Washington University St.Louis | Humanized antibodies that sequence the AB peptide |
DK1259265T3 (en) | 2000-03-03 | 2011-07-11 | Genetronics Inc | Nucleic acid formulations for delivery of genes |
EP1276702A2 (en) | 2000-03-31 | 2003-01-22 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
KR20020091170A (en) | 2000-03-31 | 2002-12-05 | 아이덱 파마슈티칼즈 코포레이션 | Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
US6565572B2 (en) | 2000-04-10 | 2003-05-20 | Sdgi Holdings, Inc. | Fenestrated surgical screw and method |
US6368801B1 (en) | 2000-04-12 | 2002-04-09 | Molecular Staging, Inc. | Detection and amplification of RNA using target-mediated ligation of DNA by RNA ligase |
EP1276849A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | Albumin fusion proteins |
US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
US6468247B1 (en) | 2000-04-21 | 2002-10-22 | Mark Zamoyski | Perfusion device for localized drug delivery |
US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US20040229271A1 (en) | 2000-05-19 | 2004-11-18 | Williams Richard B. | Compositions and methods for the identification and selection of nucleic acids and polypeptides |
WO2001092523A2 (en) | 2000-05-30 | 2001-12-06 | Curagen Corporation | Human polynucleotides and polypeptides encoded thereby |
US6537242B1 (en) | 2000-06-06 | 2003-03-25 | Becton, Dickinson And Company | Method and apparatus for enhancing penetration of a member for the intradermal sampling or administration of a substance |
EP1292331A2 (en) | 2000-06-07 | 2003-03-19 | Biosynexus Incorporated | Immunostimulatory rna/dna hybrid molecules |
US6607513B1 (en) | 2000-06-08 | 2003-08-19 | Becton, Dickinson And Company | Device for withdrawing or administering a substance and method of manufacturing a device |
CN1298738C (en) | 2000-06-23 | 2007-02-07 | 惠氏控股有限公司 | Modified morbillivirus V proteins |
US20050181033A1 (en) | 2000-06-29 | 2005-08-18 | Dekker John P.Iii | Method for delivering interferons to the intradermal compartment |
DE60139690D1 (en) | 2000-07-03 | 2009-10-08 | Novartis Vaccines & Diagnostic | IMMUNIZATION AGAINST CHLAMYDIA PNEUMONIAE |
US6440096B1 (en) | 2000-07-14 | 2002-08-27 | Becton, Dickinson And Co. | Microdevice and method of manufacturing a microdevice |
EP1301614B1 (en) | 2000-07-21 | 2006-11-29 | Glaxo Group Limited | Codon-optimized papilloma virus sequences |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
US20040142474A1 (en) | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
UA83458C2 (en) * | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf) |
AU2001290078A1 (en) | 2000-09-20 | 2002-04-02 | Ruggero Della Bitta | Stem cell therapy |
EP1334109B1 (en) | 2000-10-04 | 2006-05-10 | Santaris Pharma A/S | Improved synthesis of purine locked nucleic acid analogues |
WO2002029088A2 (en) | 2000-10-04 | 2002-04-11 | The Trustees Of The University Of Pennsylvania | Highly expressible genes |
US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
US7202226B2 (en) | 2000-10-23 | 2007-04-10 | Detroit R & D | Augmentation of wound healing by elF-4E mRNA and EGF mRNA |
US20030077604A1 (en) | 2000-10-27 | 2003-04-24 | Yongming Sun | Compositions and methods relating to breast specific genes and proteins |
CN1507357A (en) * | 2000-10-31 | 2004-06-23 | PRҩƷ����˾ | Method and compositions for enhanced delivery of bioactive molecules |
US20020132788A1 (en) | 2000-11-06 | 2002-09-19 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
WO2002040545A2 (en) | 2000-11-17 | 2002-05-23 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point |
JP2004535765A (en) | 2000-12-07 | 2004-12-02 | カイロン コーポレイション | Endogenous retrovirus up-regulated in prostate cancer |
US7708915B2 (en) | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
US7628780B2 (en) | 2001-01-13 | 2009-12-08 | Medtronic, Inc. | Devices and methods for interstitial injection of biologic agents into tissue |
SG149684A1 (en) | 2001-01-19 | 2009-02-27 | Vironovative Bv | A virus causing respiratory tract illness in susceptible animals |
EP1224943A1 (en) | 2001-01-19 | 2002-07-24 | Crucell Holland B.V. | Fibronectin as a tumor marker detected by phage antibodies |
US20040110191A1 (en) | 2001-01-31 | 2004-06-10 | Winkler Matthew M. | Comparative analysis of nucleic acids using population tagging |
JP2004527236A (en) | 2001-02-14 | 2004-09-09 | ベイラー カレッジ オブ メディスン | Methods and compositions for RNA amplification |
US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
DE10109897A1 (en) | 2001-02-21 | 2002-11-07 | Novosom Ag | Optional cationic liposomes and their use |
US7232425B2 (en) | 2001-03-02 | 2007-06-19 | Sorenson Development, Inc. | Apparatus and method for specific interstitial or subcutaneous diffusion and dispersion of medication |
DE60228212D1 (en) | 2001-03-09 | 2008-09-25 | Gene Stream Pty Ltd | NEW EXPRESSION VECTORS |
JP2002262882A (en) | 2001-03-12 | 2002-09-17 | Nisshinbo Ind Inc | Method for amplifying rna |
FR2822164B1 (en) | 2001-03-19 | 2004-06-18 | Centre Nat Rech Scient | POLYPEPTIDES DERIVED FROM POLYMERASE RNAS, AND USES THEREOF |
US6520949B2 (en) | 2001-04-02 | 2003-02-18 | Martin St. Germain | Method and apparatus for administering fluid to animals subcutaneously |
US6625486B2 (en) | 2001-04-11 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for intracellular delivery of an agent |
DE10119005A1 (en) | 2001-04-18 | 2002-10-24 | Roche Diagnostics Gmbh | Process for protein expression starting from stabilized linear short DNA in cell-free in vitro transcription / translation systems with exonuclease-containing lysates or in a cellular system containing exonucleases |
US20030171253A1 (en) | 2001-04-19 | 2003-09-11 | Averil Ma | Methods and compositions relating to modulation of A20 |
ATE376434T1 (en) | 2001-04-21 | 2007-11-15 | Curevac Gmbh | INJECTION DEVICE FOR MRNA APPLICATION |
IL158514A0 (en) | 2001-04-23 | 2004-05-12 | Amaxa Gmbh | Buffer solution for electroporation and a method comprising the use of the same |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US6777187B2 (en) | 2001-05-02 | 2004-08-17 | Rubicon Genomics, Inc. | Genome walking by selective amplification of nick-translate DNA library and amplification from complex mixtures of templates |
EP1392587A4 (en) | 2001-05-08 | 2009-03-18 | Magnatech International L P | Electronic length control wire pay-off system and method |
US20050137155A1 (en) | 2001-05-18 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA) |
US8137911B2 (en) | 2001-05-22 | 2012-03-20 | Cellscript, Inc. | Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences |
WO2002097116A2 (en) | 2001-05-30 | 2002-12-05 | The Scripps Research Institute | Delivery system for nucleic acids |
ES2340532T3 (en) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | MRNA WITH AN INCREASED G / C CONTENT THAT CODIFIES FOR A BACTERIAL ANTIGEN AND USING THE SAME. |
US20040175787A1 (en) | 2001-06-18 | 2004-09-09 | Klemens Kaupmann | Novel g-protein coupled receptors and dna sequences thereof |
EP1270732A1 (en) | 2001-06-21 | 2003-01-02 | Schuler, Gerold | Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
US7785610B2 (en) | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
US7547551B2 (en) | 2001-06-21 | 2009-06-16 | University Of Antwerp. | Transfection of eukaryontic cells with linear polynucleotides by electroporation |
EP1404716A2 (en) | 2001-06-26 | 2004-04-07 | Novartis AG | Novel g protein-coupled receptors and dna sequences thereof |
SE0102327D0 (en) | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
CN1253220C (en) | 2001-06-29 | 2006-04-26 | 贝克顿迪肯森公司 | Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
US20040236092A1 (en) | 2001-07-13 | 2004-11-25 | Roman Dziarski | Peptidologlycan recognition protein encoding nucleic acids and methods of use thereof |
US6586524B2 (en) | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
EP1430140B1 (en) | 2001-08-01 | 2010-09-15 | University of Utah | N-terminally truncated isoforms of pde3a cyclic phosphodiesterases |
WO2003018798A2 (en) | 2001-08-27 | 2003-03-06 | Novartis Ag | G-protein coupled receptor and dna sequences thereof |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
EP2428571B1 (en) | 2001-09-28 | 2018-07-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
CA2462593A1 (en) | 2001-10-03 | 2003-04-10 | Kam W. Leong | Compositions for oral gene therapy and methods of using same |
AR045702A1 (en) | 2001-10-03 | 2005-11-09 | Chiron Corp | COMPOSITIONS OF ASSISTANTS. |
DE10148886A1 (en) | 2001-10-04 | 2003-04-30 | Avontec Gmbh | Inhibition of STAT-1 |
US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
US7429258B2 (en) | 2001-10-26 | 2008-09-30 | Massachusetts Institute Of Technology | Microneedle transport device |
EP1452593B1 (en) | 2001-11-14 | 2009-04-08 | Toyo Boseki Kabushiki Kaisha | Dna synthesis promoters, dna polymerase-associated factors and utilization thereof |
US20030138419A1 (en) | 2001-11-16 | 2003-07-24 | The University Of Tennessee Research Corporation | Recombinant antibody fusion proteins and methods for detection of apoptotic cells |
WO2003046578A2 (en) | 2001-11-29 | 2003-06-05 | Novartis Ag | Method for the assessment and prognosis of sarcoidosis |
CA2409775C (en) | 2001-12-03 | 2010-07-13 | F. Hoffmann-La Roche Ag | Reversibly modified thermostable enzymes for dna synthesis and amplification in vitro |
DE60235413D1 (en) | 2001-12-07 | 2010-04-01 | Novartis Vaccines & Diagnostic | IN PROSTATE CANCER HIGHLY REGULATED ENDOGENIC RETROVIRUS |
US20060275747A1 (en) | 2001-12-07 | 2006-12-07 | Hardy Stephen F | Endogenous retrovirus up-regulated in prostate cancer |
JP4822490B2 (en) | 2001-12-07 | 2011-11-24 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Endogenous retroviral polypeptides associated with oncogenic transformation |
AU2002361429A1 (en) | 2001-12-17 | 2003-06-30 | Novartis Ag | Novel g-protein coupled receptors and dna sequences thereof |
DE10162480A1 (en) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | The application of mRNA for use as a therapeutic agent against tumor diseases |
SI1474109T1 (en) | 2001-12-21 | 2010-11-30 | Alcon Inc | Use of synthetic inorganic nanoparticles as carriers for ophthalmic drugs |
AU2003235707A1 (en) | 2002-01-18 | 2003-07-30 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
US7741297B2 (en) | 2002-02-04 | 2010-06-22 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
AU2003210802B2 (en) | 2002-02-05 | 2009-09-10 | Genentech Inc. | Protein purification |
FR2835749B1 (en) | 2002-02-08 | 2006-04-14 | Inst Nat Sante Rech Med | PHARMACEUTICAL COMPOSITION IMPROVING IN VIVO GENE TRANSFER |
DE10207178A1 (en) | 2002-02-19 | 2003-09-04 | Novosom Ag | Components for the production of amphoteric liposomes |
AR038568A1 (en) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | ANTI-A BETA ANTIBODIES AND ITS USE |
US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
US7354742B2 (en) | 2002-02-22 | 2008-04-08 | Ortho-Mcneil Pharmaceutical, Inc. | Method for generating amplified RNA |
CA2481479C (en) | 2002-02-26 | 2012-12-11 | Maxygen, Inc. | Novel flavivirus antigens |
ATE475431T1 (en) | 2002-03-04 | 2010-08-15 | Imclone Llc | KDR-SPECIFIC HUMAN ANTIBODIES AND THEIR APPLICATION |
WO2003075892A1 (en) | 2002-03-13 | 2003-09-18 | Novartis Ag | Pharmaceutical microparticles |
US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
EP3006043B1 (en) | 2002-04-04 | 2019-05-29 | Zoetis Belgium S.A. | Immunostimulatory g,u-containing oligoribonucleotides |
WO2003087815A2 (en) | 2002-04-17 | 2003-10-23 | Novartis Ag | Method for the identification of inhibitors of the binding of are-containing mrn a and an hur protein |
GB0209539D0 (en) | 2002-04-26 | 2002-06-05 | Avecia Ltd | Monomer Polymer and process |
EP1361277A1 (en) | 2002-04-30 | 2003-11-12 | Centre National De La Recherche Scientifique (Cnrs) | Optimization of transgene expression in mammalian cells |
HUE030806T2 (en) | 2002-05-02 | 2017-05-29 | Wyeth Holdings Llc | Calicheamicin derivative-carrier conjugates |
AU2003217531A1 (en) | 2002-05-02 | 2003-11-17 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
WO2003094995A1 (en) | 2002-05-06 | 2003-11-20 | Becton, Dickinson And Company | Method and device for controlling drug pharmacokinetics |
AU2003237824B9 (en) | 2002-05-08 | 2008-06-19 | The Regents Of The University Of California | System and method for treating cardiac arrhythmias with fibroblast cells |
US20040018525A1 (en) | 2002-05-21 | 2004-01-29 | Bayer Aktiengesellschaft | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
US7374930B2 (en) | 2002-05-21 | 2008-05-20 | Expression Genetics, Inc. | GLP-1 gene delivery for the treatment of type 2 diabetes |
DE10224200C1 (en) | 2002-05-31 | 2003-08-21 | Artus Ges Fuer Molekularbiolog | Replicating RNA, useful, after reverse transcription, for analysis on microarrays, comprises conversion to cDNA then reverse transcription of this to form antisense sequences |
WO2003101401A2 (en) | 2002-06-03 | 2003-12-11 | Chiron Corporation | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer |
SE0201907D0 (en) | 2002-06-19 | 2002-06-19 | Atos Medical Ab | Patches for tracheostoma valves |
WO2004002453A1 (en) | 2002-06-28 | 2004-01-08 | Protiva Biotherapeutics Ltd. | Method and apparatus for producing liposomes |
CA2491567A1 (en) | 2002-07-01 | 2004-01-08 | The Kenneth S. Warren Institute, Inc. | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
DE10229872A1 (en) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immune stimulation through chemically modified RNA |
GB0215509D0 (en) | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
DE60336736D1 (en) | 2002-07-16 | 2011-05-26 | VGX Pharmaceuticals LLC | CODON-OPTIMIZED SYNTHETIC PLASMIDE |
EP1543157A4 (en) | 2002-07-24 | 2006-11-15 | Ptc Therapeutics Inc | METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
EP1393745A1 (en) | 2002-07-29 | 2004-03-03 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends |
EP1386925A1 (en) | 2002-07-31 | 2004-02-04 | Girindus AG | Method for preparing oligonucleotides |
US6653468B1 (en) | 2002-07-31 | 2003-11-25 | Isis Pharmaceuticals, Inc. | Universal support media for synthesis of oligomeric compounds |
JP2005534389A (en) | 2002-08-01 | 2005-11-17 | アボット ラボラトリーズ バスキュラー エンタープライゼズ リミテッド | Device for sealing a puncture hole by reducing the perimeter of the puncture hole |
EP1873180B1 (en) | 2002-08-14 | 2014-05-07 | Novartis AG | Ophthalmic device made from a radiation-curable prepolymer |
BR0313890A (en) | 2002-08-30 | 2005-07-26 | Becton Dickinson Co | Pharmacokinetic control method of immunomodulatory compounds |
KR20120104412A (en) | 2002-09-06 | 2012-09-20 | 인설트 테라페틱스, 인코퍼레이티드 | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
ES2315526T3 (en) | 2002-09-09 | 2009-04-01 | Nektar Therapeutics Al, Corporation | METHOD FOR PREPARING WATER SOLUBLE POLYMER DERIVATIVES THAT CARRY A TERMINAL CARBOXYLIC ACID. |
AU2003278776A1 (en) | 2002-09-10 | 2004-04-30 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection |
US7534872B2 (en) | 2002-09-27 | 2009-05-19 | Syngen, Inc. | Compositions and methods for the use of FMOC derivatives in DNA/RNA synthesis |
SI1558648T1 (en) | 2002-10-17 | 2012-05-31 | Genmab As | Human monoclonal antibodies against cd20 |
US7622270B2 (en) | 2002-10-22 | 2009-11-24 | Eisai R&D Management Co., Ltd. | Methods of isolating dopaminergic neuron precursor cells |
US6896666B2 (en) | 2002-11-08 | 2005-05-24 | Kochamba Family Trust | Cutaneous injection delivery under suction |
AU2003294447A1 (en) | 2002-11-21 | 2004-06-18 | Epicentre Technologies | Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences |
US7491234B2 (en) | 2002-12-03 | 2009-02-17 | Boston Scientific Scimed, Inc. | Medical devices for delivery of therapeutic agents |
EP1575454A4 (en) | 2002-12-09 | 2006-11-29 | Medtronic Vascular Inc | Modular stent having polymer bridges at modular unit contact sites |
DE60332957D1 (en) | 2002-12-16 | 2010-07-22 | Genentech Inc | IMMUNOGLOBULIN VARIANTS AND ITS USES |
US7625872B2 (en) | 2002-12-23 | 2009-12-01 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
US7169892B2 (en) | 2003-01-10 | 2007-01-30 | Astellas Pharma Inc. | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems |
US20080227085A1 (en) | 2003-01-17 | 2008-09-18 | Pellegrini Matthew C | Methods and Systems for the Identification of Rna Regulatory Sequences and Compounds that Modulate their Function |
US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
EP1604011A4 (en) | 2003-01-21 | 2009-12-09 | Ptc Therapeutics Inc | Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same |
US8426194B2 (en) | 2003-01-21 | 2013-04-23 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating VEGF expression |
US20040147027A1 (en) | 2003-01-28 | 2004-07-29 | Troy Carol M. | Complex for facilitating delivery of dsRNA into a cell and uses thereof |
ZA200506159B (en) | 2003-02-10 | 2006-10-25 | Elan Pharm Inc | Immunoglobulin formulation and method of preparation thereof |
US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
CA2450289A1 (en) | 2003-03-20 | 2005-05-19 | Imclone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
US7320961B2 (en) | 2003-03-24 | 2008-01-22 | Abbott Laboratories | Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate |
ATE459710T1 (en) | 2003-03-25 | 2010-03-15 | Stratagene California | DNA POLYMERASE FUSIONS AND USES THEREOF |
CA2522213A1 (en) | 2003-04-08 | 2004-10-28 | Dante J. Marciani | Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines |
ES2322267T3 (en) | 2003-04-09 | 2009-06-18 | Genentech, Inc. | THERAPY OF AN AUTOINMUNOLOGICAL DISEASE IN A PATIENT THAT PRESENTS AN INAPPROPRIATE RESPONSE TO A TNF-ALFA INHIBITOR. |
JP2006525405A (en) | 2003-05-05 | 2006-11-09 | ベン‐グリオン ユニバーシティ オブ ザ ネゲヴ リサーチ アンド デベロップメント オーソリティ | Injectable cross-linked polymer preparations and their use |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
SI2298347T1 (en) | 2003-05-06 | 2016-03-31 | Biogen Hemophilia Inc. | Clotting factor chimeric proteins for treatment of a hemostatic disorder |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
US20040226556A1 (en) | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
US9567591B2 (en) | 2003-05-15 | 2017-02-14 | Mello Biotechnology, Inc. | Generation of human embryonic stem-like cells using intronic RNA |
GB0313132D0 (en) | 2003-06-06 | 2003-07-09 | Ich Productions Ltd | Peptide ligands |
WO2005009346A2 (en) | 2003-06-24 | 2005-02-03 | Mirus Corporation | Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo |
GB0316089D0 (en) | 2003-07-09 | 2003-08-13 | Xo Bioscience Ltd | Differentiation method |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
US7575572B2 (en) | 2003-07-15 | 2009-08-18 | Spinal Generations, Llc | Method and device for delivering medicine to bone |
US20050013870A1 (en) | 2003-07-17 | 2005-01-20 | Toby Freyman | Decellularized extracellular matrix of conditioned body tissues and uses thereof |
JP5105874B2 (en) | 2003-07-18 | 2012-12-26 | アムジエン・インコーポレーテツド | Specific binding factor for hepatocyte growth factor |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
DE10335833A1 (en) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfection of blood cells with mRNA for immune stimulation and gene therapy |
US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
US7135010B2 (en) | 2003-09-30 | 2006-11-14 | Damage Control Surgical Technologies, Inc. | Method and apparatus for rapid deployment chest drainage |
EP1673473B1 (en) | 2003-10-06 | 2011-07-06 | Novartis AG | Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease |
US20050130201A1 (en) | 2003-10-14 | 2005-06-16 | Dharmacon, Inc. | Splint-assisted enzymatic synthesis of polyribounucleotides |
DE10347710B4 (en) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Recombinant vaccines and their use |
EA036531B1 (en) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Type ii anti-cd20 humanized antibody (variants), pharmaceutical composition comprising these antibody variants, and use thereof |
WO2005047536A2 (en) | 2003-11-13 | 2005-05-26 | Novartis Ag | Detection of genomic amplification and deletion in cancer |
US7998119B2 (en) | 2003-11-18 | 2011-08-16 | Nano Pass Technologies Ltd. | System and method for delivering fluid into flexible biological barrier |
US20070054278A1 (en) | 2003-11-18 | 2007-03-08 | Applera Corporation | Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof |
US7699852B2 (en) | 2003-11-19 | 2010-04-20 | Zimmer Spine, Inc. | Fenestrated bone tap and method |
US20050153333A1 (en) | 2003-12-02 | 2005-07-14 | Sooknanan Roy R. | Selective terminal tagging of nucleic acids |
US8529939B2 (en) | 2003-12-08 | 2013-09-10 | Gel-Del Technologies, Inc. | Mucoadhesive drug delivery devices and methods of making and using thereof |
US7674884B2 (en) | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
US8034619B2 (en) | 2003-12-19 | 2011-10-11 | University Of Cincinnati | Polyamides for nucleic acid delivery |
JP4943161B2 (en) | 2003-12-23 | 2012-05-30 | ジェネンテック, インコーポレイテッド | Treatment of cancer with a novel anti-IL13 monoclonal antibody |
US20050143336A1 (en) | 2003-12-30 | 2005-06-30 | Board Of Regents, The University Of Texas System | Methods and compositions for improved non-viral gene therapy |
US7150726B2 (en) | 2004-01-23 | 2006-12-19 | Norfolk Medical | Device for subcutaneous infusion of fluids |
WO2005072710A2 (en) | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
ATE440949T1 (en) | 2004-01-30 | 2009-09-15 | Maxygen Holdings Ltd | CONTROLLED READING OF STOPCODONS |
US7309487B2 (en) | 2004-02-09 | 2007-12-18 | George Inana | Methods and compositions for detecting and treating retinal diseases |
AU2005214331B2 (en) | 2004-02-12 | 2011-09-15 | Eisai, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
EP3736295A1 (en) | 2004-03-24 | 2020-11-11 | Chugai Seiyaku Kabushiki Kaisha | Subtypes of humanized antibody against interleukin-6 receptor |
WO2005098433A2 (en) | 2004-04-01 | 2005-10-20 | Novartis Ag | Diagnostic assays for alzheimer’s disease |
BRPI0509806A (en) | 2004-04-12 | 2007-09-18 | Allergan Inc | multi-site injection system |
WO2006097793A2 (en) | 2004-04-15 | 2006-09-21 | Chiasma, Ltd. | Compositions capable of facilitating penetration across a biological barrier |
JP5848861B2 (en) | 2004-04-20 | 2016-01-27 | ジェンマブ エー/エスGenmab A/S | Human monoclonal antibody against CD20 |
ES2246694B1 (en) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | PEGILATED NANOPARTICLES. |
US20080119645A1 (en) | 2004-05-05 | 2008-05-22 | Isis Pharmaceuticals, Inc. | Amidites and Methods of Rna Synthesis |
CN1980640A (en) * | 2004-05-12 | 2007-06-13 | 巴克斯特国际公司 | Oligonucleotide-containing microspheres, manufacture and delivery thereof |
US20080103053A1 (en) | 2005-11-22 | 2008-05-01 | Helicos Biosciences Corporation | Methods and compositions for sequencing a nucleic acid |
US20060020329A1 (en) | 2004-05-26 | 2006-01-26 | Medtronic Vascular, Inc. | Semi-directional drug delivering stents |
US8012747B2 (en) | 2004-06-01 | 2011-09-06 | San Diego State University Foundation | Expression system |
ATE536418T1 (en) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | LIPID ENCAPSULATED INTERFERENCE RNA |
EP1781593B1 (en) * | 2004-06-07 | 2011-12-14 | Protiva Biotherapeutics Inc. | Cationic lipids and methods of use |
WO2005123114A2 (en) | 2004-06-11 | 2005-12-29 | Trustees Of Tufts College | Silk-based drug delivery system |
US8338648B2 (en) | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
WO2006046978A2 (en) | 2004-06-28 | 2006-05-04 | Argos Therapeutics, Inc. | Cationic peptide-mediated transformation |
KR101100059B1 (en) | 2004-06-30 | 2011-12-29 | 넥타르 테라퓨틱스 | Polymer-factor ix moiety conjugates |
EP1768742A4 (en) | 2004-07-06 | 2007-10-17 | Transpharma Medical Ltd | Delivery system for transdermal immunization |
DE102004035227A1 (en) * | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA mixture for vaccination against tumor diseases |
WO2006093526A2 (en) | 2004-07-21 | 2006-09-08 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a modified or non-natural nucleobase |
US7603349B1 (en) | 2004-07-29 | 2009-10-13 | Yahoo! Inc. | User interfaces for search systems using in-line contextual queries |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
US7291208B2 (en) | 2004-08-13 | 2007-11-06 | Gore Enterprise Holdings, Inc. | Grooved active and passive adsorbent filters |
SE0402025D0 (en) | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
JP4965447B2 (en) | 2004-08-26 | 2012-07-04 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | Delivery of functional nucleic acids to mammalian cells via intact minicells from bacteria |
DE102004042546A1 (en) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Combination therapy for immune stimulation |
US7501486B2 (en) | 2004-09-07 | 2009-03-10 | Burnham Institute For Medical Research | Peptides that selectively home to heart vasculature and related conjugates and methods |
US8396548B2 (en) | 2008-11-14 | 2013-03-12 | Vessix Vascular, Inc. | Selective drug delivery in a lumen |
US8663599B1 (en) | 2004-10-05 | 2014-03-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
EP1811018A4 (en) | 2004-10-12 | 2007-11-28 | Tissue Targeting Japan Inc | Brain disposition marrow progenitor |
BRPI0516110A (en) | 2004-10-13 | 2008-08-26 | Ptc Therapeutics Inc | senseless suppression compounds and methods for their use |
US8057821B2 (en) | 2004-11-03 | 2011-11-15 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
US20080261905A1 (en) | 2004-11-08 | 2008-10-23 | K.U. Leuven Research And Development | Modified Nucleosides for Rna Interference |
US8007466B2 (en) | 2004-11-18 | 2011-08-30 | Nanopass Technologies Ltd. | System and method for delivering fluid into flexible biological barrier |
CA2588389A1 (en) | 2004-11-23 | 2006-06-22 | Ptc Therapeutics, Inc. | Substituted phenols as active agents inhibiting vegf production |
US7964571B2 (en) | 2004-12-09 | 2011-06-21 | Egen, Inc. | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
WO2006063249A2 (en) | 2004-12-10 | 2006-06-15 | Justin Hanes | Functionalized poly (ether-anhydride) block copolymers |
US9068969B2 (en) | 2004-12-28 | 2015-06-30 | Ptc Therapeutics, Inc. | Cell based methods and systems for the identification of RNA regulatory sequences and compounds that modulate their functions |
US8187570B1 (en) | 2005-01-04 | 2012-05-29 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
US8192718B1 (en) | 2005-01-04 | 2012-06-05 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8535702B2 (en) | 2005-02-01 | 2013-09-17 | Boston Scientific Scimed, Inc. | Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility |
WO2007086883A2 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
US20060263338A1 (en) | 2005-03-04 | 2006-11-23 | Jacoby Douglas B | Catheter-based delivery of Skeletal Myoblasts to the Myocardium of Damaged Hearts |
US20100221186A1 (en) | 2005-03-11 | 2010-09-02 | Hueseyin Firat | Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds |
JP4793806B2 (en) | 2005-03-22 | 2011-10-12 | Tti・エルビュー株式会社 | Iontophoresis device |
US8415325B2 (en) | 2005-03-31 | 2013-04-09 | University Of Delaware | Cell-mediated delivery and targeted erosion of noncovalently crosslinked hydrogels |
ES2332062T3 (en) | 2005-04-01 | 2010-01-25 | Intezyne Technologies Incorporated | POLYMER MICELLS FOR THE SUPPLY OF PHARMACOS. |
EP1871911A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Cancer-related genes (prlr) |
EP1865981A2 (en) | 2005-04-07 | 2007-12-19 | Chiron Corporation | Cacna1e in cancer diagnosis, detection and treatment |
WO2006110776A2 (en) | 2005-04-12 | 2006-10-19 | Nektar Therapeutics Al, Corporation | Polyethylene glycol cojugates of antimicrobial agents |
WO2006116458A2 (en) | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhances immunostimulatory activity |
US7850656B2 (en) | 2005-04-29 | 2010-12-14 | Warsaw Orthopedic, Inc. | Devices and methods for delivering medical agents |
LT2439273T (en) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
US20070072175A1 (en) | 2005-05-13 | 2007-03-29 | Biogen Idec Ma Inc. | Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof |
US20060265771A1 (en) | 2005-05-17 | 2006-11-23 | Lewis David L | Monitoring microrna expression and function |
DE102005023170A1 (en) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimized formulation for mRNA |
WO2006133148A2 (en) | 2005-06-03 | 2006-12-14 | Genentech, Inc. | Method of producing antibodies with modified fucosylation level |
US7550264B2 (en) | 2005-06-10 | 2009-06-23 | Datascope Investment Corporation | Methods and kits for sense RNA synthesis |
US7691086B2 (en) | 2005-06-14 | 2010-04-06 | Tengiz Tkebuchava | Catheter for introduction of medications to the tissues of a heart or other organ |
EP2279758B1 (en) | 2005-06-16 | 2015-02-25 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
US8202835B2 (en) | 2005-06-17 | 2012-06-19 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
CA2611985C (en) | 2005-06-17 | 2016-08-16 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
CA2613442C (en) | 2005-06-30 | 2016-08-23 | Archemix Corp. | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts |
WO2007014363A2 (en) | 2005-07-27 | 2007-02-01 | Genentech, Inc. | Vectors for inducible expression of hairpin rna and use thereof |
US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
US20070048741A1 (en) | 2005-08-24 | 2007-03-01 | Getts Robert C | Methods and kits for sense RNA synthesis |
RU2457858C2 (en) | 2005-09-01 | 2012-08-10 | Новартис Вэксинес Энд Дайэгностикс Гмбх Унд Ко Кг | Multiple vaccination including serogroup c meningococci |
RS51840B (en) | 2005-09-01 | 2012-02-29 | Celgene Corporation | Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy |
WO2007029361A1 (en) * | 2005-09-02 | 2007-03-15 | Takeda Pharmaceutical Company Limited | Sustained-release microsphere containing short chain deoxyribonucleic acid or short chain ribonucleic acid and method of producing the same |
US8420605B2 (en) | 2005-09-07 | 2013-04-16 | The University Of Strathclyde | Hydrogel compositions |
US20120021042A1 (en) | 2005-09-15 | 2012-01-26 | Steffen Panzner | Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances |
US20070185432A1 (en) | 2005-09-19 | 2007-08-09 | Transport Pharmaceuticals, Inc. | Electrokinetic system and method for delivering methotrexate |
DE102005046490A1 (en) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency |
US20070087437A1 (en) | 2005-10-14 | 2007-04-19 | Jifan Hu | Methods for rejuvenating cells in vitro and in vivo |
US8012096B2 (en) | 2005-10-17 | 2011-09-06 | Cardiogenesis Corporation | Surgical device and method for performing combination revascularization and therapeutic substance delivery to tissue |
PT1951299E (en) | 2005-11-04 | 2012-02-28 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
US20070105124A1 (en) | 2005-11-08 | 2007-05-10 | Getts Robert C | Methods and kits for nucleic acid amplification |
WO2007057167A2 (en) | 2005-11-18 | 2007-05-24 | Bioline Limited | A method for enhancing enzymatic dna polymerase reactions |
EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
CA2639819C (en) | 2005-11-30 | 2012-10-23 | Epicentre Technologies Corporation | Selective terminal tagging of nucleic acids |
TWI389709B (en) | 2005-12-01 | 2013-03-21 | Novartis Ag | Transdermal therapeutic system |
ES2564241T3 (en) | 2005-12-02 | 2016-03-21 | Glaxosmithkline Biologicals Sa | Nanoparticles for use in immunogenic compositions |
US8603457B2 (en) | 2005-12-02 | 2013-12-10 | University Of Rochester | Nonsense suppression and genetic codon alteration by targeted modification |
US7579318B2 (en) | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
US8242081B2 (en) | 2005-12-06 | 2012-08-14 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
CA2630597A1 (en) | 2005-12-08 | 2007-06-14 | Novartis Ag | Effects of inhibitors of fgfr3 on gene transcription |
EP4223769A3 (en) | 2005-12-13 | 2023-11-01 | Kyoto University | Nuclear reprogramming factor |
CA2633063A1 (en) | 2005-12-16 | 2007-06-21 | Diatos | Cell penetrating peptide conjugates for delivering of nucleic acids intocells |
AU2007204617A1 (en) | 2006-01-12 | 2007-07-19 | Massachusetts Institute Of Technology | Biodegradable elastomers |
CA2636867C (en) | 2006-01-13 | 2015-12-01 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using codon optimized il-15 and methods for using the same |
CN103215293B (en) | 2006-01-27 | 2015-10-28 | 比奥根Ma公司 | NOGO receptor antagonist |
KR20130042043A (en) | 2006-01-27 | 2013-04-25 | 아이시스 파마수티컬즈 인코포레이티드 | 6-modified bicyclic nucleic acid analogs |
US20070178103A1 (en) | 2006-01-30 | 2007-08-02 | Fey Georg H | CD19-specific immunotoxin and treatment method |
US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
DE102006007433A1 (en) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Immunostimulant adjuvant useful in vaccines against cancer or infectious diseases comprises a lipid-modified nucleic acid |
WO2007097561A1 (en) | 2006-02-20 | 2007-08-30 | Ewha University - Industry Collaboration Foundation | Peptide having cell membrane penetrating activity |
EP2319542B1 (en) | 2006-02-21 | 2018-03-21 | Nektar Therapeutics | Segmented degradable polymers and conjugates made therefrom |
WO2007100789A2 (en) | 2006-02-24 | 2007-09-07 | Wyeth | Gpat3 encodes a mammalian, microsomal acyl-coa:glycerol 3-phosphate acyltransferase |
CA2643322C (en) | 2006-02-24 | 2015-07-21 | Novartis Ag | Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions |
EP3620469A1 (en) | 2006-02-28 | 2020-03-11 | Biogen MA Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
US7910152B2 (en) | 2006-02-28 | 2011-03-22 | Advanced Cardiovascular Systems, Inc. | Poly(ester amide)-based drug delivery systems with controlled release rate and morphology |
GB0605217D0 (en) | 2006-03-15 | 2006-04-26 | Novartis Ag | Method and compositions for assessing acute rejection |
WO2007109244A2 (en) | 2006-03-21 | 2007-09-27 | Morehouse School Of Medicine | Novel nanoparticles for delivery of active agents |
ES2776100T3 (en) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | System for targeted delivery of therapeutic agents |
WO2007123793A2 (en) | 2006-04-04 | 2007-11-01 | Stc.Unm | Swellable particles for drug delivery |
US20070281336A1 (en) | 2006-04-14 | 2007-12-06 | Epicentre Technologies | Kits and methods for generating 5' capped RNA |
EP1852127A1 (en) | 2006-05-02 | 2007-11-07 | Charité - Universitätsmedizin Berlin | Use of a B-cell-depleting antibody for treatment of polyoma virus infections |
WO2007133807A2 (en) | 2006-05-15 | 2007-11-22 | Massachusetts Institute Of Technology | Polymers for functional particles |
MX2008014971A (en) | 2006-05-24 | 2008-12-05 | Serono Lab | Cladribine regimen for treating multiple sclerosis. |
WO2007143574A1 (en) | 2006-06-02 | 2007-12-13 | President And Fellows Of Harvard College | Protein surface remodeling |
EP2046383B1 (en) | 2006-07-04 | 2014-11-19 | Genmab A/S | Cd20 binding molecules for the treatment of copd |
WO2008008752A2 (en) | 2006-07-12 | 2008-01-17 | Novartis Ag | Actinically crosslinkable copolymers for manufacturing contact lenses |
KR20090039748A (en) | 2006-07-20 | 2009-04-22 | 노파르티스 아게 | Amigo-2 inhibitors for treating, diagnosing or detecting cancer |
US8728527B2 (en) | 2006-07-24 | 2014-05-20 | Luminus Biosciences, Inc. | Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening |
JP2009544754A (en) | 2006-07-28 | 2009-12-17 | アプライド バイオシステムズ, エルエルシー | Dinucleotide MRNA cap analog |
AU2007280690C1 (en) | 2006-07-31 | 2012-08-23 | Curevac Gmbh | Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant |
DE102006035618A1 (en) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | New nucleic acid useful as immuno-stimulating adjuvant for manufacture of a composition for treatment of cancer diseases e.g. colon carcinomas and infectious diseases e.g. influenza and malaria |
JP2010507567A (en) | 2006-08-07 | 2010-03-11 | ジェンザイム・コーポレーション | Combination therapy |
US8658211B2 (en) | 2006-08-18 | 2014-02-25 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
CA2661093A1 (en) | 2006-08-18 | 2008-02-21 | Nastech Pharmaceutical Company Inc. | Dicer substrate rna peptide conjugates and methods for rna therapeutics |
WO2008030988A2 (en) | 2006-09-06 | 2008-03-13 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
PL2059532T3 (en) | 2006-09-07 | 2013-05-31 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
WO2008030557A2 (en) | 2006-09-08 | 2008-03-13 | Johns Hopkins University | Compositions and methods for enhancing transport through mucus |
ATE489048T1 (en) | 2006-09-08 | 2010-12-15 | Arbel Medical Ltd | DEVICE FOR COMBINED TREATMENT |
US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
GB0619182D0 (en) | 2006-09-29 | 2006-11-08 | Leuven K U Res & Dev | Oligonucleotide arrays |
DK2068886T3 (en) | 2006-10-03 | 2013-11-18 | Tekmira Pharmaceuticals Corp | Lipid-containing preparations |
CN101583379B (en) | 2006-10-05 | 2013-04-03 | 约翰斯霍普金斯大学 | Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles |
DE102006051516A1 (en) * | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Base) modified RNA to increase the expression of a protein |
US8414927B2 (en) | 2006-11-03 | 2013-04-09 | Boston Scientific Scimed, Inc. | Cross-linked polymer particles |
US7999087B2 (en) | 2006-11-15 | 2011-08-16 | Agilent Technologies, Inc. | 2′-silyl containing thiocarbonate protecting groups for RNA synthesis |
US8242258B2 (en) | 2006-12-03 | 2012-08-14 | Agilent Technologies, Inc. | Protecting groups for RNA synthesis |
US8399007B2 (en) | 2006-12-05 | 2013-03-19 | Landec Corporation | Method for formulating a controlled-release pharmaceutical formulation |
ES2480491T3 (en) | 2006-12-06 | 2014-07-28 | Novartis Ag | Vaccines including four influenza virus strains antigen |
US9034348B2 (en) | 2006-12-11 | 2015-05-19 | Chi2Gel Ltd. | Injectable chitosan mixtures forming hydrogels |
NZ707292A (en) | 2006-12-18 | 2017-06-30 | Acceleron Pharma Inc | Activin-actrii antagonists and uses for increasing red blood cell levels |
ES2447516T3 (en) | 2006-12-21 | 2014-03-12 | Stryker Corporation | Sustained release formulations comprising BMP-7 crystals |
DK2104739T3 (en) | 2006-12-21 | 2013-10-07 | Novozymes Inc | Modified messenger RNA stabilization sequences for expression of genes in bacterial cells |
CA2673029C (en) | 2006-12-22 | 2017-03-28 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
DE102006061015A1 (en) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Process for the purification of RNA on a preparative scale by HPLC |
US8057426B2 (en) | 2007-01-03 | 2011-11-15 | Medtronic Vascular, Inc. | Devices and methods for injection of multiple-component therapies |
US8338166B2 (en) | 2007-01-04 | 2012-12-25 | Lawrence Livermore National Security, Llc | Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture |
DE102007001370A1 (en) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-encoded antibodies |
WO2008091799A2 (en) | 2007-01-22 | 2008-07-31 | The Trustees Of Columbia University In The City Of New York | Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants |
US7884184B2 (en) | 2007-01-30 | 2011-02-08 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
TW202021980A (en) | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | Variants derived from actriib and uses therefor |
US8859229B2 (en) | 2007-02-02 | 2014-10-14 | Yale University | Transient transfection with RNA |
WO2008096370A2 (en) | 2007-02-05 | 2008-08-14 | Natco Pharma Limited | An efficient and novel purification method of recombinant hg-csf |
US8333799B2 (en) | 2007-02-12 | 2012-12-18 | C. R. Bard, Inc. | Highly flexible stent and method of manufacture |
WO2008103276A2 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
US8242087B2 (en) | 2007-02-27 | 2012-08-14 | K.U.Leuven Research & Development | Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents |
MY148472A (en) | 2007-03-02 | 2013-04-30 | Boehringer Ingelheim Pharma | Improvement of protein production |
EP1964922A1 (en) | 2007-03-02 | 2008-09-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
US8029496B2 (en) | 2007-03-05 | 2011-10-04 | Ebrahim Versi | Method and device for delivering drug to the trigone of the bladder |
JP5249248B2 (en) | 2007-03-05 | 2013-07-31 | ワシントン ユニバーシティー | Nanoparticle transport system for membrane-embedded peptides |
US20100297699A1 (en) | 2007-03-20 | 2010-11-25 | Millennium Pharmaceuticals, Inc. | Nucleic Acids Encoding Humanized Immunoglobulin That Binds Alpha4Beta7 Integrin |
EP2136788B1 (en) | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
WO2014064687A1 (en) | 2012-10-22 | 2014-05-01 | Deliversir Ltd | A system for delivering therapeutic agents into living cells and cells nuclei |
EP2152358B1 (en) | 2007-04-27 | 2011-03-02 | Echo Therapeutics, Inc. | Skin permeation device for analyte sensing or transdermal drug delivery |
WO2008134724A2 (en) | 2007-04-30 | 2008-11-06 | Smithkline Beecham Corporation | Methods for administering anti-il-5 antibodies |
WO2008135855A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer |
HUE040417T2 (en) | 2007-05-04 | 2019-03-28 | Marina Biotech Inc | Amino acid lipids and uses thereof |
WO2009023311A2 (en) | 2007-05-07 | 2009-02-19 | Alba Therapeutics Corporation | Transcutaneous delivery of therapeutic agents |
JP5296328B2 (en) | 2007-05-09 | 2013-09-25 | 独立行政法人理化学研究所 | Single-stranded circular RNA and method for producing the same |
EP2160396B1 (en) | 2007-05-10 | 2018-11-21 | Agilent Technologies, Inc. | Thiocarbon-protecting groups for rna synthesis |
EP2068927B1 (en) | 2007-05-14 | 2015-10-21 | MedImmune, LLC | Methods of reducing eosinophil levels |
WO2008144365A2 (en) | 2007-05-17 | 2008-11-27 | Novartis Ag | Method for making dry powder compositions containing ds-rna based on supercritical fluid technology |
US20110002845A1 (en) | 2007-05-22 | 2011-01-06 | Novartis Ag | Methods of treating, diagnosing or detecting fgf21-associated disorders |
AU2008259907B2 (en) | 2007-05-30 | 2014-12-04 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US20100184051A1 (en) | 2007-05-30 | 2010-07-22 | The General Hospital Corporation | Methods of generating pluripotent cells from somatic cells |
ES2500515T3 (en) | 2007-06-19 | 2014-09-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogues of the messenger RNA cap |
EP2173872B1 (en) | 2007-06-29 | 2014-04-02 | CellScript, Inc. | Copy dna and sense rna |
US8367318B2 (en) | 2007-07-23 | 2013-02-05 | Dharmacon, Inc. | Screening of micro-RNA cluster inhibitor pools |
US9144546B2 (en) | 2007-08-06 | 2015-09-29 | Clsn Laboratories, Inc. | Nucleic acid-lipopolymer compositions |
US20090042825A1 (en) | 2007-08-06 | 2009-02-12 | Majed Matar | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer |
CN101801445B (en) | 2007-08-14 | 2013-04-17 | 弗雷德哈钦森癌症研究中心 | Needle array assembly for delivering therapeutic agents |
WO2009023770A1 (en) | 2007-08-15 | 2009-02-19 | Avellanet Francisco J | Biologically engineered stent |
EP2183390A1 (en) | 2007-08-23 | 2010-05-12 | Novartis Ag | Methods for detecting oligonucleotides |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
KR101234436B1 (en) | 2007-09-05 | 2013-02-18 | 로슈 글리카트 아게 | Combination therapy with type i and type ii anti-cd20 antibodies |
US8506928B2 (en) | 2007-09-07 | 2013-08-13 | The Regents Of The University Of California | Methods and compounds for targeting tissues |
US20110086904A1 (en) | 2007-09-17 | 2011-04-14 | The Trustees Of The University Of Pennsylvania | GENERATION OF HYPERSTABLE mRNAs |
AU2008304313B2 (en) | 2007-09-26 | 2013-01-10 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
KR101541935B1 (en) | 2007-09-26 | 2015-08-05 | 인트렉손 코포레이션 | Synthetic 5'UTRs, expression vectors, and methods for increasing transgene expression |
EP2042193A1 (en) | 2007-09-28 | 2009-04-01 | Biomay AG | RNA Vaccines |
US8470560B2 (en) | 2007-10-03 | 2013-06-25 | The United States Of America As Represented By The Secretary Of The Army | CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
US10736848B2 (en) * | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US20090098118A1 (en) | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
KR101198354B1 (en) * | 2007-10-17 | 2013-03-14 | 주식회사 삼양바이오팜 | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
US20110091473A1 (en) | 2007-10-22 | 2011-04-21 | Genmab A/S | Novel antibody therapies |
WO2009058446A1 (en) | 2007-11-01 | 2009-05-07 | University Of Rochester | Recombinant factor viii having increased stability |
JP5559695B2 (en) | 2007-11-09 | 2014-07-23 | ノバルティス アーゲー | Use of anti-CD40 antibodies |
US8470771B2 (en) | 2007-11-14 | 2013-06-25 | Institute Of Microbiology, Chinese Academy Of Sciences | Method and medicament for inhibiting the infection of influenza virus |
US20090137945A1 (en) | 2007-11-28 | 2009-05-28 | Claire Marquez | Electro Collagen Induction Therapy Device |
TW200944231A (en) | 2007-11-30 | 2009-11-01 | Glaxo Group Ltd | Antigen-binding constructs |
EP2610340B1 (en) | 2007-12-11 | 2014-10-01 | The Scripps Research Institute | Compositions and methods related to mRNA translational enhancer elements |
US20090238772A1 (en) | 2007-12-13 | 2009-09-24 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of rsv infection |
EP2072618A1 (en) | 2007-12-14 | 2009-06-24 | Johannes Gutenberg-Universität Mainz | Use of RNA for reprogramming somatic cells |
JP2011507897A (en) | 2007-12-21 | 2011-03-10 | ジェネンテック, インコーポレイテッド | Treatment of patients with rituximab-resistant rheumatoid arthritis |
EP2248906A4 (en) | 2008-01-23 | 2012-07-11 | Ajinomoto Kk | Method of producing l-amino acid |
EP2246422A4 (en) | 2008-01-24 | 2012-07-25 | Nat Inst Of Advanced Ind Scien | Polynucleotide or analogue thereof, and gene expression regulation method using the polynucleotide or the analogue thereof |
CA2710534C (en) | 2008-01-31 | 2018-09-04 | Curevac Gmbh | Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant |
EP2250252A2 (en) | 2008-02-11 | 2010-11-17 | Cambridge Enterprise Limited | Improved reprogramming of mammalian cells, and the cells obtained |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
DE102008009920A1 (en) | 2008-02-15 | 2009-08-20 | Aj Innuscreen Gmbh | Mobile device for nucleic acid isolation |
US20120027813A1 (en) | 2008-02-22 | 2012-02-02 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines for pediatric use |
US8506966B2 (en) | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
US20100004313A1 (en) | 2008-02-29 | 2010-01-07 | Tbd | Modified Poloxamers for Gene Expression and Associated Methods |
PL2993186T3 (en) | 2008-03-14 | 2020-02-28 | Biocon Limited | A monoclonal antibody and a method thereof |
US20100004315A1 (en) | 2008-03-14 | 2010-01-07 | Gregory Slobodkin | Biodegradable Cross-Linked Branched Poly(Alkylene Imines) |
EP2274009B1 (en) | 2008-03-28 | 2013-11-13 | GlaxoSmithKline LLC | Methods of treatment |
AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
WO2009127230A1 (en) * | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
JP5539962B2 (en) | 2008-04-25 | 2014-07-02 | ノースウェスタン、ユニバーシティ | Nanostructure suitable for sequestering cholesterol |
AU2009243187C1 (en) | 2008-04-28 | 2015-12-24 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
WO2009134717A1 (en) | 2008-04-30 | 2009-11-05 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Chimeric west nile/dengue viruses |
US9394538B2 (en) | 2008-05-07 | 2016-07-19 | Shi-Lung Lin | Development of universal cancer drugs and vaccines |
US8231609B2 (en) | 2008-05-08 | 2012-07-31 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
US8697098B2 (en) | 2011-02-25 | 2014-04-15 | South Dakota State University | Polymer conjugated protein micelles |
KR101661636B1 (en) | 2008-05-13 | 2016-09-30 | 유니버시티 오브 워싱톤 | Diblock copolymers and polynucleotide complexes thereof for delivery into cells |
US9738680B2 (en) | 2008-05-21 | 2017-08-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5′ triphosphate oligonucleotide with blunt end and uses thereof |
EP2306993B1 (en) | 2008-05-26 | 2014-03-12 | Universität Zürich | Protamine/rna nanoparticles for immunostimulation |
KR101275950B1 (en) | 2008-05-29 | 2013-06-25 | 한올바이오파마주식회사 | Modified erythropoietin (epo) polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof |
FR2931824B1 (en) | 2008-05-29 | 2014-11-28 | Centre Nat Rech Scient | PROCESS FOR RNA SYNTHESIS THROUGH CHEMICAL. |
US20100086922A1 (en) | 2008-05-30 | 2010-04-08 | Millennium Pharmaceuticals, Inc. | Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment |
EP2433664B1 (en) | 2008-06-06 | 2016-08-10 | Wockhardt Limited | A device for delivery of biological material |
PL215513B1 (en) | 2008-06-06 | 2013-12-31 | Univ Warszawski | New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein |
TWI451876B (en) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | Pegylated insulin lispro compounds |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
EP2285350B1 (en) | 2008-06-16 | 2017-11-15 | Pfizer Inc | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles |
JP2012501966A (en) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | Vinca alkaloid-containing therapeutic polymer nanoparticles and methods for making and using the same |
AU2009268923B2 (en) | 2008-06-16 | 2015-09-17 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US7799016B2 (en) | 2008-06-20 | 2010-09-21 | Pharmaco-Kinesis Corporation | Magnetic breather pump and a method for treating a brain tumor using the same |
JP2011525916A (en) | 2008-06-25 | 2011-09-29 | エフイー3 メディカル, インコーポレイテッド | Patches and methods for transdermal delivery of therapeutically effective amounts of iron |
US20100009424A1 (en) | 2008-07-14 | 2010-01-14 | Natasha Forde | Sonoporation systems and methods |
WO2010009065A2 (en) | 2008-07-15 | 2010-01-21 | Novartis Ag | Amphipathic peptide compositions |
US20110250237A1 (en) | 2008-07-15 | 2011-10-13 | O'hagan Derek | Immunogenic amphipathic peptide compositions |
US20110224447A1 (en) | 2008-08-18 | 2011-09-15 | Bowman Keith A | Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids |
WO2010024871A1 (en) | 2008-08-26 | 2010-03-04 | Med Institute, Inc. | Balloon catheters having a plurality of needles for the injection of one or more therapeutic agents |
US20110172126A1 (en) | 2008-09-03 | 2011-07-14 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
JP5714490B2 (en) | 2008-09-06 | 2015-05-07 | ケムジーンズ コーポレーション | Methods for preparing oligonucleotides by RNA synthesis, phosphoramidites for synthetic RNA in the reverse direction, and bond formation in the 5 'to 3' direction for synthesis of RNA oligomers |
WO2010027903A2 (en) | 2008-09-08 | 2010-03-11 | Fred Hutchinson Cancer Research Center | Lung cancer diagnosis |
WO2010030763A2 (en) | 2008-09-10 | 2010-03-18 | Bind Biosciences, Inc. | High throughput fabrication of nanoparticles |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
US20120021519A1 (en) | 2008-09-19 | 2012-01-26 | Presidents And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
WO2010042490A1 (en) | 2008-10-06 | 2010-04-15 | Boston Medical Center Corporation | A single lentiviral vector system for induced pluripotent (ips) stem cells derivation |
AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
US9801722B2 (en) | 2008-10-10 | 2017-10-31 | Peter Forsell | Infusion of drugs |
US8535655B2 (en) | 2008-10-10 | 2013-09-17 | Polyactiva Pty Ltd. | Biodegradable polymer—bioactive moiety conjugates |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
ITVI20080239A1 (en) | 2008-10-14 | 2010-04-15 | Antoine Assaf | MEDICAL APPARATUS FOR MULTIPLE INJECTIONS. |
WO2010047765A2 (en) | 2008-10-20 | 2010-04-29 | Massachussetts Institute Of Technology | Nanostructures for drug delivery |
US20120015899A1 (en) | 2008-10-25 | 2012-01-19 | Plant Bioscience, Limited | Modified plant virus particles and uses therefor |
JP6087504B2 (en) | 2008-11-07 | 2017-03-01 | マサチューセッツ インスティテュート オブ テクノロジー | Amino alcohol lipidoids and uses thereof |
HUE037082T2 (en) | 2008-11-10 | 2018-08-28 | Arbutus Biopharma Corp | Novel lipids and compositions for the delivery of therapeutics |
WO2010057160A1 (en) | 2008-11-17 | 2010-05-20 | Enzon Pharmaceuticals, Inc. | Releasable fusogenic lipids for nucleic acids delivery systems |
CA2780482A1 (en) | 2008-11-17 | 2010-05-10 | Anil K. Sood | Hdl particles for delivery of nucleic acids |
KR101073875B1 (en) | 2008-11-28 | 2011-10-14 | 한국생명공학연구원 | Diagnostic kit of colon cancer using colon cancer related marker, and Diagnostic method therof |
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
AU2009324534B2 (en) | 2008-12-10 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | GNAQ targeted dsRNA compositions and methods for inhibiting expression |
EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
WO2010068866A2 (en) | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
EP2376091A4 (en) | 2008-12-12 | 2012-08-01 | Univ California | Novel targets for treatment of hypercholesterolemia |
JP2012512175A (en) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | Long-circulating nanoparticles for sustained release of therapeutic agents |
CN102137713A (en) * | 2008-12-24 | 2011-07-27 | 生物制药开发股份有限公司 | Method for producing liposome and method for dissolving cholesterol |
WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
EP2405937A4 (en) | 2009-01-16 | 2012-06-20 | Glaxosmithkline Llc | Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody |
WO2010084371A1 (en) | 2009-01-26 | 2010-07-29 | Mitoprod | Novel circular interfering rna molecules |
US20120101148A1 (en) | 2009-01-29 | 2012-04-26 | Alnylam Pharmaceuticals, Inc. | lipid formulation |
US8669085B2 (en) | 2009-02-05 | 2014-03-11 | Ut-Battelle, Llc | Transformation of gram positive bacteria by sonoporation |
WO2010088927A1 (en) | 2009-02-09 | 2010-08-12 | Curevac Gmbh | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds |
US20140141089A1 (en) | 2009-02-11 | 2014-05-22 | Colorado School Of Mines | Nanoparticles, Compositions Thereof, and Methods of Use, and Methods of Making the Same |
SG174150A1 (en) | 2009-02-24 | 2011-10-28 | Scripps Research Inst | Reengineering mrna primary structure for enhanced protein production |
WO2010141135A2 (en) | 2009-03-05 | 2010-12-09 | Trustees Of Boston University | Bacteriophages expressing antimicrobial peptides and uses thereof |
WO2010102065A1 (en) | 2009-03-05 | 2010-09-10 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
AU2010223888A1 (en) | 2009-03-13 | 2011-10-06 | Egen, Inc. | Compositions and methods for the delivery of biologically active RNAs |
CN104922676B (en) | 2009-03-20 | 2019-03-12 | Clsn实验室股份有限公司 | Polyamine derivatives |
WO2010111290A1 (en) | 2009-03-23 | 2010-09-30 | University Of Utah Research Foundation | Methods and compositions related to modified guanine bases for controlling off-target effects in rna interference |
JP5622254B2 (en) | 2009-03-31 | 2014-11-12 | 国立大学法人東京大学 | Double-stranded ribonucleic acid polyion complex |
EP3281947B1 (en) | 2009-04-03 | 2020-02-12 | The University of Chicago | Compositions and methods related to protein a (spa) variants |
WO2010120266A1 (en) | 2009-04-13 | 2010-10-21 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Hpv particles and uses thereof |
AU2010236257A1 (en) | 2009-04-17 | 2011-11-03 | Biogen Idec Ma Inc. | Compositions and methods to treat acute myelogenous leukemia |
US20110223201A1 (en) | 2009-04-21 | 2011-09-15 | Selecta Biosciences, Inc. | Immunonanotherapeutics Providing a Th1-Biased Response |
WO2010123501A1 (en) | 2009-04-22 | 2010-10-28 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
JP5766179B2 (en) | 2009-04-27 | 2015-08-19 | ノバルティス アーゲー | Compositions and methods for increasing muscle growth |
US8715736B2 (en) | 2009-04-30 | 2014-05-06 | Florida Agricultural And Mechanical University | Nanoparticle formulations for skin delivery |
WO2010127159A2 (en) | 2009-04-30 | 2010-11-04 | Intezyne Technologies, Incorporated | Polymeric micelles for polynucleotide encapsulation |
JP5769701B2 (en) | 2009-05-05 | 2015-08-26 | テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation | Lipid composition |
AU2010245933B2 (en) * | 2009-05-05 | 2016-06-16 | Arbutus Biopharma Corporation | Methods of delivering oligonucleotides to immune cells |
DE202009007116U1 (en) | 2009-05-18 | 2010-10-14 | Amoena Medizin-Orthopädie-Technik GmbH | Anti decubitus cushions |
AU2010254550B2 (en) | 2009-05-27 | 2015-10-15 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents |
US8574835B2 (en) | 2009-05-29 | 2013-11-05 | Life Technologies Corporation | Scaffolded nucleic acid polymer particles and methods of making and using |
DK2440183T3 (en) | 2009-06-10 | 2018-10-01 | Arbutus Biopharma Corp | Improved lipid formulation |
EP2440556A1 (en) | 2009-06-10 | 2012-04-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
EA201270019A1 (en) | 2009-06-15 | 2012-06-29 | Элнилэм Фармасьютикалз, Инк. | BENTROVAL RNA INCLUDED IN LIPID COMPOSITION AND WHICH IS THE PCSK9 GENE |
US20110097329A1 (en) | 2009-06-26 | 2011-04-28 | Massachusetts Institute Of Technology | Compositions and methods for treating cancer and modulating stress granule formation |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
US20110300205A1 (en) | 2009-07-06 | 2011-12-08 | Novartis Ag | Self replicating rna molecules and uses thereof |
EP2459231B1 (en) | 2009-07-31 | 2016-06-08 | Ethris Gmbh | Rna with a combination of unmodified and modified nucleotides for protein expression |
EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
WO2011022460A1 (en) | 2009-08-20 | 2011-02-24 | Merck Sharp & Dohme Corp. | Novel cationic lipids with various head groups for oligonucleotide delivery |
EP2470554B1 (en) | 2009-08-26 | 2017-06-28 | Selecta Biosciences, Inc. | Compositions that induce t cell help |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
US20110070227A1 (en) | 2009-09-18 | 2011-03-24 | Anna-Marie Novotney-Barry | Treatment of Autoimmune and Inflammatory Diseases |
EP2485770A4 (en) | 2009-10-08 | 2013-04-10 | Merck Sharp & Dohme | Novel cationic lipids with short lipid chains for oligonucleotide delivery |
US8859284B2 (en) | 2009-10-22 | 2014-10-14 | The United States Of America, As Represented By The Secretary Of The Navy | Delivery of nanoparticles to neurons |
RU2573409C2 (en) | 2009-11-04 | 2016-01-20 | Дзе Юниверсити Оф Бритиш Коламбиа | Lipid particles containing nucleic acids and related methods |
US8449916B1 (en) | 2009-11-06 | 2013-05-28 | Iowa State University Research Foundation, Inc. | Antimicrobial compositions and methods |
WO2011060250A1 (en) | 2009-11-13 | 2011-05-19 | Bend Research, Inc. | Cationic dextran polymer derivatives |
US9415113B2 (en) | 2009-11-18 | 2016-08-16 | University Of Washington | Targeting monomers and polymers having targeting blocks |
US8530429B2 (en) | 2009-11-24 | 2013-09-10 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
US20110245756A1 (en) | 2009-12-03 | 2011-10-06 | Rishi Arora | Devices for material delivery, electroporation, sonoporation, and/or monitoring electrophysiological activity |
DE102009056884B4 (en) | 2009-12-03 | 2021-03-18 | Novartis Ag | Vaccine Adjuvants and Improved Methods for Making Same |
CN102791285A (en) | 2009-12-06 | 2012-11-21 | 比奥根艾迪克依蒙菲利亚公司 | Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof |
US20130189741A1 (en) | 2009-12-07 | 2013-07-25 | Cellscript, Inc. | Compositions and methods for reprogramming mammalian cells |
KR102505097B1 (en) | 2009-12-07 | 2023-03-02 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Rna preparations comprising purified modified rna for reprogramming cells |
US9687550B2 (en) | 2009-12-07 | 2017-06-27 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
WO2011069528A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Lyophilization of nucleic acids in lactate-containing solutions |
ES2721898T3 (en) | 2009-12-11 | 2019-08-06 | Pfizer | Stable formulations to lyophilize therapeutic particles |
WO2011084513A2 (en) | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
JP5898627B2 (en) | 2009-12-15 | 2016-04-06 | バインド セラピューティックス インコーポレイテッド | Therapeutic polymer nanoparticles containing epothilone and methods of making and using the same |
EP2512487A4 (en) | 2009-12-15 | 2013-08-07 | Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same | |
EP2512522A4 (en) | 2009-12-16 | 2013-09-25 | Brigham & Womens Hospital | Particles for multiple agent delivery |
DE102009058769A1 (en) | 2009-12-16 | 2011-06-22 | MagForce Nanotechnologies AG, 10589 | Temperature-dependent activation of catalytic nucleic acids for controlled drug release |
ES2749426T3 (en) | 2009-12-18 | 2020-03-20 | Univ British Columbia | Nucleic Acid Administration Methods and Compositions |
EP2338520A1 (en) | 2009-12-21 | 2011-06-29 | Ludwig Maximilians Universität | Conjugate with targeting ligand and use of same |
EP2516010A2 (en) | 2009-12-23 | 2012-10-31 | Novartis AG | Lipids, lipid compositions, and methods of using them |
WO2011085231A2 (en) | 2010-01-08 | 2011-07-14 | Selecta Biosciences, Inc. | Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines |
WO2011088309A1 (en) | 2010-01-14 | 2011-07-21 | Regulus Therapeutics Inc. | Microrna compositions and methods |
EP2525781A1 (en) | 2010-01-22 | 2012-11-28 | Schering Corporation | Novel cationic lipids for oligonucleotide delivery |
JP5988435B2 (en) | 2010-01-24 | 2016-09-07 | ノバルティス アーゲー | Irradiated biodegradable microparticles |
NZ601737A (en) | 2010-02-24 | 2013-06-28 | Arrowhead Res Corp | Compositions for targeted delivery of sirna |
US8889193B2 (en) | 2010-02-25 | 2014-11-18 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
US20130133483A1 (en) | 2010-03-08 | 2013-05-30 | University Of Rochester | Synthesis of Nanoparticles Using Reducing Gases |
WO2011116072A1 (en) | 2010-03-16 | 2011-09-22 | Escape Therapeutics, Inc. | Hybrid hydrogel scaffold compositions and methods of use |
WO2011116107A2 (en) | 2010-03-16 | 2011-09-22 | University Of Utah Research Foundation | Cleavable modifications to reducible poly (amido ethylenimines)s to enhance nucleotide delivery |
US20130005797A1 (en) | 2010-03-18 | 2013-01-03 | Merck Sharp & Dohme Corp. | Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides |
US20110230816A1 (en) | 2010-03-18 | 2011-09-22 | Tyco Healthcare Group Lp | Gels for Transdermal Delivery |
US9149432B2 (en) | 2010-03-19 | 2015-10-06 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
KR20180044433A (en) * | 2010-03-24 | 2018-05-02 | 알엑스아이 파마슈티칼스 코포레이션 | Rna interference in dermal and fibrotic indications |
GB201005005D0 (en) | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
WO2011120053A1 (en) | 2010-03-26 | 2011-09-29 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
WO2011119262A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
US20110247090A1 (en) | 2010-04-02 | 2011-10-06 | Intrexon Corporation | Synthetic 5'UTRs, Expression Vectors, and Methods for Increasing Transgene Expression |
US8808699B2 (en) | 2010-04-05 | 2014-08-19 | The University Of Chicago | Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response |
JP2013529894A (en) | 2010-04-07 | 2013-07-25 | ノバルティス アーゲー | Method for generating parvovirus B19 virus-like particles |
WO2011127255A1 (en) | 2010-04-08 | 2011-10-13 | Merck Sharp & Dohme Corp. | Preparation of lipid nanoparticles |
WO2011127456A2 (en) | 2010-04-09 | 2011-10-13 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
CA2795695A1 (en) | 2010-04-09 | 2011-10-13 | The University Of Tokyo | Microrna-controlled recombinant vaccinia virus and use thereof |
US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
KR101196667B1 (en) | 2010-04-15 | 2012-11-02 | 포항공과대학교 산학협력단 | A DELEVERY SYSTEM OF ANTI-CANCER AGENT USING pH SENSITIVE METAL NANOPARTICLE |
US11225655B2 (en) | 2010-04-16 | 2022-01-18 | Nuevolution A/S | Bi-functional complexes and methods for making and using such complexes |
EP2377938A1 (en) | 2010-04-16 | 2011-10-19 | Eukarys | Capping-prone RNA polymerase enzymes and their applications |
US20130260460A1 (en) | 2010-04-22 | 2013-10-03 | Isis Pharmaceuticals Inc | Conformationally restricted dinucleotide monomers and oligonucleotides |
MX2012012567A (en) | 2010-04-28 | 2012-11-21 | Kimberly Clark Co | Method for increasing permeability of an epithelial barrier. |
US9629979B2 (en) | 2010-04-28 | 2017-04-25 | Sanovas, Inc. | Pressure/Vacuum actuated catheter drug delivery probe |
US20130156845A1 (en) | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
JP2013524840A (en) | 2010-04-30 | 2013-06-20 | ノバルティス アーゲー | Predictive markers useful in the treatment of fragile X syndrome (FXS) |
WO2011143230A1 (en) | 2010-05-10 | 2011-11-17 | Alnylam Pharmaceuticals | Methods and compositions for delivery of active agents |
JP2013527856A (en) | 2010-05-12 | 2013-07-04 | プロチバ バイオセラピューティクス インコーポレイティッド | Cationic lipids and methods of use |
WO2011141704A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc | Novel cyclic cationic lipids and methods of use |
EP2387999A1 (en) | 2010-05-21 | 2011-11-23 | CureVac GmbH | Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof |
WO2011149733A2 (en) | 2010-05-24 | 2011-12-01 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
AU2011258156B2 (en) | 2010-05-26 | 2016-11-24 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
JP5957646B2 (en) | 2010-06-04 | 2016-07-27 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
AU2011267078B2 (en) | 2010-06-14 | 2014-09-25 | F. Hoffmann-La Roche Ag | Cell-penetrating peptides and uses therof |
WO2011163264A2 (en) | 2010-06-21 | 2011-12-29 | Candela Corporation | Driving microneedle arrays into skin and delivering rf energy |
WO2011163121A1 (en) | 2010-06-21 | 2011-12-29 | Alnylam Pharmaceuticals, Inc. | Multifunctional copolymers for nucleic acid delivery |
CA2803239A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
KR101752506B1 (en) | 2010-07-01 | 2017-06-30 | 포항공과대학교 산학협력단 | Method for treatment and diagnosis of cancer using microvesicles derived from bacteria |
AU2011274367B2 (en) | 2010-07-02 | 2015-04-23 | The University Of Chicago | Compositions and methods related to protein A (SpA) variants |
KR101130137B1 (en) | 2010-07-02 | 2012-03-28 | 연세대학교 산학협력단 | Led module |
US8353871B2 (en) | 2010-07-05 | 2013-01-15 | Roller Jet Ltd. | Drug delivery device with needles and roller |
US20130171241A1 (en) | 2010-07-06 | 2013-07-04 | Novartis Ag | Liposomes with lipids having an advantageous pka-value for rna delivery |
US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
DK2591114T3 (en) | 2010-07-06 | 2016-08-29 | Glaxosmithkline Biologicals Sa | Immunization of large mammals with low doses of RNA |
LT2590676T (en) | 2010-07-06 | 2016-10-25 | Glaxosmithkline Biologicals Sa | Virion-like delivery particles for self-replicating rna molecules |
LT3243526T (en) | 2010-07-06 | 2020-02-10 | Glaxosmithkline Biologicals S.A. | Delivery of rna to trigger multiple immune pathways |
WO2012006623A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systems for factor viii processing and methods thereof |
CN103140237A (en) | 2010-07-09 | 2013-06-05 | 比奥根艾迪克依蒙菲利亚公司 | Factor ix polypeptides and methods of use thereof |
US20130177523A1 (en) | 2010-07-13 | 2013-07-11 | University Of Utah Research Foundation | Gold particles and methods of making and using the same in cancer treatment |
GB201012410D0 (en) | 2010-07-23 | 2010-09-08 | Medical Res Council | Intracellular immunity |
DE102010032758B4 (en) | 2010-07-29 | 2012-02-23 | Fujitsu Technology Solutions Intellectual Property Gmbh | Computer system, method of programming a real time clock and computer program product |
EP2449113B8 (en) | 2010-07-30 | 2015-11-25 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
US20130190626A1 (en) | 2010-08-02 | 2013-07-25 | Curtin University Of Technology | Determining location of, and imaging, a subsurface boundary |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012021516A2 (en) | 2010-08-09 | 2012-02-16 | The Trustees Of The University Of Pennsylvania | Nanoparticle-oligonucletide hybrid structures and methods of use thereof |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
ES2531577T3 (en) | 2010-08-20 | 2015-03-17 | Novartis Ag | Needle sets for administration of soluble flu vaccine |
CA2808901A1 (en) | 2010-08-20 | 2012-02-23 | Cerulean Pharma Inc. | Conjugates, particles, compositions, and related methods |
WO2012024595A2 (en) | 2010-08-20 | 2012-02-23 | University Of Washington | Circumferential aerosol device for delivering drugs to olfactory epithelium and brain |
US20120058154A1 (en) | 2010-08-20 | 2012-03-08 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus m2e |
JP2013538211A (en) | 2010-08-23 | 2013-10-10 | セレクタ バイオサイエンシーズ インコーポレーテッド | Targeted multi-epitope dosage forms that elicit an immune response to an antigen |
WO2012025129A1 (en) | 2010-08-24 | 2012-03-01 | Gkn Driveline International Gmbh | Boot for joints, especially for constant velocity joints, with a transition area |
ES2918649T3 (en) | 2010-08-31 | 2022-07-19 | Glaxosmithkline Biologicals Sa | Pegylated liposomes for delivery of RNA encoding an immunogen |
JP6165629B2 (en) | 2010-08-31 | 2017-07-19 | キヤノン ユー.エス. ライフ サイエンシズ, インコーポレイテッドCanon U.S. Life Sciences, Inc. | Method, device and system for fluid mixing and chip interface |
KR20130100278A (en) | 2010-08-31 | 2013-09-10 | 머크 샤프 앤드 돔 코포레이션 | Novel single chemical entities and methods for delivery of oligonucleotides |
PT3556396T (en) | 2010-08-31 | 2022-07-04 | Scripps Research Inst | Human immunodeficiency virus (hiv)-neutralizing antibodies |
RU2577983C2 (en) | 2010-08-31 | 2016-03-20 | Новартис Аг | Lipids suitable for liposomal delivery of rna encoding protein |
MX341989B (en) | 2010-08-31 | 2016-09-09 | Novartis Ag * | Small liposomes for delivery of immunogen-encoding rna. |
WO2012031205A2 (en) | 2010-09-03 | 2012-03-08 | The Brigham And Women's Hospital, Inc. | Lipid-polymer hybrid particles |
WO2012034067A1 (en) | 2010-09-09 | 2012-03-15 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens |
WO2012034077A2 (en) | 2010-09-09 | 2012-03-15 | The University Of Chicago | Compositions and methods related to attenuated staphylococcal strains |
WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
EP2618847A4 (en) | 2010-09-20 | 2014-04-02 | Merck Sharp & Dohme | Novel low molecular weight cationic lipids for oligonucleotide delivery |
WO2012038448A1 (en) | 2010-09-21 | 2012-03-29 | Riboxx Gmbh | Method for synthesizing rna using dna template |
EP3412279B1 (en) | 2010-09-24 | 2021-02-17 | The Brigham and Women's Hospital, Inc. | Nanostructured gels capable of controlled release of encapsulated agents |
WO2012050975A2 (en) | 2010-09-29 | 2012-04-19 | The University Of North Carolina At Chapel Hill | Novel circular mammalian rna molecules and uses thereof |
CN103260611A (en) | 2010-09-30 | 2013-08-21 | 默沙东公司 | Low molecular weight cationic lipids for oligonucleotide delivery |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
US10078075B2 (en) | 2011-12-09 | 2018-09-18 | Vanderbilt University | Integrated organ-on-chip systems and applications of the same |
WO2012051220A1 (en) | 2010-10-11 | 2012-04-19 | Wichita State University | Composite magnetic nanoparticle drug delivery system |
BR112013008700B8 (en) | 2010-10-11 | 2022-10-04 | Novartis Ag | SELF-REPLICATING RNA MOLECULE, ALPHAVIRUS REPLICON PARTICLE, COMPOSITION, RECOMBINANT DNA MOLECULE, USE OF SELF-REPLICATING RNA MOLECULE |
EP2629802B1 (en) | 2010-10-21 | 2019-12-04 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
US20150056300A1 (en) | 2010-10-22 | 2015-02-26 | Bind Therapeutics, Inc. | Therapeutic nanoparticles with high molecular weight copolymers |
WO2012154202A1 (en) | 2010-10-29 | 2012-11-15 | Merck Sharp & Dohme Corp. | Recombinant subunit dengue virus vaccine |
EP2635254B1 (en) | 2010-11-05 | 2019-05-15 | The John Hopkins University | Compositions and methods relating to reduced mucoadhesion |
WO2012061259A2 (en) | 2010-11-05 | 2012-05-10 | Merck Sharp & Dohme Corp. | Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
EP2638162B1 (en) | 2010-11-09 | 2016-08-10 | The Regents of The University of California | Skin permeating and cell entering (space) peptides and methods of use thereof |
SI3536703T1 (en) | 2010-11-12 | 2022-04-29 | The Trustees Of The University Of Pennsylvania | Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof |
WO2012068295A1 (en) | 2010-11-16 | 2012-05-24 | Selecta Biosciences, Inc. | Immunostimulatory oligonucleotides |
CA2818353A1 (en) | 2010-11-17 | 2012-05-24 | Aduro Biotech | Methods and compositions for inducing an immune response to egfrviii |
EP3213770B1 (en) | 2010-11-19 | 2021-02-24 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
WO2012068187A1 (en) | 2010-11-19 | 2012-05-24 | Merck Sharp & Dohme Corp. | Poly(amide) polymers for the delivery of oligonucleotides |
WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
WO2012072096A1 (en) | 2010-12-03 | 2012-06-07 | Biontech Ag | Method for cellular rna expression |
EP2651445A2 (en) | 2010-12-16 | 2013-10-23 | SPRNA GmbH | Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications |
US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
US8901101B2 (en) | 2010-12-17 | 2014-12-02 | Sirna Therapeutics, Inc. | Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides |
WO2012088381A2 (en) | 2010-12-22 | 2012-06-28 | President And Fellows Of Harvard College | Continuous directed evolution |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
CA2976966C (en) | 2010-12-29 | 2021-11-09 | F. Hoffmann-La Roche Ag | Small molecule conjugates for intracellular delivery of nucleic acids |
WO2012092552A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
WO2012092569A2 (en) | 2010-12-31 | 2012-07-05 | Selecta Biosciences, Inc. | Compositions comprising immunostimulatory nucleic acids and related methods |
US10364440B2 (en) | 2011-01-04 | 2019-07-30 | Brown University | Nanotubes as carriers of nucleic acids into cells |
WO2012094574A2 (en) | 2011-01-06 | 2012-07-12 | The Johns Hopkins University | Stabilized polyribonucleotide nanoparticles |
WO2012094653A2 (en) | 2011-01-07 | 2012-07-12 | Massachusetts Institute Of Technology | Compositions and methods for macromolecular drug delivery |
AU2012207606B2 (en) | 2011-01-11 | 2017-02-23 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
DE102011082231A1 (en) | 2011-01-12 | 2012-07-12 | Robert Bosch Gmbh | Ignition coil, especially for small engines |
WO2012099805A2 (en) | 2011-01-19 | 2012-07-26 | Ocean Nanotech, Llc | Nanoparticle based immunological stimulation |
CA2825023A1 (en) | 2011-01-26 | 2012-08-02 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
US10363309B2 (en) | 2011-02-04 | 2019-07-30 | Case Western Reserve University | Targeted nanoparticle conjugates |
US20140066363A1 (en) | 2011-02-07 | 2014-03-06 | Arun K. Bhunia | Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
US20120207840A1 (en) | 2011-02-10 | 2012-08-16 | Aura Biosciences, Inc. | Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment Of Non-Melanoma Skin Cancer |
EP2675921A4 (en) | 2011-02-14 | 2014-12-03 | Swift Biosciences Inc | Polynucleotide primers and probes |
US20140081012A1 (en) | 2011-02-15 | 2014-03-20 | The University Of North Carolina At Chapel Hill | Nanoparticle, liposomes, polymers, agents and proteins modified with reversible linkers |
EP2675918B1 (en) | 2011-02-15 | 2017-11-08 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
EP2489371A1 (en) | 2011-02-18 | 2012-08-22 | Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria | Carrier peptides for drug delivery |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
JP6091435B2 (en) | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | Protein delivery using adeno-associated virus (AAV) vectors |
US8696637B2 (en) | 2011-02-28 | 2014-04-15 | Kimberly-Clark Worldwide | Transdermal patch containing microneedles |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
RU2013144207A (en) | 2011-03-02 | 2015-04-10 | Новартис Аг | COMBINED VACCINES WITH REDUCED DOSES OF ANTIGEN AND / OR ADJUVANT |
CN103502436A (en) | 2011-03-07 | 2014-01-08 | 麻省理工学院 | Methods for transfecting cells with nucleic acids |
US20120237565A1 (en) | 2011-03-14 | 2012-09-20 | Intezyne Technologies, Incorporated | Pegylated polyplexes containing two or more different polymers for polynucleotide delivery |
WO2012125680A1 (en) | 2011-03-16 | 2012-09-20 | Novartis Ag | Methods of treating vasculitis using an il-17 binding molecule |
US20140212503A1 (en) | 2011-03-17 | 2014-07-31 | Hyukjin Lee | Delivery system |
MA34966B1 (en) | 2011-03-17 | 2014-03-01 | Novartis Ag | FGFR AND ITS LIGANDS USED AS BIOMARKERS OF BREAST CANCER IN POSITIVE RH SUBJECTS |
WO2012129483A1 (en) | 2011-03-24 | 2012-09-27 | Novartis Ag | Adjuvant nanoemulsions with phospholipids |
CA2830948A1 (en) | 2011-03-25 | 2012-10-04 | Selecta Biosciences, Inc. | Osmotic mediated release synthetic nanocarriers |
PL2691443T3 (en) | 2011-03-28 | 2021-08-30 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
WO2012131594A1 (en) | 2011-03-28 | 2012-10-04 | Novartis Ag | Markers associated with cyclin-dependent kinase inhibitors |
WO2012131106A1 (en) | 2011-03-31 | 2012-10-04 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
EP2691079B1 (en) | 2011-03-31 | 2020-06-24 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
EP2694660B1 (en) | 2011-04-03 | 2018-08-08 | The General Hospital Corporation | Efficient protein expression in vivo using modified rna (mod-rna) |
EP2694524B1 (en) | 2011-04-04 | 2016-05-18 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides |
WO2012142132A1 (en) | 2011-04-11 | 2012-10-18 | Life Technologies Corporation | Polymer particles and methods of making and using same |
US11135174B2 (en) | 2011-04-13 | 2021-10-05 | The Trustees Of The University Of Pennsylvania | Coated mesoporous nanoparticles |
WO2013158127A1 (en) | 2012-04-16 | 2013-10-24 | Molecular Transfer, Inc. | Agents for improved delivery of nucleic acids to eukaryotic cells |
US20140178894A1 (en) | 2011-04-20 | 2014-06-26 | Novartis Forschungsstiftung, Zweigniederlassung | Culture medium suitable for the culture of undifferentiated cells |
EA034702B1 (en) | 2011-04-26 | 2020-03-10 | Молекулар Экспресс, Инк. | Liposomal compositions |
WO2012148684A1 (en) | 2011-04-27 | 2012-11-01 | President And Fellows Of Harvard College | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation |
CA2834365A1 (en) | 2011-04-28 | 2012-11-01 | Sandia Corporation | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same |
WO2012149536A1 (en) | 2011-04-28 | 2012-11-01 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Neutralizing antibodies to nipah and hendra virus |
WO2012149393A2 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells |
JP2014515759A (en) | 2011-04-29 | 2014-07-03 | ノバルティス アーゲー | Applications related to methods of treating squamous cell carcinoma |
US20120283503A1 (en) | 2011-04-29 | 2012-11-08 | The Johns Hopkins University | Nanoparticle loaded stem cells and their use in mri guided hyperthermia |
DK2705143T3 (en) | 2011-05-02 | 2021-05-10 | Univ Wayne State | PROTEIN-INDUCED PLURIPOTENT CELL TECHNOLOGY AND ITS USE |
UA116189C2 (en) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
EP2704565B1 (en) | 2011-05-04 | 2018-08-22 | The University Of Nottingham | Novel polymers which resist bacterial attachment |
US9327029B2 (en) | 2011-05-05 | 2016-05-03 | Celacare Technologies, Llc | Antimicrobial silver hydrogel composition for the treatment of burns and wounds |
US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
WO2012152810A1 (en) | 2011-05-10 | 2012-11-15 | Basf Se | Oil-in-water emulsions |
US9283279B2 (en) | 2011-05-11 | 2016-03-15 | Ramot At Tel-Aviv University Ltd. | Targeted polymeric conjugates and uses thereof |
US20140072657A1 (en) | 2011-05-12 | 2014-03-13 | Helmut Vockner | Novel pharmaceutical formulation |
DK2706988T3 (en) | 2011-05-12 | 2020-01-20 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | LIPOSOMES COMPREHENSIVE POLYMER CONJUGATED LIPIDS AND RELATED USE |
ES2651143T3 (en) | 2011-05-13 | 2018-01-24 | Glaxosmithkline Biologicals Sa | RS prefusion F antigens |
US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
CA2835428A1 (en) | 2011-05-17 | 2012-11-22 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof for non-human vertebrates |
US8978170B2 (en) | 2011-05-20 | 2015-03-17 | Kohler Co. | Toilet installation system and method |
HRP20211595T1 (en) | 2011-05-24 | 2022-01-21 | BioNTech SE | Individualized vaccines for cancer |
US20140227372A1 (en) | 2011-05-25 | 2014-08-14 | Novartis Ag | Biomarkers for lung cancer |
US20120302940A1 (en) | 2011-05-26 | 2012-11-29 | Jackson State University | Popcorn Shape Gold Nanoparticle For Targeted Diagnosis, Photothermal Treatment and In-Situ Monitoring Therapy Response for Cancer and Multiple Drug Resistance Bacteria |
WO2012166923A2 (en) | 2011-05-31 | 2012-12-06 | Bind Biosciences | Drug loaded polymeric nanoparticles and methods of making and using same |
CN107115314B (en) | 2011-06-02 | 2022-04-29 | 加利福尼亚大学董事会 | Film-encapsulated nanoparticles and methods of use |
US20140094461A1 (en) | 2011-06-02 | 2014-04-03 | Novartis Ag | Biomarkers for hedgehog inhibitor therapy |
WO2012168259A1 (en) | 2011-06-06 | 2012-12-13 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
CN103748078B (en) | 2011-06-08 | 2016-11-09 | 夏尔人类遗传性治疗公司 | Cleavable lipid |
EP4043025A1 (en) | 2011-06-08 | 2022-08-17 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
CA2836805C (en) | 2011-06-10 | 2023-03-07 | Novartis Ag | Bovine vaccines and methods |
WO2012170607A2 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Use of pcsk9 antagonists |
US8636696B2 (en) | 2011-06-10 | 2014-01-28 | Kimberly-Clark Worldwide, Inc. | Transdermal device containing microneedles |
US8916696B2 (en) | 2011-06-12 | 2014-12-23 | City Of Hope | Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use |
WO2012172495A1 (en) | 2011-06-14 | 2012-12-20 | Novartis Ag | Compositions and methods for antibodies targeting tem8 |
EP2720740A1 (en) | 2011-06-15 | 2014-04-23 | ChronTech Pharma AB | Injection needle and device |
JP2014519338A (en) | 2011-06-16 | 2014-08-14 | ノバルティス アーゲー | Soluble proteins used as therapeutic agents |
CA2839995A1 (en) | 2011-06-20 | 2012-12-27 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for h1n1 influenza |
WO2013003475A1 (en) | 2011-06-27 | 2013-01-03 | Cellscript, Inc. | Inhibition of innate immune response |
KR102436439B1 (en) | 2011-06-28 | 2022-08-25 | 이노비오 파마수티컬즈, 인크. | A miniminally invasive dermal electroporation device |
ES2692519T3 (en) | 2011-07-01 | 2018-12-04 | Novartis Ag | Method to treat metabolic disorders |
AU2012278910A1 (en) | 2011-07-04 | 2014-01-16 | Commonwealth Scientific And Industrial Research Organisation | Nucleic acid complex |
WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
EP2729168A2 (en) | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
MX350198B (en) | 2011-07-06 | 2017-08-30 | Novartis Ag | Oil-in-water emulsions that contain nucleic acids. |
MX350258B (en) | 2011-07-06 | 2017-08-31 | Novartis Ag | Cationic oil-in-water emulsions. |
ES2861428T3 (en) | 2011-07-06 | 2021-10-06 | Glaxosmithkline Biologicals Sa | Liposomes that have a useful N: P ratio for delivery of RNA molecules |
US8975302B2 (en) | 2011-07-07 | 2015-03-10 | Life Technologies Corporation | Polymer particles, nucleic acid polymer particles and methods of making and using the same |
US20130012566A1 (en) | 2011-07-10 | 2013-01-10 | Aura Biosciences, Inc. | Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment of Alopecia |
WO2013009717A1 (en) | 2011-07-10 | 2013-01-17 | Elisabet De Los Pinos | Virion derived protein nanoparticles for delivering diagnostic or therapeutic agents for the treatment of skin-related diseases |
EP2758458A4 (en) | 2011-07-10 | 2015-10-21 | Harvard College | Compositions and methods for self-assembly of polymers with complementary macroscopic and microscopic scale units |
GB2492999A (en) | 2011-07-20 | 2013-01-23 | Univ Central Lancashire | Neutron detector |
US20140148503A1 (en) | 2011-07-20 | 2014-05-29 | University Of Iowa Research Foundation | Nucleic acid aptamers |
ES2670944T3 (en) | 2011-07-21 | 2018-06-04 | Croda International Plc | Branched polyether polyamide block copolymers and methods of preparing and using them |
WO2013016460A1 (en) | 2011-07-25 | 2013-01-31 | Novartis Ag | Compositions and methods for assessing functional immunogenicity of parvovirus vaccines |
US9493549B2 (en) | 2011-07-25 | 2016-11-15 | The Rockefeller University | Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth |
AU2012290306B2 (en) | 2011-07-29 | 2017-08-17 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses |
US9556281B2 (en) | 2011-08-15 | 2017-01-31 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein A |
KR20140051357A (en) | 2011-08-26 | 2014-04-30 | 애로우헤드 리서치 코오포레이션 | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
TR201900264T4 (en) | 2011-08-31 | 2019-02-21 | Glaxosmithkline Biologicals Sa | Pegylated liposomes for delivery of the immunogen encoding RNA. |
KR20140067070A (en) | 2011-08-31 | 2014-06-03 | 말린크로트 엘엘씨 | Nanoparticle peg modification with h-phosphonates |
US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
WO2013033620A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as pdgfr kinase inhibitors |
WO2013030778A2 (en) | 2011-09-02 | 2013-03-07 | Novartis Ag | Organic compositions to treat hsf1-related diseases |
WO2013039857A1 (en) * | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
WO2013039861A2 (en) * | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CN103917245B (en) | 2011-09-14 | 2017-06-06 | 葛兰素史密丝克莱恩生物有限公司 | Method for preparing glycoprotein glycoconjugate |
WO2013040557A2 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
WO2013044219A1 (en) | 2011-09-22 | 2013-03-28 | Bind Biosciences | Methods of treating cancers with therapeutic nanoparticles |
US9375388B2 (en) | 2011-09-23 | 2016-06-28 | Indian Institute Of Technology, Bombay | Nanoparticle based cosmetic composition |
US9006400B2 (en) | 2011-09-26 | 2015-04-14 | Novartis Ag | Fibroblast growth factor-21-Fc fusion proteins |
TW201315742A (en) | 2011-09-26 | 2013-04-16 | Novartis Ag | Dual fuction proteins for treating metabolic disorders |
US9701623B2 (en) | 2011-09-27 | 2017-07-11 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
WO2013045505A1 (en) | 2011-09-28 | 2013-04-04 | Novartis Ag | Biomarkers for raas combination therapy |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
CA2872033A1 (en) | 2011-10-11 | 2013-04-18 | Novartis Ag | Recombinant self-replicating polycistronic rna molecules |
WO2013055971A1 (en) | 2011-10-11 | 2013-04-18 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Polymers for delivering a substance into a cell |
US20190209690A9 (en) | 2011-10-12 | 2019-07-11 | The Johns Hopkins University | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery |
EP2766407B1 (en) | 2011-10-12 | 2018-06-27 | The Curators Of The University Of Missouri | Pentablock polymers |
JP2014530816A (en) | 2011-10-14 | 2014-11-20 | ノバルティスアーゲー | Antibodies and methods for Wnt pathway related diseases |
WO2013056132A2 (en) | 2011-10-14 | 2013-04-18 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
PT3597644T (en) | 2011-10-18 | 2021-11-03 | Dicerna Pharmaceuticals Inc | Amine cationic lipids and uses thereof |
CA2852260C (en) | 2011-10-18 | 2020-09-22 | Micell Technologies, Inc. | Drug delivery medical device |
WO2013057715A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
KR102043077B1 (en) | 2011-10-20 | 2019-11-11 | 노파르티스 아게 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
EP3069785A1 (en) | 2011-10-25 | 2016-09-21 | The University Of British Columbia | Limit size lipid nanoparticles and related methods |
US20130110043A1 (en) | 2011-10-26 | 2013-05-02 | Nanopass Technologies Ltd. | Microneedle Intradermal Drug Delivery Device with Auto-Disable Functionality |
AU2012328037B2 (en) | 2011-10-27 | 2017-11-02 | Sorrento Therapeutics, Inc. | Transdermal delivery of high viscosity bioactive agents |
AU2012328570B2 (en) | 2011-10-27 | 2017-08-31 | Massachusetts Institute Of Technology | Amino acid derivatives functionalized on the n-terminus capable of forming drug encapsulating microspheres and uses thereof |
JP2014534864A (en) | 2011-10-28 | 2014-12-25 | プレサージュ バイオサイエンシズ,インコーポレイテッド | Drug delivery method |
WO2013062140A1 (en) | 2011-10-28 | 2013-05-02 | Kyoto University | Method for efficiently inducing differentiation of pluripotent stem cells into hepatic lineage cells |
CN108771655A (en) | 2011-10-28 | 2018-11-09 | 诚信生物公司 | Protein formulation containing amino acid |
EP2773426B1 (en) | 2011-10-31 | 2018-08-22 | Mallinckrodt LLC | Combinational liposome compositions for cancer therapy |
MX363226B (en) | 2011-10-31 | 2019-03-15 | Genentech Inc | Antibody formulations. |
LT2773326T (en) | 2011-11-04 | 2019-04-25 | Nitto Denko Corporation | Method for sterilely producing lipid-nucleic acid particles |
US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
SG11201401964TA (en) | 2011-11-04 | 2014-05-29 | Agency Science Tech & Res | Self-assembled composite ultrasmall peptide-polymer hydrogels |
WO2013067537A1 (en) | 2011-11-04 | 2013-05-10 | Univertiy Of Notre Dame Du Lac | Nanoparticle-based drug delivery |
EP2773669B1 (en) | 2011-11-04 | 2018-03-28 | Novartis AG | Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs |
US20130116408A1 (en) | 2011-11-05 | 2013-05-09 | Aura Biosciences, Inc. | Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy |
US20130115247A1 (en) | 2011-11-05 | 2013-05-09 | Aura Biosciences, Inc. | Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy |
EP2776022A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
EP2776838A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
US9849087B2 (en) | 2011-11-08 | 2017-12-26 | The Board Of Trustees Of The University Of Arkansas | Methods and compositions for X-ray induced release from pH sensitive liposomes |
EP2776459A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Rod cell-specific promoter |
US10203325B2 (en) | 2011-11-09 | 2019-02-12 | Board Of Trustees Of Michigan State University | Metallic nanoparticle synthesis with carbohydrate capping agent |
DK2776567T3 (en) | 2011-11-11 | 2021-04-26 | Variation Biotechnologies Inc | Compositions and methods of treatment of cytomegalovirus. |
WO2013071047A1 (en) | 2011-11-11 | 2013-05-16 | Children's Medical Center Corporation | Compositions and methods for in vitro transcription of rna |
JP2014533290A (en) | 2011-11-14 | 2014-12-11 | ノバルティス アーゲー | Immunogenic complexes of polyanionic carbomers and Env polypeptides and methods for making and using the same |
KR20140091695A (en) | 2011-11-15 | 2014-07-22 | 노파르티스 아게 | Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway |
EP2790681B9 (en) | 2011-11-18 | 2023-07-26 | Regeneron Pharmaceuticals, Inc. | Method of manufacturing an extended release pharmaceutical formulation comprising polymer coated protein microparticles using spray-drying |
BR112014012101A2 (en) | 2011-11-21 | 2019-09-24 | Novartis Ag | psoriatic arthritis (psa) treatment methods using il-17 antagonists and psa response or non-response alleles |
WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
TR201111743A2 (en) | 2011-11-28 | 2012-04-24 | Nesl�Han G�Rsoy Reyhan | Oil based nanocarrier systems for use in cancer treatment. |
US20150037428A1 (en) | 2011-11-29 | 2015-02-05 | The University Of North Carolina At Chapel Hill | Geometrically engineered particles and methods for modulating macrophage or immune responses |
US9364549B2 (en) | 2011-11-30 | 2016-06-14 | Andreas Voigt | Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition |
CN104080441B (en) | 2011-11-30 | 2020-02-28 | 3M创新有限公司 | Microneedle devices comprising peptide therapeutics and amino acids, methods of making and using the same |
EP2785333A4 (en) | 2011-12-02 | 2015-04-01 | Pegasus Lab Inc | Amphipathic lipid-based sustained release compositions |
US20130142781A1 (en) | 2011-12-02 | 2013-06-06 | Invivo Therapeutics Corporation | Peg based hydrogel for peripheral nerve injury applications and compositions and method of use of synthetic hydrogel sealants |
WO2013082529A1 (en) | 2011-12-02 | 2013-06-06 | Yale University | Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery |
JP6073916B2 (en) | 2011-12-05 | 2017-02-01 | ファクター バイオサイエンス インコーポレイテッド | Methods and products for transfecting cells |
KR102055772B1 (en) | 2011-12-05 | 2019-12-13 | 나노 프리시전 메디컬, 인코포레이티드 | Device having titania nanotube membrane for drug delivery |
US8497124B2 (en) | 2011-12-05 | 2013-07-30 | Factor Bioscience Inc. | Methods and products for reprogramming cells to a less differentiated state |
ES2921724T1 (en) | 2011-12-07 | 2022-08-31 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the administration of active agents |
WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
EP2788316B1 (en) | 2011-12-07 | 2019-04-24 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
US10087422B2 (en) | 2011-12-09 | 2018-10-02 | President And Fellows Of Harvard College | Organ chips and uses thereof |
WO2013086526A1 (en) | 2011-12-09 | 2013-06-13 | The Regents Of The University Of California | Liposomal drug encapsulation |
WO2013086486A1 (en) | 2011-12-09 | 2013-06-13 | President And Fellows Of Harvard College | Integrated human organ-on-chip microphysiological systems |
WO2013089151A1 (en) | 2011-12-12 | 2013-06-20 | 協和発酵キリン株式会社 | Lipid nanoparticles for drug delivery system containing cationic lipids |
US20140045913A1 (en) | 2011-12-12 | 2014-02-13 | Kyowa Hakko Kirin Co., Ltd. | Lipid nano particles comprising combination of cationic lipid |
JP6407028B2 (en) | 2011-12-12 | 2018-10-17 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Protein containing MRSA PBP2a and fragments thereof, nucleic acid encoding the same, composition for preventing and treating MRSA infection and use thereof |
EP2604253A1 (en) | 2011-12-13 | 2013-06-19 | Otto Glatter | Water-in-oil emulsions and methods for their preparation |
US20150000936A1 (en) | 2011-12-13 | 2015-01-01 | Schlumberger Technology Corporation | Energization of an element with a thermally expandable material |
MX359410B (en) | 2011-12-13 | 2018-09-27 | Engeneic Molecular Delivery Pty Ltd | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors. |
US20140378538A1 (en) | 2011-12-14 | 2014-12-25 | Moderma Therapeutics, Inc. | Methods of responding to a biothreat |
US20140343129A1 (en) | 2011-12-14 | 2014-11-20 | Moderna Therapeutics, Inc. | Modified nucleic acids, and acute care uses thereof |
US9636414B2 (en) | 2011-12-15 | 2017-05-02 | Biontech Ag | Particles comprising single stranded RNA and double stranded RNA for immunomodulation |
WO2013090897A1 (en) | 2011-12-15 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Using adaptive immunity to detect drug resistance |
KR20140102759A (en) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | Modified nucleoside, nucleotide, and nucleic acid compositions |
CA2859205A1 (en) | 2011-12-16 | 2013-06-20 | Massachusetts Institute Of Technology | Alpha-aminoamidine polymers and uses thereof |
RU2014129268A (en) | 2011-12-16 | 2016-02-10 | Аллерган, Инк. | OPHTHALMIC COMPOSITIONS THAT CONTAIN GRAVITY POLYVINYL POLYVINYL PROCALT-POLYVINYL ACETATE-POLYETHYLENE Glycol copolymers |
AU2012351947B2 (en) | 2011-12-16 | 2017-08-17 | Novartis Ag | Aerosolization apparatus for inhalation profile-independent drug delivery |
WO2013090601A2 (en) | 2011-12-16 | 2013-06-20 | Massachusetts Institute Of Technology | Compact nanoparticles for biological applications |
WO2013087913A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
US9546235B2 (en) | 2011-12-19 | 2017-01-17 | The University Of Sydney | Peptide-hydrogel composite |
US9241829B2 (en) | 2011-12-20 | 2016-01-26 | Abbott Medical Optics Inc. | Implantable intraocular drug delivery apparatus, system and method |
AU2012358384A1 (en) | 2011-12-21 | 2014-07-31 | Moderna Therapeutics, Inc. | Methods of increasing the viability or longevity of an organ or organ explant |
US20130195851A1 (en) | 2011-12-23 | 2013-08-01 | Genentech, Inc. | Articles of manufacture and methods for co-administration of antibodies |
WO2013101908A1 (en) | 2011-12-27 | 2013-07-04 | Massachusetts Institute Of Technology | Microneedle devices and uses thereof |
AU2011384634A1 (en) | 2011-12-29 | 2014-06-19 | Novartis Ag | Adjuvanted combinations of meningococcal factor H binding proteins |
US20140371302A1 (en) | 2011-12-29 | 2014-12-18 | Modema Therapeutics, Inc. | Modified mrnas encoding cell-penetrating polypeptides |
PL3421601T3 (en) | 2011-12-30 | 2020-06-01 | Cellscript, Llc | Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect |
CN110025608A (en) | 2012-01-06 | 2019-07-19 | 燿石治疗公司 | The method for reducing risk of cardiovascular diseases |
US20150030576A1 (en) | 2012-01-10 | 2015-01-29 | Moderna Therapeutics, Inc. | Methods and compositions for targeting agents into and across the blood-brain barrier |
US20150017703A1 (en) | 2012-01-26 | 2015-01-15 | Life Technologies Corporation | Methods for increasing the infectivity of viruses |
CN104245925A (en) | 2012-01-26 | 2014-12-24 | 生命科技公司 | Methods for increasing the infectivity of viruses |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
KR102019297B1 (en) | 2012-02-09 | 2019-09-06 | 라이프 테크놀로지스 코포레이션 | Hydrophilic polymeric particles and methods for making same |
MX2014010161A (en) | 2012-02-22 | 2015-03-09 | Univ Northwestern | Nanostructures for treating cancers and other conditions. |
EP2817345A1 (en) | 2012-02-22 | 2014-12-31 | Cerulean Pharma Inc. | Conjugates, particles, compositions, and related methods |
US20130243867A1 (en) | 2012-02-23 | 2013-09-19 | University Of South Florida (A Florida Non-Profit Corporation) | Micelle compositions and methods for their use |
WO2013129936A1 (en) | 2012-02-27 | 2013-09-06 | Epitarget As | Use of an antibody and a particulate immunomodulator in therapy |
WO2013130535A1 (en) | 2012-02-27 | 2013-09-06 | Newgen Biopharma Corporation | Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same |
WO2013129935A1 (en) | 2012-02-27 | 2013-09-06 | Epitarget As | Use of a particulate immunomodulator in cancer therapy |
JP6407726B2 (en) | 2012-03-01 | 2018-10-24 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | Long-life polypeptide binding molecule |
US20130236504A1 (en) | 2012-03-06 | 2013-09-12 | Medical University Of South Carolina | Delivery System for Enhancing Drug Efficacy |
WO2013136234A1 (en) | 2012-03-13 | 2013-09-19 | University Of Kwazulu-Natal | Transdermal delivery devices |
US10322089B2 (en) | 2012-03-14 | 2019-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Nanoparticles, nanoparticle delivery methods, and systems of delivery |
US8962577B2 (en) | 2012-03-16 | 2015-02-24 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
EA030318B1 (en) | 2012-03-16 | 2018-07-31 | Дзе Джонс Хопкинс Юниверсити | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
JP6527331B2 (en) | 2012-03-16 | 2019-06-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Target-directed amino acid lipid |
US9610346B2 (en) | 2012-03-23 | 2017-04-04 | International Aids Vaccine Initiative | Recombinant viral vectors |
WO2013142349A1 (en) | 2012-03-23 | 2013-09-26 | University Of Chicago | Compositions and methods related to staphylococcal sbi |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
EP2830991A1 (en) | 2012-03-26 | 2015-02-04 | President and Fellows of Harvard College | Lipid-coated nucleic acid nanostructures of defined shape |
AU2013242404B2 (en) | 2012-03-27 | 2018-08-30 | CureVac SE | Artificial nucleic acid molecules for improved protein or peptide expression |
WO2013148541A1 (en) | 2012-03-27 | 2013-10-03 | Merck Sharp & Dohme Corp. | DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY |
ES2660459T3 (en) | 2012-03-27 | 2018-03-22 | Curevac Ag | Artificial Nucleic Acid Molecules |
CN104321432B (en) | 2012-03-27 | 2018-08-10 | 库瑞瓦格股份公司 | Include the artificial nucleic acid molecule of 5 ' TOP UTR |
CN104487055A (en) | 2012-03-29 | 2015-04-01 | 夏尔人类遗传性治疗公司 | Lipid-derived neutral nanoparticles |
US20140275229A1 (en) | 2012-04-02 | 2014-09-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1 |
AU2013243949A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
CA2868398A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US20150050354A1 (en) | 2012-04-02 | 2015-02-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for the treatment of otic diseases and conditions |
WO2013151650A1 (en) | 2012-04-05 | 2013-10-10 | University Of Florida Research Foundation, Inc. | Neurophilic nanoparticles |
EP3563872A1 (en) | 2012-04-05 | 2019-11-06 | Massachusetts Institute Of Technology | Immunostimulatory compositions and methods of use thereof |
WO2013152351A2 (en) | 2012-04-06 | 2013-10-10 | The Trustees Of Columbia University In The City Of New York | Fusion polypeptides and methods of use thereof |
ES2821098T3 (en) | 2012-04-08 | 2021-04-23 | Urogen Pharma Ltd | Reversible thermal hydrogel preparations for use in the treatment of urothelial disorders |
WO2013154774A1 (en) | 2012-04-11 | 2013-10-17 | Intezyne Technologies, Inc. | Block copolymers for stable micelles |
JP6378170B2 (en) | 2012-04-12 | 2018-08-22 | イェール ユニバーシティーYale University | Vehicle for controlled delivery of different pharmaceuticals |
WO2013155513A1 (en) | 2012-04-13 | 2013-10-17 | President And Fellows Of Harvard College | Devices and methods for in vitro aerosol delivery |
WO2013154766A1 (en) | 2012-04-13 | 2013-10-17 | New York University | Microrna control of ldl receptor pathway |
AU2012377385A1 (en) | 2012-04-18 | 2014-01-23 | Arrowhead Research Corporation | Poly(acrylate) polymers for in vivo nucleic acid delivery |
EP3434667B1 (en) | 2012-04-19 | 2020-11-04 | Sirna Therapeutics, Inc. | Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
EP2841056A4 (en) | 2012-04-23 | 2015-09-16 | Massachusetts Inst Technology | Stable layer-by-layer coated particles |
NZ630591A (en) | 2012-04-25 | 2017-02-24 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-21 activity |
JP6360039B2 (en) | 2012-05-03 | 2018-07-18 | カラ ファーマシューティカルズ インコーポレイテッド | Composition comprising a plurality of coated particles, pharmaceutical composition, pharmaceutical formulation and method of forming the particles |
CA2872519C (en) | 2012-05-04 | 2017-09-05 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
WO2013173657A1 (en) | 2012-05-16 | 2013-11-21 | Micell Technologies, Inc. | Low burst sustained release lipophilic and biologic agent compositions |
US9399672B2 (en) | 2012-05-17 | 2016-07-26 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Hepatitis C virus neutralizing antibody |
WO2013173693A1 (en) | 2012-05-18 | 2013-11-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nanoparticles with enhanced entry into cancer cells |
CN104582691A (en) | 2012-05-23 | 2015-04-29 | 俄亥俄州立大学 | Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same |
US20150306249A1 (en) | 2012-05-25 | 2015-10-29 | Curevac Gmbh | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
AU2013271548B2 (en) | 2012-06-06 | 2017-05-25 | Loma Vista Medical, Inc. | Inflatable medical devices |
EP3884949A1 (en) | 2012-06-08 | 2021-09-29 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
WO2013185116A1 (en) | 2012-06-08 | 2013-12-12 | Payne Joseph E | Lipids for therapeutic agent delivery formulations |
CA2873274C (en) | 2012-06-08 | 2021-06-01 | Ethris Gmbh | Pulmonary delivery of messenger rna |
US20150218252A1 (en) | 2012-06-20 | 2015-08-06 | President And Fellows Of Harvard College | Self-assembling peptides, peptide nanostructures and uses thereof |
ES2658972T3 (en) | 2012-06-20 | 2018-03-13 | University Of Waterloo | Mucoadhesive nanoparticle administration system |
EP2866833B1 (en) | 2012-06-27 | 2019-05-15 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
US9956291B2 (en) | 2012-07-10 | 2018-05-01 | Shaker A. Mousa | Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting |
WO2014014890A1 (en) | 2012-07-16 | 2014-01-23 | Nanoderm Sciences, Inc. | Targeted therapeutic nanoparticles |
EP2687252A1 (en) | 2012-07-17 | 2014-01-22 | Sanofi-Aventis Deutschland GmbH | Drug delivery device |
EP2687251A1 (en) | 2012-07-17 | 2014-01-22 | Sanofi-Aventis Deutschland GmbH | Drug delivery device |
CN112587658A (en) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | Targeted immunotherapy for cancer |
WO2014015334A1 (en) | 2012-07-20 | 2014-01-23 | Brown University | System and methods for nanostructure protected delivery of treatment agent and selective release thereof |
KR20160073936A (en) | 2012-07-24 | 2016-06-27 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Self-assembly of nucleic acid nanostructures |
WO2014015422A1 (en) | 2012-07-27 | 2014-01-30 | Ontario Institute For Cancer Research | Cellulose-based nanoparticles for drug delivery |
GB201213624D0 (en) | 2012-07-27 | 2012-09-12 | Univ Ulster The | Method and system for production of conjugated nanoparticles |
US9931418B2 (en) | 2012-08-07 | 2018-04-03 | Northeastern University | Compositions for the delivery of RNA and drugs into cells |
WO2014024193A1 (en) | 2012-08-07 | 2014-02-13 | Prodel Pharma Ltd. | Compositions and methods for rapid transmucosal delivery of pharmaceutical ingredients |
AU2013299537A1 (en) | 2012-08-08 | 2015-02-19 | Presage Biosciences, Inc. | Extrusion methods and devices for drug delivery |
SG11201500188YA (en) | 2012-08-08 | 2015-02-27 | Univ Nanyang Tech | Methods of manufacturing hydrogel microparticles having living cells, and compositions for manufacturing a scaffold for tissue engineering |
WO2014025890A1 (en) | 2012-08-10 | 2014-02-13 | University Of North Texas Health Science Center | Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids |
WO2014027006A1 (en) | 2012-08-13 | 2014-02-20 | Edko Pazarlama Tanitim Ticaret Limited Sirketi | Bioadhesive formulations for use in drug delivery |
WO2014028487A1 (en) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
US9775804B2 (en) | 2012-08-14 | 2017-10-03 | Aaron Froese | Internal structured self assembling liposomes |
US9827321B2 (en) | 2012-08-14 | 2017-11-28 | The Trustees Of The University Of Pennsylvania | Stabilizing shear-thinning hydrogels |
CA2882248A1 (en) | 2012-08-15 | 2014-02-20 | The University Of Chicago | Exosome-based therapeutics against neurodegenerative disorders |
WO2014039185A1 (en) | 2012-09-05 | 2014-03-13 | Creighton University | Polymeric nanoparticles in a thermosensitive gel for coital-independent vaginal prophylaxis of hiv |
US8703197B2 (en) | 2012-09-13 | 2014-04-22 | International Business Machines Corporation | Branched polyamines for delivery of biologically active materials |
CN104812381B (en) | 2012-09-17 | 2018-01-26 | 辉瑞大药厂 | Method for preparing therapeutic nano particle |
WO2014047649A1 (en) | 2012-09-24 | 2014-03-27 | The Regents Of The University Of California | Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy |
US20150246137A1 (en) | 2012-09-27 | 2015-09-03 | The University Of North Carolina At Chapel Hill | Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof |
US20150307542A1 (en) | 2012-10-03 | 2015-10-29 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
WO2014053880A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
WO2014054026A1 (en) | 2012-10-04 | 2014-04-10 | University Of The Witwatersrand, Johannesburg | Liposomal drug delivery system |
US20140100178A1 (en) | 2012-10-04 | 2014-04-10 | Aslam Ansari | Composition and methods for site-specific drug delivery to treat malaria and other liver diseases |
EP2716655A1 (en) | 2012-10-04 | 2014-04-09 | Institut Pasteur | Neutralizing antibodies directed against Hepatitis C virus ectodomain glycoprotein E2 |
WO2014053879A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
WO2014053882A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
WO2014053881A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
WO2014064534A2 (en) | 2012-10-05 | 2014-05-01 | Chrontech Pharma Ab | Injection needle, device, immunogenic compositions and method of use |
EP2716689A1 (en) | 2012-10-05 | 2014-04-09 | National University of Ireland, Galway | Polymer comprising a plurality of branches having at least one disulfide group and/or at least one vinyl group |
US9931410B2 (en) | 2012-10-09 | 2018-04-03 | The Brigham And Women's Hospital, Inc. | Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use |
US20140106260A1 (en) | 2012-10-11 | 2014-04-17 | The Trustees Of The University Of Pennsylvania | Core-shell nanoparticulate compositions and methods |
EA201590622A1 (en) | 2012-10-16 | 2015-10-30 | Эндосайт, Инк. | CONJUGATES FOR DELIVERY OF MEDICINES CONTAINING NOT MEETING IN THE NATURE OF AMINO ACID AND METHODS OF APPLICATION |
PL2908912T3 (en) | 2012-10-18 | 2021-05-17 | The Rockefeller University | Broadly-neutralizing anti-hiv antibodies |
ES2912033T3 (en) * | 2012-10-23 | 2022-05-24 | Caris Science Inc | Aptamers and uses thereof |
WO2014066912A1 (en) | 2012-10-26 | 2014-05-01 | Vanderbilt University | Polymeric nanoparticles |
US20140315795A1 (en) | 2012-10-26 | 2014-10-23 | Nlife Therapeutics, S.L. | Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types |
WO2014066898A1 (en) | 2012-10-26 | 2014-05-01 | The Johns Hopkins University | A layer-by-layer approach to co-deliver dna and sirna via aunps: a potential platform for modifying release kinetics |
US20150376581A1 (en) | 2012-10-29 | 2015-12-31 | Technische Universitaet Dortmund | T7 rna polymerase variants and methods of using the same |
KR20230154283A (en) | 2012-11-01 | 2023-11-07 | 팩터 바이오사이언스 인크. | Methods and products for expressing proteins in cells |
WO2014071072A2 (en) | 2012-11-02 | 2014-05-08 | Pungente Michael D | Novel cationic carotenoid-based lipids for cellular nucleic acid uptake |
EP2914723B1 (en) | 2012-11-05 | 2018-06-13 | Fondazione Centro San Raffaele | Novel targets in multiple myeloma and other disorders |
AU2013341646B2 (en) | 2012-11-06 | 2017-08-31 | Rochal Technologies, Llc | Delivery of biologically-active agents using volatile, hydrophobic solvents |
US9975916B2 (en) | 2012-11-06 | 2018-05-22 | President And Fellows Of Harvard College | Compositions and methods relating to complex nucleic acid nanostructures |
US9669104B2 (en) | 2012-11-07 | 2017-06-06 | Council Of Scientific And Industrial Research | Nanocomplex containing amphipathic peptide useful for efficient transfection of biomolecules |
WO2014072999A1 (en) | 2012-11-07 | 2014-05-15 | Council Of Scientific And Industrial Research | Nanocomplex containing cationic peptide for biomolecule delivery |
KR20150083117A (en) | 2012-11-08 | 2015-07-16 | 클리어사이드 바이오메디컬, 인코포레이드 | Methods and devices for the treatment of ocular disease in human subjects |
TW201920677A (en) | 2012-11-08 | 2019-06-01 | 美商武田疫苗股份有限公司 | Compositions, methods and uses for dengue virus serotype-4 constructs |
SG10201608703SA (en) | 2012-11-08 | 2016-12-29 | Eleven Biotherapeutics Inc | Il-6 antagonists and uses thereof |
MX2015005363A (en) | 2012-11-08 | 2015-11-06 | Novozymes Biopharma Dk As | Albumin variants. |
ES2676470T3 (en) | 2012-11-09 | 2018-07-19 | Biontech Rna Pharmaceuticals Gmbh | Method for RNA expression in cells |
US9200119B2 (en) | 2012-11-09 | 2015-12-01 | Momentive Performance Materials Inc. | Silicon-containing zwitterionic linear copolymer composition |
WO2014072468A1 (en) | 2012-11-09 | 2014-05-15 | Velin-Pharma A/S | Compositions for pulmonary delivery |
WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
GB201220354D0 (en) | 2012-11-12 | 2012-12-26 | Medpharm Ltd | Dermal compositions |
WO2014075047A2 (en) | 2012-11-12 | 2014-05-15 | Genvec, Inc. | Malaria antigens and methods of use |
AU2013341711A1 (en) | 2012-11-12 | 2015-05-21 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
WO2014078399A1 (en) | 2012-11-13 | 2014-05-22 | Baylor College Of Medicine | Multi-arm biodegradable polymers for nucleic acid delivery |
US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
WO2014078636A1 (en) | 2012-11-16 | 2014-05-22 | President And Fellows Of Harvard College | Nucleic acid hydrogel self-assembly |
US9655848B2 (en) | 2012-11-19 | 2017-05-23 | Technion Research & Development Foundation Limited | Liposomes for in-vivo delivery |
EP2732825B1 (en) | 2012-11-19 | 2015-07-01 | Invivogen | Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist |
US20150290328A1 (en) | 2012-11-20 | 2015-10-15 | Phasebio Pharmaceuticals, Inc. | Formulations of active agents for sustained release |
US20140141037A1 (en) | 2012-11-20 | 2014-05-22 | Novartis Ag | Rsv f prefusion trimers |
WO2014081299A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
EP2922574B1 (en) | 2012-11-22 | 2023-05-17 | Tagworks Pharmaceuticals B.V. | Chemically cleavable group |
WO2014081300A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
JP6144355B2 (en) * | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Chemically modified mRNA |
WO2014093574A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for altering cell phenotype |
MX2015008847A (en) | 2013-01-10 | 2015-10-30 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof. |
CA2897941A1 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
EP2964234A4 (en) | 2013-03-09 | 2016-12-07 | Moderna Therapeutics Inc | Heterologous untranslated regions for mrna |
WO2014158795A1 (en) | 2013-03-12 | 2014-10-02 | Moderna Therapeutics, Inc. | Diagnosis and treatment of fibrosis |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
WO2014144711A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
US20160032273A1 (en) | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
DK3019619T3 (en) | 2013-07-11 | 2021-10-11 | Modernatx Inc | COMPOSITIONS INCLUDING SYNTHETIC POLYNUCLEOTIDES CODING CRISPR-RELATED PROTEINS, SYNTHETIC SGRNAs, AND USES OF USE |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015038892A1 (en) | 2013-09-13 | 2015-03-19 | Moderna Therapeutics, Inc. | Polynucleotide compositions containing amino acids |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
JP2016538829A (en) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | Polynucleotide encoding low density lipoprotein receptor |
EP3058082A4 (en) | 2013-10-18 | 2017-04-26 | ModernaTX, Inc. | Compositions and methods for tolerizing cellular systems |
EP3092250A4 (en) | 2014-01-08 | 2017-05-24 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
EP3159407A1 (en) * | 2015-10-23 | 2017-04-26 | Silence Therapeutics (London) Ltd | Guide rnas, methods and uses |
WO2017075038A1 (en) * | 2015-10-26 | 2017-05-04 | Rana Therapeutics, Inc. | Nanoparticle formulations for delivery of nucleic acid complexes |
CN110719954B (en) | 2017-05-31 | 2023-12-26 | 奥特吉尼克斯制药公司 | Therapeutic agent for glycogen storage disease type III |
BR112019028280A2 (en) * | 2017-07-04 | 2020-07-14 | Curevac Ag | nucleic acid molecules |
MX2021011565A (en) * | 2019-03-28 | 2021-11-12 | Intellia Therapeutics Inc | Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent. |
CN116710079A (en) * | 2020-07-24 | 2023-09-05 | 斯特兰德生物科技公司 | Lipid nanoparticles comprising modified nucleotides |
-
2012
- 2012-12-14 KR KR1020147019601A patent/KR20140102759A/en not_active Application Discontinuation
- 2012-12-14 AU AU2012352180A patent/AU2012352180A1/en not_active Abandoned
- 2012-12-14 WO PCT/US2012/069610 patent/WO2013090648A1/en active Application Filing
- 2012-12-14 PL PL12858350T patent/PL2791160T3/en unknown
- 2012-12-14 US US13/714,458 patent/US20130156849A1/en not_active Abandoned
- 2012-12-14 ES ES12858350T patent/ES2923757T3/en active Active
- 2012-12-14 SG SG11201402666WA patent/SG11201402666WA/en unknown
- 2012-12-14 PT PT128583507T patent/PT2791160T/en unknown
- 2012-12-14 JP JP2014547454A patent/JP2015501844A/en active Pending
- 2012-12-14 CN CN201280069609.3A patent/CN104114572A/en active Pending
- 2012-12-14 HU HUE12858350A patent/HUE059110T2/en unknown
- 2012-12-14 CA CA2859387A patent/CA2859387A1/en not_active Abandoned
- 2012-12-14 SI SI201232001T patent/SI2791160T1/en unknown
- 2012-12-14 MX MX2014007233A patent/MX2014007233A/en unknown
- 2012-12-14 RU RU2014129004A patent/RU2649364C2/en active
- 2012-12-14 SG SG10201604896TA patent/SG10201604896TA/en unknown
- 2012-12-14 RS RS20220503A patent/RS63244B1/en unknown
- 2012-12-14 HR HRP20220717TT patent/HRP20220717T1/en unknown
- 2012-12-14 DE DE12858350.7T patent/DE12858350T1/en active Pending
- 2012-12-14 CA CA3018046A patent/CA3018046A1/en not_active Abandoned
- 2012-12-14 EP EP22159380.9A patent/EP4144378A1/en active Pending
- 2012-12-14 DK DK12858350.7T patent/DK2791160T3/en active
- 2012-12-14 CN CN201910369662.9A patent/CN110201187A/en active Pending
- 2012-12-14 EP EP12858350.7A patent/EP2791160B1/en active Active
- 2012-12-14 LT LTEPPCT/US2012/069610T patent/LT2791160T/en unknown
-
2013
- 2013-05-18 US US13/897,367 patent/US8680069B2/en active Active
- 2013-05-18 US US13/897,372 patent/US20130244279A1/en not_active Abandoned
- 2013-05-18 US US13/897,371 patent/US9271996B2/en active Active
- 2013-05-18 US US13/897,375 patent/US9295689B2/en active Active
- 2013-05-21 US US13/898,758 patent/US8664194B2/en active Active
- 2013-05-21 US US13/898,512 patent/US20130237592A1/en not_active Abandoned
- 2013-05-21 US US13/898,699 patent/US20130236974A1/en not_active Abandoned
- 2013-05-21 US US13/898,536 patent/US20130237593A1/en not_active Abandoned
- 2013-05-21 US US13/898,588 patent/US9186372B2/en active Active
- 2013-05-21 US US13/898,983 patent/US20130245106A1/en not_active Abandoned
- 2013-05-21 US US13/898,870 patent/US8754062B2/en active Active
- 2013-05-22 US US13/899,641 patent/US20130245107A1/en not_active Abandoned
- 2013-06-14 US US13/917,720 patent/US20130266640A1/en not_active Abandoned
-
2014
- 2014-05-22 IL IL232749A patent/IL232749A0/en unknown
- 2014-05-23 ZA ZA2014/03783A patent/ZA201403783B/en unknown
-
2015
- 2015-04-13 HK HK15103589.4A patent/HK1203077A1/en unknown
-
2016
- 2016-03-22 US US15/077,705 patent/US20160193299A1/en not_active Abandoned
- 2016-09-20 AU AU2016231503A patent/AU2016231503A1/en not_active Abandoned
-
2017
- 2017-06-13 US US15/621,693 patent/US20180125937A1/en not_active Abandoned
-
2018
- 2018-07-23 AU AU2018207584A patent/AU2018207584A1/en not_active Abandoned
-
2019
- 2019-01-24 JP JP2019009835A patent/JP2019059793A/en not_active Withdrawn
- 2019-07-29 US US16/525,145 patent/US20200164038A1/en not_active Abandoned
-
2023
- 2023-03-02 US US18/177,455 patent/US20240123035A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303378B1 (en) * | 1997-10-24 | 2001-10-16 | Valentis, Inc. | Methods for preparing polynucleotide transfection complexes |
US20020064517A1 (en) * | 1998-04-30 | 2002-05-30 | Stewart A. Cederholm-Williams | Fibrin sealant as a transfection/transformation vehicle for gene therapy |
US20020130430A1 (en) * | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
US20060018971A1 (en) * | 2004-05-12 | 2006-01-26 | Terrence Scott | Nucleic acid microspheres, production and delivery thereof |
US20090286852A1 (en) | 2005-08-23 | 2009-11-19 | Katalin Kariko | RNA containing modified nucleosides and methods of use thereof |
US20100015232A1 (en) * | 2006-07-07 | 2010-01-21 | Aarhus Universitet | Nanoparticles for nucleic acid delivery |
US20080274463A1 (en) * | 2007-05-04 | 2008-11-06 | Ventana Medical Systems, Inc. | Method for quantifying biomolecules conjugated to a nanoparticle |
US20090264511A1 (en) * | 2007-12-10 | 2009-10-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor vii gene |
US20110244026A1 (en) * | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
WO2011130624A2 (en) * | 2010-04-16 | 2011-10-20 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
Non-Patent Citations (9)
Title |
---|
AKINC, NATURE BIOTECHNOLOGY, vol. 26, 2008, pages 561 - 569 |
BASHA ET AL.: "Infuence of Cationic lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells.", MOLECULAR THERAPY., vol. 19, no. 12, October 2011 (2011-10-01), pages 2186 - 2200, XP055024764 * |
GREENE ET AL.: "Protective Groups in Organic Synthesis,", 1991, WILEY & SONS |
GREENE, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS |
HEYES, J. CONTROL RELEASE, vol. 107, 2005, pages 276 - 287 |
LOVE, PNAS, vol. 107, 2010, pages 1864 - 1869 |
See also references of EP2791160A1 |
SEMPLE ET AL.: "Rational design of cationic lipids for siRNA delivery.", NATURE BIOTECHNOLOGY, vol. 28, no. 2, February 2010 (2010-02-01), pages 172 - 176+2PP, XP002633693 * |
SEMPLE, NATURE BIOTECHNOLOGY, vol. 28, 2010, pages 172 - 176 |
Cited By (278)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11298426B2 (en) | 2003-10-14 | 2022-04-12 | BioNTech SE | Recombinant vaccines and use thereof |
US10106800B2 (en) | 2005-09-28 | 2018-10-23 | Biontech Ag | Modification of RNA, producing an increased transcript stability and translation efficiency |
US11141378B2 (en) | 2008-04-15 | 2021-10-12 | Arbutus Biopharma Corporation | Lipid formulations for nucleic acid delivery |
US11446383B2 (en) | 2009-07-01 | 2022-09-20 | Arbutus Biopharma Corporation | Lipid formulations for delivery of therapeutic agents |
US11786598B2 (en) | 2009-07-01 | 2023-10-17 | Arbutus Biopharma Corporation | Lipid formulations for delivery of therapeutic agents |
US11718852B2 (en) | 2010-06-30 | 2023-08-08 | Arbutus Biopharma Corporation | Non-liposomal systems for nucleic acid delivery |
US11857562B2 (en) | 2010-07-06 | 2024-01-02 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11766401B2 (en) | 2010-07-06 | 2023-09-26 | Glaxosmithkline Biologicals Sa | Methods of administering lipid formulations with immunogens |
US11638694B2 (en) | 2010-07-06 | 2023-05-02 | Glaxosmithkline Biologicals Sa | Vaccine for eliciting immune response comprising lipid formulations and RNA encoding multiple immunogens |
US11638693B2 (en) | 2010-07-06 | 2023-05-02 | Glaxosmithkline Biologicals Sa | Vaccine for eliciting immune response comprising RNA encoding an immunogen and lipid formulations comprising mole percentage of lipids |
US11905514B2 (en) | 2010-07-06 | 2024-02-20 | Glaxosmithkline Biological Sa | Immunisation of large mammals with low doses of RNA |
US11655475B2 (en) | 2010-07-06 | 2023-05-23 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
US11666534B2 (en) | 2010-07-06 | 2023-06-06 | Glaxosmithkline Biologicals Sa | Methods of administering lipid formulations with viral immunogens |
US11690864B2 (en) | 2010-07-06 | 2023-07-04 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11690865B2 (en) | 2010-07-06 | 2023-07-04 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11690861B2 (en) | 2010-07-06 | 2023-07-04 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11690862B1 (en) | 2010-07-06 | 2023-07-04 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11690863B2 (en) | 2010-07-06 | 2023-07-04 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11696923B2 (en) | 2010-07-06 | 2023-07-11 | Glaxosmithkline Biologicals, Sa | Delivery of RNA to trigger multiple immune pathways |
US20220125723A1 (en) | 2010-07-06 | 2022-04-28 | Glaxosmithkline Biologicals Sa | Lipid formulations with viral immunogens |
US11891608B2 (en) | 2010-07-06 | 2024-02-06 | Glaxosmithkline Biologicals Sa | Immunization of large mammals with low doses of RNA |
US11707482B2 (en) | 2010-07-06 | 2023-07-25 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11883534B2 (en) | 2010-07-06 | 2024-01-30 | Glaxosmithkline Biologicals Sa | Immunisation with lipid formulations with RNA encoding immunogens |
US11717529B2 (en) | 2010-07-06 | 2023-08-08 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11730754B2 (en) | 2010-07-06 | 2023-08-22 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11739334B2 (en) | 2010-07-06 | 2023-08-29 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
US11865080B2 (en) | 2010-07-06 | 2024-01-09 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11913001B2 (en) | 2010-07-06 | 2024-02-27 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
US11759475B2 (en) | 2010-07-06 | 2023-09-19 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11596645B2 (en) | 2010-07-06 | 2023-03-07 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11773395B1 (en) | 2010-07-06 | 2023-10-03 | Glaxosmithkline Biologicals Sa | Immunization of large mammals with low doses of RNA |
US11857681B2 (en) | 2010-07-06 | 2024-01-02 | Glaxosmithkline Biologicals Sa | Lipid formulations with RNA encoding immunogens |
US11786467B2 (en) | 2010-07-06 | 2023-10-17 | Glaxosmithkline Biologicals Sa | Lipid formulations with immunogens |
US11839686B2 (en) | 2010-07-06 | 2023-12-12 | Glaxosmithkline Biologicals Sa | Lipid formulations with viral immunogens |
US11845925B2 (en) | 2010-07-06 | 2023-12-19 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
US11851660B2 (en) | 2010-07-06 | 2023-12-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
US11850305B2 (en) | 2010-07-06 | 2023-12-26 | Glaxosmithkline Biologicals Sa | Method of making lipid formulations with RNA encoding immunogens |
US9181319B2 (en) | 2010-08-06 | 2015-11-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9447164B2 (en) | 2010-08-06 | 2016-09-20 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9937233B2 (en) | 2010-08-06 | 2018-04-10 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US11759422B2 (en) | 2010-08-31 | 2023-09-19 | Glaxosmithkline Biologicals Sa | Pegylated liposomes for delivery of immunogen-encoding RNA |
US9657295B2 (en) | 2010-10-01 | 2017-05-23 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US10064959B2 (en) | 2010-10-01 | 2018-09-04 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US11639370B2 (en) | 2010-10-11 | 2023-05-02 | Glaxosmithkline Biologicals Sa | Antigen delivery platforms |
US10898574B2 (en) | 2011-03-31 | 2021-01-26 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9950068B2 (en) | 2011-03-31 | 2018-04-24 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US11911474B2 (en) | 2011-03-31 | 2024-02-27 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US11248264B2 (en) | 2011-05-24 | 2022-02-15 | Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh | Individualized vaccines for cancer |
US10738355B2 (en) | 2011-05-24 | 2020-08-11 | Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh | Individualized vaccines for cancer |
US11951181B2 (en) | 2011-06-08 | 2024-04-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11547764B2 (en) | 2011-06-08 | 2023-01-10 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US11951179B2 (en) | 2011-06-08 | 2024-04-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US11951180B2 (en) | 2011-06-08 | 2024-04-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US11730825B2 (en) | 2011-06-08 | 2023-08-22 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US10022425B2 (en) | 2011-09-12 | 2018-07-17 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US10751386B2 (en) | 2011-09-12 | 2020-08-25 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9295689B2 (en) | 2011-12-16 | 2016-03-29 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9271996B2 (en) | 2011-12-16 | 2016-03-01 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
US10485884B2 (en) | 2012-03-26 | 2019-11-26 | Biontech Rna Pharmaceuticals Gmbh | RNA formulation for immunotherapy |
US11559587B2 (en) | 2012-03-26 | 2023-01-24 | Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh | RNA formulation for immunotherapy |
US9050297B2 (en) | 2012-04-02 | 2015-06-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator |
US10385106B2 (en) | 2012-04-02 | 2019-08-20 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
US10772975B2 (en) | 2012-04-02 | 2020-09-15 | Modernatx, Inc. | Modified Polynucleotides for the production of biologics and proteins associated with human disease |
US9782462B2 (en) | 2012-04-02 | 2017-10-10 | Modernatx, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9675668B2 (en) | 2012-04-02 | 2017-06-13 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding hepatitis A virus cellular receptor 2 |
US9220792B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aquaporin-5 |
US10577403B2 (en) | 2012-04-02 | 2020-03-03 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
US9220755B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9587003B2 (en) | 2012-04-02 | 2017-03-07 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
US9216205B2 (en) | 2012-04-02 | 2015-12-22 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding granulysin |
US11564998B2 (en) | 2012-04-02 | 2023-01-31 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9221891B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | In vivo production of proteins |
US10703789B2 (en) | 2012-04-02 | 2020-07-07 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
EP3978030A1 (en) * | 2012-04-02 | 2022-04-06 | ModernaTX, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9572896B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | In vivo production of proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9255129B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 |
US10583203B2 (en) | 2012-04-02 | 2020-03-10 | Modernatx, Inc. | In vivo production of proteins |
US9233141B2 (en) | 2012-04-02 | 2016-01-12 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
AU2017232121B2 (en) * | 2012-04-02 | 2019-05-09 | Modernatx, Inc. | In vivo production of proteins |
WO2013151665A3 (en) * | 2012-04-02 | 2014-02-20 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
US9149506B2 (en) | 2012-04-02 | 2015-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding septin-4 |
US9828416B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
EP3501550A1 (en) * | 2012-04-02 | 2019-06-26 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9827332B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of proteins |
EP3505176A1 (en) * | 2012-04-02 | 2019-07-03 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
EP2833921A2 (en) * | 2012-04-02 | 2015-02-11 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9114113B2 (en) | 2012-04-02 | 2015-08-25 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding citeD4 |
EP3520821A1 (en) * | 2012-04-02 | 2019-08-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US9061059B2 (en) | 2012-04-02 | 2015-06-23 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating protein deficiency |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9089604B2 (en) | 2012-04-02 | 2015-07-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating galactosylceramidase protein deficiency |
US9095552B2 (en) | 2012-04-02 | 2015-08-04 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 |
US9301993B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding apoptosis inducing factor 1 |
US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US10463751B2 (en) | 2012-04-02 | 2019-11-05 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9814760B2 (en) | 2012-04-02 | 2017-11-14 | Modernatx, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US10493167B2 (en) | 2012-04-02 | 2019-12-03 | Modernatx, Inc. | In vivo production of proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US10758592B2 (en) | 2012-10-09 | 2020-09-01 | Sanofi | Exendin-4 derivatives as dual GLP1/glucagon agonists |
US10155029B2 (en) | 2012-11-26 | 2018-12-18 | Modernatx, Inc. | Terminally modified RNA |
WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
US10925935B2 (en) | 2012-11-26 | 2021-02-23 | Modernatx, Inc. | Terminally Modified RNA |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
AU2017202228B2 (en) * | 2012-11-26 | 2019-03-14 | Modernatx, Inc. | Terminally modified RNA |
US11504419B2 (en) | 2012-11-28 | 2022-11-22 | BioNTech SE | Individualized vaccines for cancer |
US10155031B2 (en) | 2012-11-28 | 2018-12-18 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
EP2931319A4 (en) * | 2012-12-13 | 2016-05-04 | Moderna Therapeutics Inc | Modified nucleic acid molecules and uses thereof |
US9670261B2 (en) | 2012-12-21 | 2017-06-06 | Sanofi | Functionalized exendin-4 derivatives |
US9745360B2 (en) | 2012-12-21 | 2017-08-29 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists |
US10253079B2 (en) | 2012-12-21 | 2019-04-09 | Sanofi | Functionalized Exendin-4 derivatives |
US11708396B2 (en) | 2013-01-17 | 2023-07-25 | Modernatx, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
WO2014113089A2 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
US11007210B2 (en) | 2013-02-22 | 2021-05-18 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds, compositions, methods, and kits relating to telomere extension |
US11872243B2 (en) | 2013-02-22 | 2024-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds, compositions, methods, and kits relating to telomere extension |
US10525075B2 (en) | 2013-02-22 | 2020-01-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds, compositions, methods, and kits relating to telomere extension |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US11845772B2 (en) | 2013-03-15 | 2023-12-19 | Modernatx, Inc. | Ribonucleic acid purification |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
US10858647B2 (en) | 2013-03-15 | 2020-12-08 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
US11222711B2 (en) | 2013-05-10 | 2022-01-11 | BioNTech SE | Predicting immunogenicity of T cell epitopes |
EP3019619B1 (en) | 2013-07-11 | 2021-08-25 | ModernaTX, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
US11027025B2 (en) | 2013-07-11 | 2021-06-08 | Modernatx, Inc. | Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use |
WO2015006747A2 (en) | 2013-07-11 | 2015-01-15 | Moderna Therapeutics, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use. |
JP7136826B2 (en) | 2013-07-11 | 2022-09-13 | モデルナティエックス インコーポレイテッド | Compositions Comprising Synthetic Polynucleotides Encoding CRISPR-Related Proteins and Synthetic sgRNAs and Methods of Use |
JP2020108379A (en) * | 2013-07-11 | 2020-07-16 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING CRISPR RELATED PROTEINS AND SYNTHETIC sgRNAS, AND METHODS OF USE |
EP3971287A1 (en) | 2013-07-11 | 2022-03-23 | ModernaTX, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US10633659B2 (en) | 2013-11-22 | 2020-04-28 | Mina Therapeutics Limited | C/EBPα short activating RNA compositions and methods of use |
EP3594348A1 (en) | 2013-11-22 | 2020-01-15 | Mina Therapeutics Limited | C/ebp alpha short activating rna compositions and methods of use |
US10202601B2 (en) | 2013-11-22 | 2019-02-12 | Mina Therapeutics Limited | C/EBPα short activating RNA compositions and methods of use |
EP3985118A1 (en) | 2013-11-22 | 2022-04-20 | MiNA Therapeutics Limited | C/ebp alpha short activating rna compositions and methods of use |
WO2015075557A2 (en) | 2013-11-22 | 2015-05-28 | Mina Alpha Limited | C/ebp alpha compositions and methods of use |
US9789165B2 (en) | 2013-12-13 | 2017-10-17 | Sanofi | Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists |
EP3053585A1 (en) * | 2013-12-13 | 2016-08-10 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
US9694053B2 (en) | 2013-12-13 | 2017-07-04 | Sanofi | Dual GLP-1/glucagon receptor agonists |
US9750788B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Non-acylated exendin-4 peptide analogues |
US9751926B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Dual GLP-1/GIP receptor agonists |
EP3080289A4 (en) * | 2013-12-13 | 2017-11-15 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
RU2714404C2 (en) * | 2014-01-31 | 2020-02-14 | Фэктор Байосайенс Инк. | Methods and products for producing and delivering nucleic acids |
EP3699274A1 (en) * | 2014-03-24 | 2020-08-26 | Translate Bio, Inc. | Mrna therapy for the treatment of ocular diseases |
EP3122878B1 (en) | 2014-03-24 | 2018-10-24 | Translate Bio, Inc. | Mrna therapy for the treatment of ocular diseases |
US9771406B2 (en) | 2014-04-07 | 2017-09-26 | Sanofi | Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9775904B2 (en) | 2014-04-07 | 2017-10-03 | Sanofi | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
US9758561B2 (en) | 2014-04-07 | 2017-09-12 | Sanofi | Dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US10709779B2 (en) | 2014-04-23 | 2020-07-14 | Modernatx, Inc. | Nucleic acid vaccines |
EP3134131B1 (en) | 2014-04-23 | 2021-12-22 | ModernaTX, Inc. | Nucleic acid vaccines |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
EP4159741A1 (en) | 2014-07-16 | 2023-04-05 | ModernaTX, Inc. | Method for producing a chimeric polynucleotide encoding a polypeptide having a triazole-containing internucleotide linkage |
US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
EP3177732A4 (en) * | 2014-08-08 | 2018-04-25 | ModernaTX, Inc. | Compositions and methods for the treatment of ophthalmic diseases and conditions |
US11173120B2 (en) | 2014-09-25 | 2021-11-16 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
US11344608B2 (en) | 2014-11-12 | 2022-05-31 | Ucl Business Ltd | Factor IX gene therapy |
US10413598B2 (en) | 2014-11-12 | 2019-09-17 | Ucl Business Plc | Factor IX gene therapy |
US11761009B2 (en) | 2014-12-12 | 2023-09-19 | CureVac SE | Artificial nucleic acid molecules for improved protein expression |
EP4023755B1 (en) | 2014-12-12 | 2023-04-26 | CureVac SE | Artificial nucleic acid molecules for improved protein expression |
EP3708668B1 (en) | 2014-12-12 | 2022-07-27 | CureVac AG | Artificial nucleic acid molecules for improved protein expression |
US11156617B2 (en) | 2015-02-12 | 2021-10-26 | BioNTech RNA Pharmaceuticals GbmH | Predicting T cell epitopes useful for vaccination |
US10806797B2 (en) | 2015-06-05 | 2020-10-20 | Sanofi | Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate |
US9982029B2 (en) | 2015-07-10 | 2018-05-29 | Sanofi | Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
EP3324979B1 (en) | 2015-07-21 | 2022-10-12 | ModernaTX, Inc. | Infectious disease vaccines |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
US11590157B2 (en) * | 2015-10-05 | 2023-02-28 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
US20180256628A1 (en) * | 2015-10-05 | 2018-09-13 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
US10849920B2 (en) | 2015-10-05 | 2020-12-01 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
WO2017062513A1 (en) | 2015-10-05 | 2017-04-13 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
EP3359670B1 (en) | 2015-10-05 | 2020-05-13 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
US20230338410A1 (en) * | 2015-10-05 | 2023-10-26 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
US11492628B2 (en) | 2015-10-07 | 2022-11-08 | BioNTech SE | 3′-UTR sequences for stabilization of RNA |
EP3364981A4 (en) * | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Human cytomegalovirus vaccine |
US10933127B2 (en) | 2015-10-22 | 2021-03-02 | Modernatx, Inc. | Betacoronavirus mRNA vaccine |
EP3718565A1 (en) * | 2015-10-22 | 2020-10-07 | ModernaTX, Inc. | Respiratory virus vaccines |
EP4011451A1 (en) * | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
EP3365007A4 (en) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | Broad spectrum influenza virus vaccine |
US10675342B2 (en) | 2015-10-22 | 2020-06-09 | Modernatx, Inc. | Chikungunya virus RNA vaccines |
EP3718565B1 (en) | 2015-10-22 | 2022-04-27 | ModernaTX, Inc. | Respiratory virus vaccines |
EP3364983A4 (en) * | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Respiratory virus vaccines |
EP3364950A4 (en) * | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Tropical disease vaccines |
EP3365009A4 (en) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | Herpes simplex virus vaccine |
US11278611B2 (en) | 2015-10-22 | 2022-03-22 | Modernatx, Inc. | Zika virus RNA vaccines |
US11235052B2 (en) | 2015-10-22 | 2022-02-01 | Modernatx, Inc. | Chikungunya virus RNA vaccines |
US11643441B1 (en) | 2015-10-22 | 2023-05-09 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (VZV) |
US11872278B2 (en) | 2015-10-22 | 2024-01-16 | Modernatx, Inc. | Combination HMPV/RSV RNA vaccines |
EP3364980A4 (en) * | 2015-10-22 | 2019-07-10 | ModernaTX, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
EP3364982A4 (en) * | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | Sexually transmitted disease vaccines |
EP3369816A4 (en) * | 2015-10-30 | 2019-06-26 | Bonac Corporation | Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-beta1 gene |
US10751426B2 (en) | 2015-10-30 | 2020-08-25 | Bonac Corporation | Composition stably containing single-stranded nucleic acid molecule that suppresses expression of TGF-β1 gene |
WO2017112943A1 (en) | 2015-12-23 | 2017-06-29 | Modernatx, Inc. | Methods of using ox40 ligand encoding polynucleotides |
EP4039699A1 (en) | 2015-12-23 | 2022-08-10 | ModernaTX, Inc. | Methods of using ox40 ligand encoding polynucleotides |
WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
US11564997B2 (en) | 2016-06-29 | 2023-01-31 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
WO2018009838A1 (en) | 2016-07-07 | 2018-01-11 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems expressing exogenous rna |
CN109562153A (en) * | 2016-08-07 | 2019-04-02 | 诺华股份有限公司 | The immunization method that mRNA is mediated |
US11878060B2 (en) | 2016-08-07 | 2024-01-23 | Novartis Ag | mRNA-mediated immunization methods |
CN106047879A (en) * | 2016-08-18 | 2016-10-26 | 广州市锐博生物科技有限公司 | Oligonucleotide molecule used for inhibiting expression of mRNA of target gene and composition set thereof |
US11920148B2 (en) | 2017-02-22 | 2024-03-05 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
US11407997B2 (en) | 2017-02-22 | 2022-08-09 | Crispr Therapeutics Ag | Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders |
US11559588B2 (en) | 2017-02-22 | 2023-01-24 | Crispr Therapeutics Ag | Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders |
WO2018213731A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
EP4219715A2 (en) | 2017-09-08 | 2023-08-02 | MiNA Therapeutics Limited | Stabilized cebpa sarna compositions and methods of use |
EP4233880A2 (en) | 2017-09-08 | 2023-08-30 | MiNA Therapeutics Limited | Hnf4a sarna compositions and methods of use |
WO2019048632A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | Stabilized hnf4a sarna compositions and methods of use |
WO2019048631A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | Hnf4a sarna compositions and methods of use |
EP4183882A1 (en) | 2017-09-08 | 2023-05-24 | MiNA Therapeutics Limited | Stabilized hnf4a sarna compositions and methods of use |
US11207398B2 (en) | 2017-09-14 | 2021-12-28 | Modernatx, Inc. | Zika virus mRNA vaccines |
WO2019158720A1 (en) | 2018-02-16 | 2019-08-22 | Mina Therapeutics Limited | C/ebp alpha sarna compositions and methods of use |
EP4242307A2 (en) | 2018-04-12 | 2023-09-13 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
WO2019197845A1 (en) | 2018-04-12 | 2019-10-17 | Mina Therapeutics Limited | Sirt1-sarna compositions and methods of use |
WO2019239144A1 (en) | 2018-06-15 | 2019-12-19 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
US11517631B2 (en) | 2018-08-20 | 2022-12-06 | Ucl Business Ltd | Factor IX encoding nucleotides |
US11913012B2 (en) | 2018-08-30 | 2024-02-27 | Tenaya Therapeutics, Inc. | Cardiac cell reprogramming with myocardin and ASCL1 |
US11015211B2 (en) | 2018-08-30 | 2021-05-25 | Tenaya Therapeutics, Inc. | Cardiac cell reprogramming with myocardin and ASCL1 |
US11008586B2 (en) | 2018-09-07 | 2021-05-18 | Crispr Therapeutics Ag | Universal donor cells |
US11008587B2 (en) | 2018-09-07 | 2021-05-18 | Crispr Therapeutics Ag | Universal donor cells |
US10724052B2 (en) | 2018-09-07 | 2020-07-28 | Crispr Therapeutics Ag | Universal donor cells |
US10865424B2 (en) | 2018-09-07 | 2020-12-15 | Crispr Therapeutics Ag | Universal donor cells |
US11180776B1 (en) | 2018-09-07 | 2021-11-23 | Crispr Therapeutics Ag | Universal donor cells |
WO2020056155A3 (en) * | 2018-09-13 | 2020-04-16 | Modernatx, Inc. | Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease |
WO2020208361A1 (en) | 2019-04-12 | 2020-10-15 | Mina Therapeutics Limited | Sirt1-sarna compositions and methods of use |
WO2021007515A1 (en) | 2019-07-11 | 2021-01-14 | Tenaya Therapeutics, Inc. | Cardiac cell reprogramming with micrornas and other factors |
US11926817B2 (en) | 2019-08-09 | 2024-03-12 | Nutcracker Therapeutics, Inc. | Microfluidic apparatus and methods of use thereof |
WO2021032777A1 (en) | 2019-08-19 | 2021-02-25 | Mina Therapeutics Limited | Oligonucleotide conjugate compositions and methods of use |
US11118195B2 (en) | 2019-09-05 | 2021-09-14 | Crispr Therapeutics Ag | Universal donor cells |
US11433103B2 (en) | 2019-09-05 | 2022-09-06 | Crispr Therapeutics Ag | Universal donor cells |
US11434505B2 (en) | 2019-09-05 | 2022-09-06 | Crispr Therapeutics Ag | Universal donor cells |
US11118196B2 (en) | 2019-09-05 | 2021-09-14 | Crispr Therapeutics Ag | Universal donor cells |
US11104918B2 (en) | 2019-09-05 | 2021-08-31 | Crispr Therapeutics Ag | Universal donor cells |
US11116797B2 (en) | 2019-09-05 | 2021-09-14 | Crispr Therapeutics Ag | Universal donor cells |
US11116798B2 (en) | 2019-09-05 | 2021-09-14 | Crispr Therapeutics Ag | Universal donor cells |
WO2021178246A1 (en) | 2020-03-02 | 2021-09-10 | Tenaya Therapeutics, Inc. | Gene vector control by cardiomyocyte-expressed micrornas |
US11925694B2 (en) | 2020-04-22 | 2024-03-12 | BioNTech SE | Coronavirus vaccine |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
US11779659B2 (en) | 2020-04-22 | 2023-10-10 | BioNTech SE | RNA constructs and uses thereof |
US11951185B2 (en) | 2020-04-22 | 2024-04-09 | BioNTech SE | RNA constructs and uses thereof |
WO2022113056A1 (en) | 2020-11-30 | 2022-06-02 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
US11578309B2 (en) | 2020-12-31 | 2023-02-14 | Crispr Therapeutics Ag | Universal donor cells |
US11566230B2 (en) | 2020-12-31 | 2023-01-31 | Crispr Therapeutics Ag | Universal donor cells |
WO2022200810A1 (en) | 2021-03-26 | 2022-09-29 | Mina Therapeutics Limited | Tmem173 sarna compositions and methods of use |
WO2022229644A1 (en) | 2021-04-28 | 2022-11-03 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
WO2023031394A1 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
WO2023069498A1 (en) | 2021-10-22 | 2023-04-27 | Senda Biosciences, Inc. | Mrna vaccine composition |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
WO2023096858A1 (en) | 2021-11-23 | 2023-06-01 | Senda Biosciences, Inc. | A bacteria-derived lipid composition and use thereof |
WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
WO2023122080A1 (en) | 2021-12-20 | 2023-06-29 | Senda Biosciences, Inc. | Compositions comprising mrna and lipid reconstructed plant messenger packs |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240123035A1 (en) | Modified nucleoside, nucleotide, and nucleic acid compositions | |
AU2016202985A1 (en) | Methods of increasing the viability or longevity of an organ or organ explant | |
WO2013106496A1 (en) | Methods and compositions for targeting agents into and across the blood-brain barrier | |
US20140378538A1 (en) | Methods of responding to a biothreat | |
EP2791159A1 (en) | Modified nucleic acids, and acute care uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12858350 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 232749 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2859387 Country of ref document: CA Ref document number: 2014547454 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/007233 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20147019601 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014129004 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2012352180 Country of ref document: AU Date of ref document: 20121214 Kind code of ref document: A |